


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update April 19 - April 25, 2021,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 16 2021 972 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashbord](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford Universtiy Press](#)

[Cambridge Univeristy Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[German \(ICU\) bed capacity](#)

[COVID-19 Projections tracker](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[COVID reference \(Steinhauser Verlag\)](#)

[Retracted papers](#)

[COVID-19 risk tools - Apps](#)

[Web app for SARS-CoV2 mutations](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

[COVID-19 prevention network](#)

[Covid-Plex trial - \(plasma exchange & convalescent plasma trial\)](#)

**Re: Plasma exchange and convalescent plasma in COVID-19 patients with
multi-organ failure –**

**The COVID-19 PLEX + Convalescent Plasma trial –
Enrollment initiated**

The Covid-Plex trial is an investigator initiated, multicenter, parallel-group, open-label randomized clinical trial aiming to randomize patients with severe COVID-19 to standard care or standard care plus plasmapheresis and convalescent plasma.

If you are interested to participate Please contact Wladimir Szpirt, Nicholas Carlson Anders, or Perner Bo Feldt-Rasmussen. Depts. Of Intensive Care Therapy and Nephrology, Copenhagen University Hospital Rigshospitalet, Denmark

[Covid-Plex trial](#)

Mainstream Media

New York Times - Corona update

[What to Know About India's Coronavirus Crisis](#)

[Vaccine Skepticism Was Viewed as a Knowledge Problem. It's Gut Beliefs.](#)

[How Pfizer Makes Its Covid-19 Vaccine](#)

[Turkey braces for its strictest lockdown yet, as the virus surges and vaccinations lag](#)

[Pakistan warns of new strictures as its daily Covid death toll sets a record.](#)

[The Pfizer and Moderna vaccines are 94 percent effective at preventing hospitalization in older adults](#)

[Brazil's health authority rejects importing Russia's Sputnik V vaccine.](#)

[The European Union sues AstraZeneca over missing vaccine doses.](#)

Washington Post - Corona update

[our questions about coronavirus vaccines, answered](#)

[What you need to know about the coronavirus variants](#)

[The pandemic's chilling effect on free speech](#)

[J&J coronavirus vaccine needs rare blood clot warning but that benefits outweigh risks](#)

[jump the vaccine line? In Germany, you could face prosecution.](#)

[Should I wear a mask outside? Experts weigh in on scenarios.](#)

[What to expect if you're traveling this summer](#)

Guardian - Corona update

[How continental Europe is emerging from Covid lockdown](#)

[Figures on Covid deaths post-jab show vaccine's success, scientists say](#)

[Australian government may make it a crime for citizens to return from Covid-ravaged countries](#)

Key Articles

1. **COVID-19 and thrombotic microangiopathies.** Thromb Res 2021; 202:191-198 Tiwari NR, Phatak S, Sharma VR, Agarwal SK.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894421>

This global literature review evaluated the impact of thrombotic complications in severely affected COVID-19 patients. The use of conventional prophylactic and therapeutic doses of anticoagulation was ineffective in preventing thrombotic complications in roughly one-third of patients. The review suggests several assessments as well as therapeutic strategies to improve survival and outcomes in severe COVID-19 patients.

2. **Eight-month follow-up of olfactory and gustatory dysfunctions in recovered COVID-19 patients.** Am. J. Otolaryngol. 2021; 42:103065 Biadsee A, Dagan O, Ormianer Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894627>

Loss of smell and taste are common clinical features in patients with symptomatic SARS-CoV-2 infections. In this small Israeli study, 97 patients were followed for a mean period of 229 days, recovery of smell and taste occurred in 52% and 61.5% respectively of the participants; however, a large number of patients continue to experience these serious complaints after 6-8 months of follow-up.

3. **Retrospective observational RT-PCR analyses on 688 babies born to 843 SARS-CoV-2 positive mothers, placental analyses and diagnostic analyses limitations suggest vertical transmission is possible.** Facts Views Vis Obgyn 2021; 13:53-66 Bahadur G, Bhat M, Acharya S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889861>

The scale of the COVID-19 pandemic ensures that the risk of getting infected does include pregnant women and their unborn fetus. The risk of vertical transmission of the SARS-CoV-2 virus was evaluated in this systematic review of 82 studies that included 862 pregnant women with a positive RT-PCR. After birth, 14 babies had a positive RT-PCR test at birth; three babies showed positive test results on days 6 and 7. Placental swabs were positive in four studies, and this was observed in 10 fetal amniotic fluid swabs as well. These results indicate a substantial likelihood of vertical transmission from mother to baby is possible

4. **Cause of death based on systematic postmortem studies in patients with positive SARS-CoV2 tissue PCR during the COVID-19 pandemic.** J Intern Med 2021; Romanova ES, Vasilyev VV, Startseva G *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33872433>

5. **Prevalence of proximal deep vein thrombosis in hospitalized COVID-19 patients.** Eur J Intern Med 2021; Reichert G, Bunel V, Dreyfuss D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875336>
6. **An international perspective of out-of-hospital cardiac arrest and cardiopulmonary resuscitation during the COVID-19 pandemic.** Am J Emerg Med 2021; 47:192-197 Ong J, O'Connell F, Mazer-Amirshahi M, Pourmand A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894661>
7. **An evaluation of venous thromboembolism by whole-body enhanced CT scan for critical COVID-19 pneumonia with markedly rises of coagulopathy related factors: a case series study.** Thromb J 2021; 19:26 Ogawa F, Oi Y, Nakajima K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879177>
8. **Angiotensin-converting enzyme 2 (ACE2): role in the pathogenesis of diseases outside of COVID-19.** Nephrologie 2021; Mülling N, Rohn H.
9. **Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.** Clin. Appl. Thromb. Hemost. 2021; 27:10760296211008999 Moonla C, Sosothikul D, Chiasakul T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874753>
10. **The effect of cardiovascular disease and acute cardiac injury on fatal COVID-19: a meta-analysis.** Am J Emerg Med 2021; 48:128-139 Long J, Luo Y, Wei Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895644>
11. **Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units.** Crit Care 2021; 25:155 Lavinio A, Ercole A, Battaglini D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888132>
12. **Status Report on COVID-19 Vaccines Development.** Curr. Infect. Dis. Rep. 2021; 23:9 Kumar A, Dowling WE, Román RG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867863>
13. **Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain.** Lancet Reg Health Eur 2021; 3:100041 Garcia-Vidal C, Cózar-Llistó A, Meira F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870249>
14. **Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.** Euro

Surveill 2021; 26Funk T, Pharris A, Spiteri G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33890566>

15. **The use of direct acting oral anticoagulants in patients with COVID-19 infection.** J Community Hosp Intern Med Perspect 2021; 11:184-186Aly R, Gupta S, Singh B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889317>

Basic Science (45 articles)

1. **Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum.** ACS Infect Dis 2021; Fiedler S, Piziorska MA, Denninger V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876632>
2. **A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.** Antiviral Res 2021; 190:105078Zhao J, Guo S, Yi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894278>
3. **Antiviral peptides from aquatic organisms: Functionality and potential inhibitory effect on SARS-CoV-2.** Aquaculture 2021; 541:736783Sumon TA, Hussain MA, Hasan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883784>
4. **Prediction of Anti-COVID 19 Therapeutic Power of Medicinal Moroccan Plants Using Molecular Docking.** Bioinform. Biol. Insights 2021; 15:11779322211009199Nouadi B, Ezaouine A, El Messal M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888980>
5. **Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy.** Biomed. Pharmacother. 2021; 139:111626Kelleni MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894625>
6. **Development of ciclesonide analogues that block SARS-CoV-2 RNA replication.** Bioorg. Med. Chem. Lett. 2021; 43:128052Tsuji G, Yonemitsu K, Ito T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887440>
7. **Sensitive quantitative detection of SARS-CoV-2 in clinical samples using digital warm-start CRISPR assay.** Biosens. Bioelectron. 2021; 184:113218Ding X, Yin K, Li Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878591>
8. **Online biophysical predictions for SARS-CoV-2 proteins.** BMC Mol Cell Biol 2021; 22:23Kagami L, Roca-Martínez J, Gavalda-García J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892639>
9. **Epidemiological and virological characteristics of respiratory tract infections in children during COVID-19 outbreak.** BMC Pediatr. 2021; 21:195Zhu Y, Li W, Yang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888063>
10. **Computational Design and Modeling of Nanobodies toward SARS-CoV-2 Receptor Binding Domain.** Chem. Biol. Drug Des. 2021; Yang J, Zhang Z, Yang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894099>
11. **Comprehensive profiling and characterization of the absorbed components and metabolites in mice serum and tissues following oral administration of Qing-Fei-Pai-Du decoction by UHPLC-Q-Exactive-Orbitrap HRMS.** Chin J Nat

Med 2021; 19:305-320Liu W, Huang J, Zhang F *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33875170>

12. **SARS-CoV-2 proteins regulate inflammatory, thrombotic and diabetic responses in human arterial fibroblasts.** Clin Immunol 2021; 227:108733Freda CT, Yin W, Ghebrehiwet B, Rubenstein DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895357>
13. **SARS-CoV-2 Entry inhibitors targeting virus-ACE2 or virus-TMPRSS2 interactions.** Curr Med Chem 2021; Lin H, Cherukupalli S, Feng D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881969>
14. **A Network Pharmacology Study to Uncover the Multiple Molecular Mechanism of the Chinese Patent Medicine Toujiequwen Granules in the Treatment of Corona Virus Disease 2019 (COVID-19).** Curr Med Sci 2021; 41:297-305Yang BY, Wang HZ, Ma ZZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877545>
15. **COVID-19: A Mitochondrial Perspective.** DNA Cell Biol. 2021; Prasun P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872068>
16. **Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients.** EBioMedicine 2021:103341Balestrieri E, Minutolo A, Petrone V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867312>
17. **Epigenomics in COVID-19; the link between DNA methylation, histone modifications and SARS-CoV-2 infection.** Epigenomics 2021; Shirvaliloo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876664>
18. **Angiotensin-Converting Enzyme 2 Gene Expression in Breast Tissue.** Eur J Breast Health 2021; 17:112-115Al-Benna S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870109>
19. **Mutations in the SARS-CoV-2 spike protein modulate the virus affinity to the human ACE2 receptor, an in silico analysis.** Excli j 2021; 20:585-600Ortega JT, Pujol FH, Jastrzebska B, Rangel HR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883984>
20. **MicroLet-7b Regulates Neutrophil Function and Dampens Neutrophilic Inflammation by Suppressing the Canonical TLR4/NF- κ B Pathway.** Front. Immunol. 2021; 12:653344Chen B, Han J, Chen S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868293>
21. **Mink, SARS-CoV-2, and the Human-Animal Interface.** Front. Microbiol. 2021; 12:663815Fenollar F, Mediannikov O, Maurin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868218>
22. **Haplotype Explorer: an infection cluster visualization tool for spatiotemporal dissection of the COVID-19 pandemic.** G3 (Bethesda) 2021; Kawano-Sugaya T, Yatsu K, Sekizuka T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892501>
23. **Mutation rates and selection on synonymous mutations in SARS-CoV-2.** Genome Biol. Evol. 2021; De Maio N, Walker CR, Turakhia Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895815>
24. **Profiling SARS-CoV-2 mutation fingerprints that range from the viral pangenome to individual infection quasispecies.** Genome Med. 2021; 13:62Lau BT, Pavlichin D, Hooker AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875001>

25. **CRISPR/Cas-New Molecular Scissors in Diagnostics and Therapeutics of COVID-19.** Indian J. Clin. Biochem. 2021:1-9Gadwal A, Roy D, Khokhar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879980>
26. **Acute and post-acute phase of COVID-19: Analyzing expression patterns of miRNA-29a-3p, 146a-3p, 155-5p, and let-7b-3p in PBMC.** Int Immunopharmacol 2021; 97:107641Donyavi T, Bokharaei-Salim F, Baghi HB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895478>
27. **In Silico Identification of Multi-target Anti-SARS-CoV-2 Peptides from Quinoa Seed Proteins.** Int. J. Pept. Res. Ther. 2021:1-11Wong FC, Ong JH, Kumar DT, Chai TT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867899>
28. **Modeling SARS-CoV-2 infection and its individual differences with ACE2-expressing human iPS cells.** iScience 2021:102428Sano E, Deguchi S, Sakamoto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880436>
29. **ACE2, TMPRSS2 and L-SIGN expression in placentae from HIV-positive pregnancies exposed to antiretroviral therapy-implications for SARS-CoV-2 placental infection.** J Infect Dis 2021; Kala S, Meteleva K, Serghides L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880537>
30. **Introduction, Transmission Dynamics, and Fate of Early SARS-CoV-2 Lineages in Santa Clara County, California.** J Infect Dis 2021; Villarino E, Deng X, Kemper CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893501>
31. **N-Terminal finger stabilizes the S1 pocket for the reversible feline drug GC376 in the SARS-CoV-2 M(pro) dimer.** J. Mol. Biol. 2021:167003Arutyunova E, Bashir Khan M, Fischer C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895266>
32. **Structurally modified compounds of hydroxychloroquine, remdesivir and tetrahydrocannabinol against main protease of SARS-CoV-2, a possible hope for COVID-19: Docking and molecular dynamics simulation studies.** J. Mol. Liq. 2021; 335:116185Mishra D, Maurya RR, Kumar K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879934>
33. **Virtual screening by targeting proteolytic sites of furin and TMPRSS2 to propose potential compounds obstructing the entry of SARS-CoV-2 virus into human host cells.** J Tradit Complement Med 2021; Vardhan S, Sahoo SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868970>
34. **Electrostatic features for nucleocapsid proteins of SARS-CoV and SARS-CoV-2.** Math Biosci Eng 2021; 18:2372-2383Guo W, Xie Y, A EL-H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892550>
35. **Novel RT-ddPCR assays for measuring the levels of subgenomic and genomic SARS-CoV-2 transcripts.** Methods 2021; Telwatte S, Martin HA, Marczak R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882362>
36. **SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020.** PeerJ 2021; 9:e11210Díaz-Vélez C, Failoc-Rojas VE, Valladares-Garrido MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868828>
37. **Bioinformatic prediction of immunodominant regions in spike protein for early diagnosis of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).** PeerJ 2021; 9:e11232Zhuang S, Tang L, Dai Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889450>

38. **Brazilian essential oils as source for the discovery of new anti-COVID-19 drug: a review guided by in silico study.** Phytochem Rev 2021;1-20Amparo TR, Seibert JB, Silveira BM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867898>
39. **Tackling Covid-19 using disordered-to-order transition of residues in the spike protein upon ACE2 binding.** Proteins 2021; Yesudhas D, Srivastava A, Sekijima M, Gromiha MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893649>
40. **Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry.** SLAS Discov 2021:24725552211008854Scholle MD, Liu C, Deval J, Gurard-Levin ZA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870746>
41. **The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2.** Struct Chem 2021:1-8Saha JK, Raihan MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867777>
42. **Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology.** Top Curr Chem (Cham) 2021; 379:23Zhuo LS, Wang MS, Yang JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886017>
43. **Exploring the utility of extracellular vesicles in ameliorating viral infection-associated inflammation, cytokine storm and tissue damage.** Transl. Oncol. 2021; 14:101095Pillalamarri N, Abdullah, Ren G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887552>
44. **SARS-CoV-2 in animals: potential for unknown reservoir hosts and public health implications.** Vet. Q. 2021:1-31Sharun K, Dhama K, Pawde AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892621>
45. **Detection of SARS-CoV-2 in respiratory samples from cats in the UK associated with human-to-cat transmission.** Vet Rec 2021; 188:e247Hosie MJ, Epifano I, Herder V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890314>

Biomarkers - Genetics (111 articles)

1. **Is Point-of-Care testing feasible and safe in care homes in England? An exploratory usability and accuracy evaluation of a Point-of-Care Polymerase Chain Reaction test for SARS-COV-2.** Age Ageing 2021; Micocci M, Gordon AL, Seo MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884411>
2. **On-admission anemia predicts mortality in COVID-19 patients: A single center, retrospective cohort study.** Am J Emerg Med 2021; 48:140-147Oh SM, Skendelas JP, Macdonald E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895645>
3. **Diagnostic Value of Hematological and Biochemical Parameters Combinations for Predicting Coronavirus Disease 2019 (COVID-19) in Suspected Patients.** Am. J. Med. Sci. 2021; Huang D, Yang H, Yu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894184>
4. **[Rapid SARS-CoV-2 antigenic test: definition, legislation of use, technological principles, analytical and clinical performance comparison].** Ann. Biol. Clin. (Paris) 2021; Lim I, Gautheret-Dejean A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881398>
5. **COVID-19 Nasopharyngeal Swab Causing a Traumatic Cerebrospinal Fluid Leak.** ANZ J Surg 2021; Ovenden C, Bulshara V, Patel S *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33890357>

6. **Absence of Relevant Clinical Effects of SARS-CoV-2 on the Affinity of Hemoglobin for O₂ in Patients with COVID-19.** Arch. Bronconeumol. 2021; Pascual-Guàrdia S, Ferrer A, Díaz Ó *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875283>
7. **Lupus anticoagulant single positivity at acute phase is not associated with venous thromboembolism or in-hospital mortality in COVID-19.** Arthritis Rheumatol 2021; Gendron N, Dragon-Durey MA, Chocron R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881229>
8. **Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes by disease-related blood biomarkers.** Arthritis Rheumatol 2021; Kessel C, Vollenberg R, Masjosthusmann K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880885>
9. **Seroprevalence of SARS-CoV-2 Antibodies Among Health Care Personnel at a Health Care System in Pakistan.** Asia Pac. J. Public Health 2021;10105395211011010Abbas S, Raza A, Iftikhar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880961>
10. **Sensitive quantitative detection of SARS-CoV-2 in clinical samples using digital warm-start CRISPR assay.** Biosens. Bioelectron. 2021; 184:113218Ding X, Yin K, Li Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878591>
11. **ABO blood groups, COVID-19 infection and mortality.** Blood Cells Mol. Dis. 2021; 89:102571Lehrer S, Rheinstein PH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894687>
12. **The characteristics of laboratory tests at admission and the risk factors for adverse clinical outcomes of severe and critical COVID-19 patients.** BMC Infect. Dis. 2021; 21:371Wang L, Cheng X, Dong Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879073>
13. **Epidemiological and virological characteristics of respiratory tract infections in children during COVID-19 outbreak.** BMC Pediatr. 2021; 21:195Zhu Y, Li W, Yang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888063>
14. **Febrile neutropenia due to COVID-19 in an immunocompetent patient.** BMJ Case Rep. 2021; 14Devi YM, Sehrawat A, Panda PK, Nath UK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893137>
15. **COVID-19 and hyperammonemia: Potential interplay between liver and brain dysfunctions.** Brain Behav Immun Health 2021;100257Bobermin LD, Quincozes-Santos A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870235>
16. **Comparative analysis of three point-of-care lateral flow immunoassays for detection of anti-SARS-CoV-2 antibodies: data from 100 healthcare workers in Brazil.** Braz. J. Microbiol. 2021;1-5Conte DD, Carvalho JMA, de Souza Luna LK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871824>
17. **Classical and Counter-regulatory Renin-angiotensin System: potential key roles in COVID-19 pathophysiology.** CJC Open 2021; Almutlaq M, Alamro AA, Alroqi F, Barhoumi T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875979>
18. **Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application.** Clin Immunol 2021; 227:108727Zuo W, Zhao X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887436>

19. **Prevalence of SARS-CoV-2 antibodies among market and city bus depot workers in Lima, Peru.** Clin Infect Dis 2021; Tovar M, Peinado J, Palomino S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881476>
20. **Sample pooling: strain or solution?** Clin Microbiol Infect 2021; Grobe N, Cherif A, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878507>
21. **Laboratory predictors of severe Coronavirus Disease 2019 and lung function in followed-up.** Clin. Respir. J. 2021; Pan M, Wang RR, Chen X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33896114>
22. **High-Resolution CT Chest Findings in Suspected COVID-19 Pneumonia Patients With Negative Real-Time Polymerase Chain Reaction Assay.** Cureus 2021; 13:e14023 Yusuf S, Ahmad H, Zeb R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889463>
23. **Clinical Performance of SARS-CoV-2 IgG and IgM Tests Using an Automated Chemiluminescent Assay.** Curr Med Sci 2021; 41:318-322 Zhou JA, Zeng HL, Deng LY, Li HJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877548>
24. **Are sniffer dogs a reliable approach for diagnosing SARS-CoV-2 infection?** Diagnosis (Berl) 2021; Lippi G, Mattiuzzi C, Henry BM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33873262>
25. **Addressing Pediatric Mental Health during COVID-19 and other Disasters: A National Tabletop Exercise.** Disaster Med Public Health Prep 2021;1-13 Gupta S, Schreiber M, McGuire T, Newton C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867004>
26. **Epigenome-wide association study of COVID-19 severity with respiratory failure.** EBioMedicine 2021;103339 Castro de Moura M, Davalos V, Planas-Serra L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867313>
27. **Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019.** EClinicalMedicine 2021; 34:100829 Ranjeva S, Pinciroli R, Hodell E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875978>
28. **Sensitivity of ID NOW and RT-PCR for detection of SARS-CoV-2 in an ambulatory population.** Elife 2021; 10 Tu YP, Iqbal J, O'Leary T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876726>
29. **Respiratory Viral Shedding in Healthcare Workers Reinfected with SARS-CoV-2, Brazil, 2020.** Emerg Infect Dis 2021; 27 Amorim MR, Souza WM, Barros ACG, Jr. *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871331>
30. **Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses.** Emerg Microbes Infect 2021;1-28 Yang Y, Wang X, Du RH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870851>
31. **Persistent Antiphospholipid Antibodies, Mast Cell Activation Syndrome, Postural Orthostatic Tachycardia Syndrome and Post-COVID Syndrome: 1 Year On.** Eur J Case Rep Intern Med 2021; 8:002378 Schofield JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869099>
32. **COVID-19-Induced Hyperleucocytosis in Chronic Lymphocytic Leukaemia.** Eur J Case Rep Intern Med 2021; 8:002348 Singh B, Ayad S, Kaur P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869094>

33. **SARS-CoV-2 antibodies: comparison of three high-throughput immunoassays versus the neutralization test.** Eur. J. Clin. Invest. 2021:e13573 Laterza R, Schirinzi A, Bruno R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870493>
34. **Transmission of SARS-CoV-2 before and after symptom onset: impact of nonpharmaceutical interventions in China.** Eur. J. Epidemiol. 2021; 36:429-439 Bushman M, Worby C, Chang HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881667>
35. **Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel.** Eur. J. Epidemiol. 2021:1-8 Reicher S, Ratzon R, Ben-Sahar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884542>
36. **The contribution of testing in the fight against COVID-19: Evidence from Italy.** Eur. J. Public Health 2021; De Matteis A, Turkmen Ceylan FB, Adrianopoli M, Ertek S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876825>
37. **Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.** Euro Surveill 2021; 26 Funk T, Pharris A, Spiteri G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890566>
38. **Mutations in the SARS-CoV-2 spike protein modulate the virus affinity to the human ACE2 receptor, an in silico analysis.** Excli j 2021; 20:585-600 Ortega JT, Pujol FH, Jastrzebska B, Rangel HR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883984>
39. **Retrospective observational RT-PCR analyses on 688 babies born to 843 SARS-CoV-2 positive mothers, placental analyses and diagnostic analyses limitations suggest vertical transmission is possible.** Facts Views Vis Obgyn 2021; 13:53-66 Bahadur G, Bhat M, Acharya S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889861>
40. **Vascular Inflammation as a Therapeutic Target in COVID-19 "Long Haulers": HIITing the Spot?** Front Cardiovasc Med 2021; 8:643626 Christensen RH, Berg RMG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869305>
41. **Genetics Insight for COVID-19 Susceptibility and Severity: A Review.** Front. Immunol. 2021; 12:622176 Fricke-Galindo I, Falfán-Valencia R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868239>
42. **The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19.** Front Med (Lausanne) 2021; 8:637647 Rose L, Graham L, Koenecke A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869251>
43. **SARS-CoV-2 Diagnostic Tests: Algorithm and Field Evaluation From the Near Patient Testing to the Automated Diagnostic Platform.** Front Med (Lausanne) 2021; 8:650581 Yin N, Debuysschere C, Decroly M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889587>
44. **First Report on the Latvian SARS-CoV-2 Isolate Genetic Diversity.** Front Med (Lausanne) 2021; 8:626000 Zrelavs N, Ustinova M, Silamikelis I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889583>
45. **Plasma Linoleate Diols Are Potential Biomarkers for Severe COVID-19 Infections.** Front. Physiol. 2021; 12:663869 McReynolds CB, Cortes-Puch I, Ravindran R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868029>

46. **SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients.** Front Plant Sci 2021; 12:589940Makatsa MS, Tincho MB, Wendoh JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868324>
47. **Association of neutrophil-to-lymphocyte and lymphocyte-to-C-reactive protein ratios with COVID-19-related mortality.** Gac Med Mex 2020; 156:553-558Albarrán-Sánchez A, González-Ríos RD, Alberti-Minutti P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877103>
48. **Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index in patients with COVID-19-associated pneumonia.** Gac Med Mex 2020; 156:527-531Carpio-Orantes LD, García-Méndez S, Hernández-Hernández SN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877106>
49. **Mutation rates and selection on synonymous mutations in SARS-CoV-2.** Genome Biol. Evol. 2021; De Maio N, Walker CR, Turakhia Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895815>
50. **Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium.** Genome Med. 2021; 13:66Kasela S, Ortega VE, Martorella M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883027>
51. **Profiling SARS-CoV-2 mutation fingerprints that range from the viral pangenome to individual infection quasispecies.** Genome Med. 2021; 13:62Lau BT, Pavlichin D, Hooker AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875001>
52. **IFN- γ and TNF- α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation.** Genome Med. 2021; 13:64Zhang F, Mears JR, Shakib L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879239>
53. **Strategy for a Risk-stratified Use of Rapid Antigen Testing: Containing the SARS-CoV-2 Pandemic by Integrating Rapid Testing into Case and Contact Tracing Management.** Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany)) 2021; Arnold L, Stratil J.
54. **Commentary: mobile laboratories for SARS-CoV-2 diagnostics: what Europe could learn from the East African Community to assure trade in times of border closures.** Global Health 2021; 17:49Gehre F, Lagu H, Achol E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892773>
55. **Examining spatial inequality in COVID-19 positivity rates across New York City ZIP codes.** Health Place 2021; 69:102574Yang TC, Kim S, Zhao Y, Choi SE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895489>
56. **How Iran responded to expanding need for laboratory services for COVID-19?** Health Policy Technol 2021; 10:100506Salehi-Vaziri M, Arashkia A, Mostafavi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880324>
57. **CRISPR/Cas-New Molecular Scissors in Diagnostics and Therapeutics of COVID-19.** Indian J. Clin. Biochem. 2021:1-9Gadwal A, Roy D, Khokhar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879980>
58. **An Integrated Approach of the Potential Underlying Molecular Mechanistic Paradigms of SARS-CoV-2-Mediated Coagulopathy.** Indian J. Clin. Biochem. 2021:1-17Goyal A, Prasad R, Goel P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875909>

59. **The Role of Procalcitonin in Antibiotic Decision-Making in Covid-19 Infection.** Infect Control Hosp Epidemiol 2021:1-24 Fabre V, Karaba S, Amoah J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33866995>
60. **Virological COVID-19 surveillance in Bavaria, Germany suggests no SARS-CoV-2 spread prior to the first German case in January 2020.** Infection 2021:1-4 Eberle U, Heinzinger S, Konrad R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891281>
61. **Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study.** Infection 2021:1-12 Thibeault C, Mühlemann B, Helbig ET *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890243>
62. **Acute and post-acute phase of COVID-19: Analyzing expression patterns of miRNA-29a-3p, 146a-3p, 155-5p, and let-7b-3p in PBMC.** Int Immunopharmacol 2021; 97:107641 Donyavi T, Bokharaei-Salim F, Baghi HB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895478>
63. **The role of hemogram parameters and CRP in predicting mortality in COVID-19 infection.** Int J Clin Pract 2021:e14256 Acar E, Demir A, Yıldırım B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33887100>
64. **Combined predictive performance of age and neutrophilic percentage on admission for severe novel coronavirus disease 2019.** Int J Clin Pract 2021:e14257 Chen Y, Zhi H, Zhang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884718>
65. **Predictive value of d-dimer/albumin ratio and fibrinogen/albumin ratio for in-hospital mortality in patients with COVID-19.** Int J Clin Pract 2021:e14263 Küçükceran K, Ayranci MK, Girişgin AS, Koçak S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33891337>
66. **First COVID-19 Cases with High Secondary Infection among Health Workers, Sana'a Capital, April 2020: Lessons Learned and Future Opportunities.** Int J Infect Dis 2021; Al-Sakkaf E, Ghaleb Y, Al-Dabis E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895407>
67. **Comparative analysis of antigen and molecular tests for the detection of Sars-CoV-2 and related variants: a study on 4266 samples.** Int J Infect Dis 2021; Caputo V, Bax C, Colantoni L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878460>
68. **Serum Calcium and Vitamin D levels correlation with severity of COVID-19 in hospitalized patients in Royal Hospital, Oman.** Int J Infect Dis 2021; Osman W, Al Fahdi F, Khamis F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892191>
69. **Dramatic Rise of Seroprevalence Rates of SARS-CoV-2 Antibodies among Healthy Blood Donors: The evolution of a Pandemic.** Int J Infect Dis 2021; Sughayer MA, Mansour A, Al Nuirat A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892190>
70. **Laboratory diagnosis of COVID-19: current status and challenges.** Iran J Microbiol 2021; 13:1-7 Mathew BJ, Vyas AK, Khare P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33889356>

71. **Differential alteration trend of white blood cells (WBCs) and monocytes count in severe and non-severe COVID-19 patients within a 7-day follow-up.** Iran J Microbiol 2021; 13:8-16Pirsalehi A, Salari S, Baghestani A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33889357>
72. **Distinct cytokine profiles associated with COVID-19 severity and mortality.** J Allergy Clin Immunol 2021; Dorgham K, Quentric P, Gökkaya M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894209>
73. **Head-to-head validation of six immunoassays for SARS-CoV-2 in hospitalized patients.** J Clin Virol 2021; 139:104821Zonneveld R, Jurriaans S, van Gool T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33882373>
74. **The impact of COVID-19 testing on length of hospital stay and patient flow in hospitals.** J Community Hosp Intern Med Perspect 2021; 11:180-183Olanipekun T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33889316>
75. **Secondary transmission of SARS-CoV-2 through wastewater: Concerns and tactics for treatment to effectively control the pandemic.** J. Environ. Manage. 2021; 290:112668Thakur AK, Sathyamurthy R, Velraj R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895445>
76. **Outcomes of asymptomatic hospital employees in Covid-19-post-exposition quarantine during the 2(nd) pandemic wave in Zurich.** J Hosp Infect 2021; Uçkay I, Steinwender L, Burkhard J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891983>
77. **Real-world SARS CoV-2 Testing in Northern England during the first wave of the COVID-19 Pandemic.** J Infect 2021; Farooq HZ, Davies E, Brown B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33892016>
78. **Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units - a high risk community-hospital interface.** J Infect 2021; Li KK, Woo YM, Stirrup O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895226>
79. **Sensitivity of SARS-CoV-2 RNA polymerase chain reaction using a clinical and radiological reference standard: Clinical sensitivity of SARS-CoV-2 PCR.** J Infect 2021; Stockdale AJ, Fyles F, Farrell C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33892014>
80. **Letter of concern re: "Immunochromatographic test for the detection of SARS-CoV-2 in saliva. J Infect Chemother. 2021 Feb;27(2):384-386. doi: 10.1016/j.jiac.2020.11.016."** J Infect Chemother 2021; Sberna G, Lalle E, Capobianchi MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888419>
81. **ACE2, TMPRSS2 and L-SIGN expression in placentae from HIV-positive pregnancies exposed to antiretroviral therapy-implications for SARS-CoV-2 placental infection.** J Infect Dis 2021; Kala S, Meteleva K, Serghides L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880537>
82. **Excessive matrix metalloproteinase-1 and hyperactivation of endothelial cells occurred in COVID-19 patients and were associated with the severity of COVID-19.** J Infect Dis 2021; Syed F, Li W, Relich RF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33885811>
83. **Introduction, Transmission Dynamics, and Fate of Early SARS-CoV-2 Lineages in Santa Clara County, California.** J Infect Dis 2021; Villarino E, Deng X, Kemper CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893501>

84. **Development of in-house ELISAs for the detection of anti-SARS-CoV-2 RBD and N IgG and IgM antibodies in biological samples.** J King Saud Univ Sci 2021; 33:101439Ibrahim EH, Ghramh HA, Kilany M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879983>
85. **In silico approach for identifying natural lead molecules against SARS-COV-2.** J. Mol. Graph. Model. 2021; 106:107916Gupta SS, Kumar A, Shankar R, Sharma U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892297>
86. **Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19.** J. Neurol. 2021:1-6Geis T, Brandstetter S, Toncheva AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893540>
87. **Treatment of Severe Hypertriglyceridemia With Insulin Infusions in Severe COVID-19: A Case Series.** J. Pharm. Pract. 2021:8971900211010473Thomas CM, Vicent M, Moore S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882724>
88. **Time variation in the probability of failing to detect a case of polymerase chain reaction testing for SARS-CoV-2 as estimated from a viral dynamics model.** J R Soc Interface 2021; 18:20200947Ejima K, Kim KS, Iwanami S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878277>
89. **Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms.** J Transl Autoimmun 2021; 4:100100Wallukat G, Hohberger B, Wenzel K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880442>
90. **Comparison of four PCR and two point of care assays used in the laboratory detection of SARS-CoV-2.** J. Virol. Methods 2021:114165Kenyeres B, Ánosi N, Bányai K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872650>
91. **D-Dimer and Serum ferritin as an Independent Risk Factor for Severity in COVID-19 Patients.** Mater Today Proc 2021; A MH, Taha ZB, Gailan Malek A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868964>
92. **COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions.** mBio 2021; 12Adeniji OS, Giron LB, Purwar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879594>
93. **The role of carbohydrate antigen 125 in COVID-19.** Med. Hypotheses 2021; 151:110590Dökümcü E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33873150>
94. **Novel RT-ddPCR assays for measuring the levels of subgenomic and genomic SARS-CoV-2 transcripts.** Methods 2021; Telwatte S, Martin HA, Marczak R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882362>
95. **Combined RT-qPCR and pyrosequencing of a Spike glycoprotein polybasic cleavage motif can uncover pediatric SARS-CoV-2 infections associated with heterogeneous presentation.** Mol Cell Pediatr 2021; 8:4Weil PP, Hentschel J, Schult F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893880>
96. **Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts.** mSphere 2021; 6Bortz RH, 3rd, Florez C, Laudermlch E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883259>
97. **SARS-CoV-2 Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020.** mSphere 2021; 6Han H, Yi J, Cheng G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883260>

98. **COVID-19 and mutations a threat level assessment.** Nepal J Epidemiol 2021; 11:983-987 Robinson J, Banerjee I, Leclézio A, Sathian B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868743>
99. **Angiotensin-converting enzyme 2 (ACE2): role in the pathogenesis of diseases outside of COVID-19.** Nephrologie 2021; Mülling N, Rohn H.
100. **A nutraceutical strategy for downregulating TGF β signalling: prospects for prevention of fibrotic disorders, including post-COVID-19 pulmonary fibrosis.** Open Heart 2021; 8DiNicolantonio JJ, McCarty MF, Barroso-Aranda J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33879509>
101. **COVID-19 severity in relation to sociodemographics and vitamin D use.** Open Med (Wars) 2021; 16:591-609 Abdulateef DS, Rahman HS, Salih JM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33869781>
102. **Expanding molecular diagnostic capacity for COVID-19 in Ethiopia: operational implications, challenges and lessons learnt.** Pan Afr. Med. J. 2021; 38:68 Kebede A, Lanyero B, Beyene B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889234>
103. **SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020.** PeerJ 2021; 9:e11210 Díaz-Vélez C, Failoc-Rojas VE, Valladares-Garrido MJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868828>
104. **Automated, multiparametric monitoring of respiratory biomarkers and vital signs in clinical and home settings for COVID-19 patients.** Proc Natl Acad Sci U S A 2021; 118 Ni X, Ouyang W, Jeong H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893178>
105. **SARS-CoV-2 serology increases diagnostic accuracy in CT-suspected, PCR-negative COVID-19 patients during pandemic.** Respir Res 2021; 22:119 Schneider J, Mijočević H, Ulm K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892720>
106. **Evaluating the presence of SARS-CoV-2 RNA in the particulate matters during the peak of COVID-19 in Padua, northern Italy.** Sci Total Environ 2021; 784:147129 Pivato A, Amoroso I, Formenton G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894607>
107. **A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex.** SLAS Discov 2021:24725552211008863 Khalili Yazdi A, Li F, Devkota K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874769>
108. **Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry.** SLAS Discov 2021:24725552211008854 Scholle MD, Liu C, Deval J, Gurard-Levin ZA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870746>
109. **A 3-Case Series of Autoimmune Haemolytic Anaemia and COVID-19: Is Plasma Exchange an Alternative?** SN Compr Clin Med 2021:1-4 Ramos-Ruperto L, García-Pérez E, Hernández-Maraver D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870092>
110. **Using Quantitative D-Dimer to Determine the Need for Pulmonary CT Angiography in COVID-19 Patients.** Spartan Med Res J 2021; 6:18652 Mikhjian G, Elghoroury A, Cronovich K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870000>

111. **COVID-19 related callback in blood donors; Outcomes in blood donors and patients.** Transfus. Apher. Sci. 2021;103:129 Balaghali S, Maghsudlu M, Amini-Kafiabad S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879420>

Children (26 articles)

1. **Pediatric Trainees as Parents: Perspectives from a Pandemic.** Acad. Pediatr. 2021; Wilder JL, Hark CM, Marcus CH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872822>
2. **Epidemiological and virological characteristics of respiratory tract infections in children during COVID-19 outbreak.** BMC Pediatr. 2021; 21:195 Zhu Y, Li W, Yang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888063>
3. **Incidence of Kawasaki disease before and during the COVID-19 pandemic: a retrospective cohort study in Japan.** BMJ Paediatr Open 2021; 5:e001034 Iio K, Matsubara K, Miyakoshi C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884312>
4. **Paediatric emergency department dog bite attendance during the COVID-19 pandemic: an audit at a tertiary children's hospital.** BMJ Paediatr Open 2021; 5:e001040 Tulloch JSP, Minford S, Pimblett V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884313>
5. **Impact of COVID-19 on the Children with Cancer in 6 Pediatric Oncology Units (POU's) of Pakistan-a Multi-Center Study.** Cancer Invest. 2021;1-11 Raza MR, Maqsood S, Rana ZA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33866889>
6. **Diabetic Ketoacidosis at Onset of Pediatric Type-1 Diabetes Triggered by Covid-19: An Original Case Report.** Cureus 2021; 13:e13958 Benyakhlef S, Abdellaoui W, Tahri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880293>
7. **Internet-Related Behaviors and Psychological Distress Among Schoolchildren During the COVID-19 School Hiatus.** Cyberpsychol Behav Soc Netw 2021; Chen CY, Chen IH, Pakpour AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877905>
8. **Addressing Pediatric Mental Health during COVID-19 and other Disasters: A National Tabletop Exercise.** Disaster Med Public Health Prep 2021;1-13 Gupta S, Schreiber M, McGuire T, Newton C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867004>
9. **The Impact of COVID-19 Pandemic Lockdown on the Incidence of New-Onset Type 1 Diabetes and Ketoacidosis Among Saudi Children.** Front. Endocrinol. (Lausanne) 2021; 12:669302 Alaqeel A, Aljuraibah F, Alsuhailani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868185>
10. **Influences of digital media use on children and adolescents with ADHD during COVID-19 pandemic.** Global Health 2021; 17:48 Shuai L, He S, Zheng H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874977>
11. **COVID-19 and severe ENT infections in pediatric patients. IS there a relationship?** Int J Pediatr Otorhinolaryngol 2021; 145:110714 Enrique GL, Margarita BB, Ángel MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894522>
12. **Comparing telehealth with office-based visits for common pediatric otolaryngology complaints.** Int J Pediatr Otorhinolaryngol 2021; 145:110712 Kolb

- CM, Born K, Banker K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887549>
13. **Kawasaki disease recurrence in the COVID-19 era: a systematic review of the literature.** Ital. J. Pediatr. 2021; 47:95Medaglia AA, Siracusa L, Gioè C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874991>
 14. **Impact of COVID-19 pandemic and related isolation measures on violence against children in Egypt.** J. Egypt. Public Health Assoc. 2021; 96:11AboKresha SA, Abdelkreem E, Ali RAE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880660>
 15. **Attitude and practices of parents toward their children's oral health care during COVID-19 pandemic.** J. Indian Soc. Pedod. Prev. Dent. 2021; 39:22-28Goswami M, Grewal M, Garg A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33885383>
 16. **"It's ok, mom. I got it!": Exploring the experiences of young adults with intellectual disabilities in a postsecondary program affected by the COVID-19 pandemic from their perspective and their families' perspective.** J Intellect Disabil 2021;17446295211002346Spencer P, Van Haneghan JP, Baxter A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878973>
 17. **Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19.** J. Neurol. 2021;1-6Geis T, Brandstetter S, Toncheva AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893540>
 18. **Clinical characteristics and outcome of hospitalized children and adolescent patients with type 1 diabetes during the COVID-19 pandemic: data from a single center surveillance study in Egypt.** J. Pediatr. Endocrinol. Metab. 2021; Sherif EM, Elhenawy YI, Matter RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882200>
 19. **Multisystem Inflammatory Syndrome in Children (MIS-C) and the Prothrombotic State: Coagulation Profiles and Rotational Thromboelastometry in a MIS-C Cohort.** J Thromb Haemost 2021; Al-Ghafry M, Vagreicha A, Malik M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872443>
 20. **Learning to Interpret Pediatric Vocal Fold Mobility: A Laryngeal Ultrasound Training Module.** Laryngoscope 2021; Alexander NL, Tran B, Zhu H, Ongkasuwan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890677>
 21. **Combined RT-qPCR and pyrosequencing of a Spike glycoprotein polybasic cleavage motif can uncover pediatric SARS-CoV-2 infections associated with heterogeneous presentation.** Mol Cell Pediatr 2021; 8:4Weil PP, Hentschel J, Schult F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893880>
 22. **Acute Fulminant Cerebellitis in Children With COVID-19: A Rare But a Treatable Complication.** Pediatr. Neurol. 2021; 119:45-47Sharma S, Ruparelia J, Bhaskar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894640>
 23. **Online action planning forums to develop a roadmap to mitigate the impact of COVID-19 on the delivery of global children's surgical care.** Pediatr. Surg. Int. 2021;1-13Abbas A, Samad L, Ozgediz D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880597>
 24. **Adolescent psychopathological profiles and the outcome of the COVID-19 pandemic: Longitudinal findings from the UK Millennium Cohort Study.** Prog.

Neuropsychopharmacol. Biol. Psychiatry 2021:110330Essau CA, de la Torre-Luque A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887389>

25. **Home education for children with autism spectrum disorder during the COVID-19 pandemic: Indonesian mothers experience.** Res. Dev. Disabil. 2021; 114:103954Daulay N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882385>
26. **[Predictors of process-related and structuring parental support during distance learning due to Corona-pandemic].** Z Erziehungswiss 2021:1-24Sander A, Schäfer L, van Ophuysen S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=3387591>

Clinical Features (52 articles)

1. **Muscle manifestations and CK levels in COVID infection: results of a large cohort of patients inside a Pandemic COVID-19 Area.** Acta Myol. 2021; 40:1-7De Rosa A, Verrengia EP, Merlo I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870093>
2. **Eight-month follow-up of olfactory and gustatory dysfunctions in recovered COVID-19 patients.** Am. J. Otolaryngol. 2021; 42:103065Biadsee A, Dagan O, Ormianer Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894627>
3. **Olfactory dysfunction in SARS-CoV-2 infection: Focus on odorant specificity and chronic persistence.** Am. J. Otolaryngol. 2021; 42:103014Rebholz H, Pfaffeneder-Mantai F, Knoll W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33873048>
4. **Chemosensory dysfunction in COVID-19: Is there really a correlation with viral load?** Am. J. Otolaryngol. 2021:103037Vaira LA, Lechien JR, De Riu G, Saussez S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875304>
5. **Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.** Ann. Rheum. Dis. 2021; Martelli Júnior H, Marques NP, Marques NCT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883160>
6. **Emerging roles of coronavirus in autoimmune diseases.** Arch Med Res 2021; Zhou SY, Zhang C, Shu WJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875273>
7. **Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent.** Autoimmun Rev 2021:102822Vollmer O, Tacquard C, Dieudonné Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872769>
8. **COVID-19 in Northeast Bosnia and Herzegovina and patient's length of hospitalization.** BMC Infect. Dis. 2021; 21:367Trnacevic A, Mujkanovic A, Al-Salloum N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874896>
9. **Beware of traumatic anosmia in COVID-19 pandemic.** Cjem 2021:1-2Nagamine T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881763>
10. **Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study.** Clin. Neurophysiol. 2021; Frithiof R, Rostami E, Kumlien E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875374>
11. **Ocular Manifestations of Hospitalized COVID-19 Patients in a Tertiary Care Academic Medical Center in the United States: A Cross-Sectional Study.** Clin.

Ophthalmol. 2021; 15:1551-1556Feng Y, Park J, Zhou Y *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880013>

12. **The associations of obsessive-compulsive symptom dimensions and general severity with suicidal ideation in patients with obsessive-compulsive disorder: The role of specific stress responses to COVID-19.** Clin. Psychol. Psychother. 2021; Khosravani V, Samimi Ardestani SM, Bastan FS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33881790>
13. **Clinical Characteristics of the First 100 Patients of COVID-19 in Tobruk, Libya: A Brief Report from Low-Resource Settings.** Disaster Med Public Health Prep 2021:1-10Ismail F, Farag A, Haq S, Kamal MA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33867007>
14. **Olfactory Cleft Opacification in COVID-19 Related Smell Loss: CT Findings and Correlation With Objective Testing.** Ear Nose Throat J 2021:1455613211011285Yıldız E, Balcı A, Selendili O, Kuzu S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33881955>
15. **Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019.** EClinicalMedicine 2021; 34:100829Ranjeva S, Pincirolı R, Hodell E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33875978>
16. **Longitudinal assessment of symptoms and risk of SARS-CoV-2 infection in healthcare workers across 5 hospitals to understand ethnic differences in infection risk.** EClinicalMedicine 2021; 34:100835Valdes AM, Moon JC, Vijay A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880438>
17. **Prevalence of Incidental Gynecomastia by Chest Computed Tomography in Patients with a Prediagnosis of COVID-19 Pneumonia.** Eur J Breast Health 2021; 17:173-179Aslan Ö, Bayraktaroğlu S, Çinkooğlu A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33870118>
18. **Acute Epiglottitis Due to COVID-19 Infection.** Eur J Case Rep Intern Med 2021; 8:002280Emberey J, Velala SS, Marshall B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33869090>
19. **Prevalence and characteristics of persistent symptoms after non-severe COVID-19: a prospective cohort study.** Eur J Clin Microbiol Infect Dis 2021:1-5Armange L, Bénézit F, Picard L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893570>
20. **Spectrum and Clinical Characteristics of Symptomatic and Asymptomatic Coronavirus Disease 2019 (COVID-19) With and Without Pneumonia.** Front Med (Lausanne) 2021; 8:645651Zeng H, Ma Y, Zhou Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33869253>
21. **Deafness after COVID-19? German version.** HNO 2021; Gerstacker K, Speck I, Riemann S *et al.*
22. **Prevalence and Recovery from Newly Onset Anosmia and Ageusia in Covid 19 Patients at our Teritary Care Centre.** Indian J Otolaryngol Head Neck Surg 2021:1-8Kandakure VT, Valvi HR, Khokle P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868972>
23. **Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2**

- pandemic: a prospective observational study.** *Infection* 2021;1-12Thibeault C, Mühlemann B, Helbig ET *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890243>
24. **Assessment of global asymptomatic SARS-CoV-2 infection and management practices from China.** *Int J Biol Sci* 2021; 17:1119-1124Chen Z, Wang B, Mao S, Ye Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867834>
 25. **Clinical, SinoNasal, and Long-Term Smell and Taste Outcomes in Mildly Symptomatic COVID-19 Patients.** *Int J Clin Pract* 2021:e14260Tarifi A, Al Shdaifat AA, Al-Shudifat AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884722>
 26. **Cutaneous manifestations associated with anosmia, ageusia and enteritis in SARS-CoV-2 infection - a possible pattern? Observational study and review of the literature.** *Int J Infect Dis* 2021; Birlutiu V, Feiereisz AI, Oprinca G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887455>
 27. **COVID-19 Toes and Other Skin Lesions During the Pandemic: Emerging Entities?** *Int. J. Low. Extrem. Wounds* 2021:15347346211011843Vas PRJ, Georgiadis GS, Papanas N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891517>
 28. **COVID-19 and severe ENT infections in pediatric patients. IS there a relationship?** *Int J Pediatr Otorhinolaryngol* 2021; 145:110714Enrique GL, Margarita BB, Ángel MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894522>
 29. **Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI).** *Intern Emerg Med* 2021:1-11Corradini E, Ventura P, Ageno W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893976>
 30. **Recurrence of previous chilblain lesions during the second wave of COVID-19: can we still doubt the correlation with SARS-CoV-2?** *J Eur Acad Dermatol Venereol* 2021; Signa S, Sementa AR, Coccia MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871076>
 31. **Outcomes of asymptomatic hospital employees in Covid-19-post-exposition quarantine during the 2(nd) pandemic wave in Zurich.** *J Hosp Infect* 2021; Uçkay I, Steinwender L, Burkhard J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891983>
 32. **High Frequency of Smell and Taste Dysfunction in Health Care Professionals With COVID-19 Working in Allergy Departments.** *J. Investig. Allergol. Clin. Immunol.* 2021; 31:151-161Antolín Amérigo D, Cubero JL, Colás C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876736>
 33. **Newly detected rapid eye movement associated sleep apnea after coronavirus disease 2019 as a possible cause for chronic fatigue: two case reports.** *J Med Case Rep* 2021; 15:211Koczulla AR, Stegemann A, Gloeckl R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888154>
 34. **Hypothyroidism is associated with prolonged COVID-19-induced anosmia: a case-control study.** *J. Neurol. Neurosurg. Psychiatry* 2021; Tsivgoulis G, Fragkou PC, Karofylakis E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879534>
 35. **Clinical characteristics and outcome of hospitalized children and adolescent patients with type 1 diabetes during the COVID-19 pandemic: data from a single center surveillance study in Egypt.** *J. Pediatr. Endocrinol. Metab.* 2021;

Sherif EM, Elhenawy YI, Matter RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882200>

36. **Outcomes of COVID-19 Complications and their Possibilities as Potential Triggers of Stroke.** J. Stroke Cerebrovasc. Dis. 2021; 30:105805 Patel U, Malik P, Mehta D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892314>
37. **An unusual and atypical presentation of the novel coronavirus: A case report and brief review of the literature.** J Taibah Univ Med Sci 2021; Alshoabi SA, Haider KH, Mostafa MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867909>
38. **Epidemiology, clinical characteristics, and virologic features of COVID-19 patients in Kazakhstan: A nation-wide retrospective cohort study.** Lancet Reg Health Eur 2021; 4:100096 Yegorov S, Goremykina M, Ivanova R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880458>
39. **Transient Global Amnesia as a Possible First Manifestation of COVID-19.** Neurohospitalist 2021; 11:84-86 Hussein HM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868565>
40. **Myelopathy associated with SARS-COV-2 infection. A systematic review.** Neurol. Res. 2021;1-9 Artemiadis A, Liampas A, Hadjigeorgiou L, Zis P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870878>
41. **Persistent Symptoms in Patients Recovering From COVID-19 in Denmark.** Open Forum Infect Dis 2021; 8:ofab042 Leth S, Gunst JD, Mathiasen V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875970>
42. **Disparity in clinical characteristics between 2019 novel coronavirus pneumonia and leptospirosis.** Open Med (Wars) 2021; 16:494-497 Li B, Bao C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869775>
43. **Clinical features of hypertensive patients with COVID-19 compared with a normotensive group: Single-center experience in China.** Open Med (Wars) 2021; 16:367-374 Wang S, Zhang Q, Wang P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869774>
44. **Characteristics of patients discontinuing outpatient services under long-term care insurance and its effect on frailty during COVID-19.** PeerJ 2021; 9:e11160 Hirose T, Sawaya Y, Shiba T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868818>
45. **Functional Outcomes and Post-Discharge Care Sought by Patients with COVID-19 Compared to Matched Controls After Completing Inpatient Acute Rehabilitation.** Pm r 2021; Jain E, Harmon EY, Sonagere MB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870659>
46. **Otolaryngology manifestations of COVID-19: a contemporary viewpoint.** Postgrad. Med. J. 2021; Tuang GJ, Abdul Wahab AF, Husain S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879550>
47. **Automated, multiparametric monitoring of respiratory biomarkers and vital signs in clinical and home settings for COVID-19 patients.** Proc Natl Acad Sci U S A 2021; 118 Ni X, Ouyang W, Jeong H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893178>
48. **Can vital signs recorded in patients' homes aid decision making in emergency care? A Scoping Review.** Resusc Plus 2021; 6:100116 Hamza M, Alsma J, Kellett J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870237>

49. **A 3-Case Series of Autoimmune Haemolytic Anaemia and COVID-19: Is Plasma Exchange an Alternative?** SN Compr Clin Med 2021;1-4 Ramos-Ruperto L, García-Pérez E, Hernández-Maraver D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870092>
50. **Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy.** Transpl Infect Dis 2021:e13625 Camargo JF, Mendoza MA, Lin R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33896088>
51. **The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients.** Turk J Med Sci 2021; Karataş A, Malkan Ü Y, Velet M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878857>
52. **Epidemiological and clinical characteristics of 65 hospitalized patients with COVID-19 in Liaoning, China.** World J Clin Cases 2021; 9:2205-2217 Zhang W, Ban Y, Wu YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869596>

CNS (23 articles)

1. **Investigating the effects of the COVID-19 pandemic on the reasons for application to the emergency department in patients with neurological symptoms.** Acta Neurol. Belg. 2021;1-7 Haki C, Kaya H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881754>
2. **Electrodiagnostic findings in patients with non-COVID-19- and COVID-19-related acute respiratory distress syndrome.** Acta Neurol. Scand. 2021; Scarpino M, Bonizzoli M, Lazzeri C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890282>
3. **Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study.** Clin. Neurophysiol. 2021; Frithiof R, Rostami E, Kumlien E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875374>
4. **Early life stress and neural development: Implications for understanding the developmental effects of COVID-19.** Cogn. Affect. Behav. Neurosci. 2021;1-12 Smith KE, Pollak SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891280>
5. **Neurological Manifestations of COVID-19 in Absence of Respiratory Symptoms or Fever.** Cureus 2021; 13:e13887 Mohamed A, Qureshi AS, Mohamed SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868851>
6. **Bell's Palsy as a Late Neurologic Manifestation of COVID-19 Infection.** Cureus 2021; 13:e13881 Oke IO, Oladunjoye OO, Oladunjoye AO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868845>
7. **Excited Catatonia - A Delayed Neuropsychiatric Complication of COVID-19 Infection.** Cureus 2021; 13:e13891 Zain SM, Muthukanagaraj P, Rahman N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880247>
8. **Neurological manifestations of patients with mild-to-moderate COVID-19 attending a public hospital in Lima, Peru.** eNeurologicalSci 2021; 23:100338 Carcamo Garcia MH, Garcia Choza DD, Salazar Linares BJ, Diaz MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875971>
9. **Neuro-COVID frequency and short-term outcome in the northern Portuguese population.** Eur. J. Neurol. 2021; Oliveira V, Seabra M, Rodrigues R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884707>

10. **The Other Side of SARS-CoV-2 Infection: Neurological Sequelae in Patients.** Front. Aging Neurosci. 2021; 13:632673Alonso-Bellido IM, Bachiller S, Vázquez G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889082>
11. **Association of Guillain-Barre syndrome with COVID-19 infection: An updated systematic review.** J. Neuroimmunol. 2021; 355:577577Sheikh AB, Chourasia PK, Javed N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895700>
12. **SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients.** J. Neurol. 2021:1-8Morassi M, Palmerini F, Nici S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884450>
13. **Central nervous system vasculopathy associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a novel case report from Iran.** J. Neurovirol. 2021:1-3Hosseini MJ, Halaji M, Nejad JH, Ranjbar R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876411>
14. **COVID-19 Associated Reversible Cerebral Vasoconstriction Syndrome Successfully Treated with Nimodipine and Aspirin.** J. Stroke Cerebrovasc. Dis. 2021; 30:105822Mansoor T, Alsarrah AA, Mousavi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895426>
15. **Silent hypoxia in COVID-19: pathomechanism and possible management strategy.** Mol. Biol. Rep. 2021:1-7Rahman A, Tabassum T, Araf Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891272>
16. **Parkinson's Disease and Post-COVID-19 Syndrome: The Parkinson's Long-COVID Spectrum.** Mov Disord 2021; Leta V, Rodríguez-Violante M, Abundes A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890344>
17. **Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis.** Mult Scler Relat Disord 2021; 52:102922Bose G, Galetta K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895693>
18. **Alterations of frontal-temporal gray matter volume associate with clinical measures of older adults with COVID-19.** Neurobiol Stress 2021:100326Duan K, Premi E, Pilotto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869679>
19. **Alterations of frontal-temporal gray matter volume associate with clinical measures of older adults with COVID-19.** Neurobiol Stress 2021; 14:100326Duan K, Premi E, Pilotto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869679>
20. **The Neurobiology of Modern Viral Scourges: ZIKV and COVID-19.** Neuroscientist 2021:10738584211009149Mittal S, Federman HG, Sievert D, Gleeson JG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874789>
21. **Uptake of telehealth in Parkinson's disease clinical care and research during the COVID-19 pandemic.** Parkinsonism Relat. Disord. 2021; 86:97-100Shivkumar V, Subramanian T, Agarwal P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895540>
22. **Acute Fulminant Cerebellitis in Children With COVID-19: A Rare But a Treatable Complication.** Pediatr. Neurol. 2021; 119:45-47Sharma S, Ruparelia J, Bhaskar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894640>
23. **Painless Idiopathic Neuralgic Amyotrophy After COVID-19 Vaccination: A Case Report.** Pm r 2021; Diaz-Segarra N, Edmond A, Gilbert C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886164>

Coagulation (24 articles)

1. **An Early Unexpected Immune Thrombotic Thrombocytopenic Purpura Relapse Associated with SARS-CoV-2 Infection: A Case Report and Literature Review.** Acta Haematol. 2021;1-5Kornowski Cohen M, Sheena L, Shafir Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895748>
2. **Systematic Review of Microthrombi in COVID-19 Autopsies.** Acta Haematol. 2021;1-8Parra-Medina R, Herrera S, Mejia J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33873184>
3. **Pulmonary thromboembolism post-COVID convalescent plasma therapy: adding fuel to a smoldering fire!** Adv Respir Med 2021; Marwah V, Choudhary R, Peter D, Bhati G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881163>
4. **Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) Admitted to Hospital: Rationale and Design of the ACTION (AntiCoagulaTion cOroNavirus)-Coalition IV Trial.** Am. Heart J. 2021; Lopes RD, de Barros ESPGM, Furtado RHM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891907>
5. **Lupus anticoagulant single positivity at acute phase is not associated with venous thromboembolism or in-hospital mortality in COVID-19.** Arthritis Rheumatol 2021; Gendron N, Dragon-Durey MA, Chocron R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881229>
6. **Dialysis circuit clotting in critically ill patients with COVID-19 infection.** BMC Nephrol. 2021; 22:141Khoo BZE, Lim RS, See YP, Yeo SC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879086>
7. **Case of right ventricular and aortic thrombi in a patient with severe COVID-19.** BMJ Case Rep. 2021; 14Afari H, Tefera L, Rosovsky RP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875503>
8. **Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.** Clin. Appl. Thromb. Hemost. 2021; 27:10760296211008999Moonla C, Sosothikul D, Chiasakul T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874753>
9. **SARS-CoV-2 proteins regulate inflammatory, thrombotic and diabetic responses in human arterial fibroblasts.** Clin Immunol 2021; 227:108733Freda CT, Yin W, Ghebrehwet B, Rubenstein DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895357>
10. **Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units.** Crit Care 2021; 25:155Lavinio A, Ercole A, Battaglini D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888132>
11. **Submassive Pulmonary Embolism in Mild COVID-19 Without Lung Infiltrates.** Cureus 2021; 13:e13978Manek G, Gupta M, Congrete S, Datta D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880305>
12. **An Unusual Case of Gastrointestinal Bleeding in a Patient With COVID-19.** Cureus 2021; 13:e13901Sanku K, Siddiqui AH, Paul V, Ali M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880257>

13. **Prevalence of proximal deep vein thrombosis in hospitalized COVID-19 patients.** Eur J Intern Med 2021; Reichert G, Bunel V, Dreyfuss D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33875336>
14. **Rationales and uncertainties for aspirin use in COVID-19: a narrative review.** Fam Med Community Health 2021; 9Sayed Ahmed HA, Merrell E, Ismail M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33879541>
15. **An Integrated Approach of the Potential Underlying Molecular Mechanistic Paradigms of SARS-CoV-2-Mediated Coagulopathy.** Indian J. Clin. Biochem. 2021;1-17Goyal A, Prasad R, Goel P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875909>
16. **Thromboembolic Disease in COVID-19.** J. Clin. Imaging Sci. 2021; 11:16Tarmey T, Cullen G, Patel TY, Tandon YK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880241>
17. **The use of direct acting oral anticoagulants in patients with COVID-19 infection.** J Community Hosp Intern Med Perspect 2021; 11:184-186Aly R, Gupta S, Singh B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889317>
18. **Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).** J Thromb Haemost 2021; Thaler J, Ay C, Gleixner KV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877735>
19. **Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid.** J. Thromb. Thrombolysis 2021;1-8Paredes-Ruiz D, Gómez-Cuervo C, Gómez-Martín C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33890200>
20. **Microvascular thrombosis and clinical implications.** Med Clin (Barc) 2021; Páramo JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875227>
21. **Fatal Retroperitoneal Hematoma Associated with Covid-19 Prophylactic Anticoagulation Protocol.** Radiol Case Rep 2021; Teta M, Drabkin MJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880136>
22. **An evaluation of venous thromboembolism by whole-body enhanced CT scan for critical COVID-19 pneumonia with markedly rises of coagulopathy related factors: a case series study.** Thromb J 2021; 19:26Ogawa F, Oi Y, Nakajima K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879177>
23. **Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy.** Thromb Res 2021; 203:1-4Rhoades R, Leong R, Kopenitz J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894473>
24. **COVID-19 and thrombotic microangiopathies.** Thromb Res 2021; 202:191-198Tiwari NR, Phatak S, Sharma VR, Agarwal SK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894421>

Complications (58 articles)

1. **Development of a Prone Team and Exploration of Staff Perceptions During COVID-19.** AACN Adv. Crit. Care 2021:e1-e10Miguel K, Snyderman C, Capasso V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878151>

2. **An Early Unexpected Immune Thrombotic Thrombocytopenic Purpura Relapse Associated with SARS-CoV-2 Infection: A Case Report and Literature Review.** Acta Haematol. 2021;1-5Kornowski Cohen M, Sheena L, Shafir Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895748>
3. **Pulmonary thromboembolism post-COVID convalescent plasma therapy: adding fuel to a smoldering fire!** Adv Respir Med 2021; Marwah V, Choudhary R, Peter D, Bhati G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881163>
4. **Acute hypoxemia due to lung collapse in COVID-19: the role of therapeutic bronchoscopy.** Adv Respir Med 2021; Pb S, Madan K, Mohan A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33881156>
5. **Priority Setting of Ventilators in the COVID-19 Pandemic from the Public's Perspective.** AJOB Empir Bioeth 2021:1-13Asghari F, Parsapour A, Shamsi Gooshki E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881385>
6. **Incidence and Risk Factors for Secondary Pulmonary Infections in Patients Hospitalized with Coronavirus Disease 2019 Pneumonia.** Am. J. Med. Sci. 2021; Chong WH, Chieng H, Tiwari A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894182>
7. **Comparative outcomes between COVID-19 and influenza patients placed on veno-venous extracorporeal membrane oxygenation for severe ARDS.** Am. J. Surg. 2021; Raff LA, Reid TD, Johnson D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894980>
8. **Approach to Sedation and Analgesia in COVID-19 Patients on Venovenous Extracorporeal Membrane Oxygenation.** Ann. Pharmacother. 2021;10600280211010751Dreucean D, Harris JE, Voore P, Donahue KR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33882694>
9. **Functional electrical stimulation-cycling favours erectus position restoration and walking in patients with critical COVID-19. A proof-of-concept controlled study.** Ann. Phys. Rehabil. Med. 2021; Mateo S, Bergeron V, Cheminon M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895378>
10. **COVID-19 Nasopharyngeal Swab Causing a Traumatic Cerebrospinal Fluid Leak.** ANZ J Surg 2021; Ovenden C, Bulshara V, Patel S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33890357>
11. **Lupus anticoagulant single positivity at acute phase is not associated with venous thromboembolism or in-hospital mortality in COVID-19.** Arthritis Rheumatol 2021; Gendron N, Dragon-Durey MA, Chocron R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33881229>
12. **Dialysis circuit clotting in critically ill patients with COVID-19 infection.** BMC Nephrol. 2021; 22:141Khoo BZE, Lim RS, See YP, Yeo SC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33879086>
13. **Case of right ventricular and aortic thrombi in a patient with severe COVID-19.** BMJ Case Rep. 2021; 14Afari H, Tefera L, Rosovsky RP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33875503>
14. **Febrile neutropenia due to COVID-19 in an immunocompetent patient.** BMJ Case Rep. 2021; 14Devi YM, Sehrawat A, Panda PK, Nath UK.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33893137>

15. **Pneumatosis intestinalis and intestinal perforation in a case of multisystem inflammatory syndrome in children.** BMJ Case Rep. 2021; 14:Heza L, Olive A, Miller J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888480>
16. **Life-threatening DRESS syndrome with kidney damage following severe COVID-19 in a patient with Down syndrome.** BMJ Case Rep. 2021; 14:Mata L, Torres-Zevallos H, Guerreros AG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875507>
17. **Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1.** BMJ Case Rep. 2021; 14:Patel SU, Khurram R, Lakhani A, Quirk B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888484>
18. **Pneumatocele after recovering from COVID-19.** BMJ Case Rep. 2021; 14:Sugimoto H, Era Y, Sugimoto K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875514>
19. **Severe metabolic ketoacidosis as a primary manifestation of SARS-CoV-2 infection in non-diabetic pregnancy.** BMJ Case Rep. 2021; 14:van Amesfoort JE, Werter DE, Painter RC, Hermans FJR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875510>
20. **Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.** Clin. Appl. Thromb. Hemost. 2021; 27:10760296211008999Moonla C, Sosothikul D, Chiasakul T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874753>
21. **The Clinical Outcomes of COVID-19 infection in Patients with a History of Thyroid Cancer: A Nationwide Study.** Clin. Endocrinol. (Oxf.) 2021; Sahin M, Haymana C, Demirci I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872399>
22. **The impact of frailty on survival in elderly intensive care patients with COVID-19: the COVIP study.** Crit Care 2021; 25:149Jung C, Flaatten H, Fjølner J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874987>
23. **Ventilator-associated pneumonia in the era of COVID-19 pandemic: How common and what is the impact?** Crit Care 2021; 25:153Wicky PH, Niedermann MS, Timsit JF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882991>
24. **A Case of Isolated SARS-CoV-2 Fulminant Myopericarditis Without Respiratory Failure.** Cureus 2021; 13:e14003Afriyie F, Fohle E, Dekowski SS, Kumar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884244>
25. **Diabetic Ketoacidosis at Onset of Pediatric Type-1 Diabetes Triggered by Covid-19: An Original Case Report.** Cureus 2021; 13:e13958Benyakhlef S, Abdellaoui W, Tahri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880293>
26. **Newly Diagnosed Acute Myeloid Leukemia in a Patient With Severe SARS-CoV-2 Infection.** Cureus 2021; 13:e14480Papamichalis P, Tsinti G, Papapostolou E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880315>
27. **Clostridium Difficile and Noncirrhotic Hyperammonnemia in a Patient With COVID-19 Infection.** Cureus 2021; 13:e14533Ramalingam S, Gunasekaran K, Arora H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880318>
28. **Calculating outcome predictors of COVID-19 requires inclusion of multiple determinants.** Disaster Med Public Health Prep 2021; 1-4Finsterer J, Scorza FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888177>

29. **Outcomes of acute respiratory distress syndrome in COVID-19 patients compared to the general population: A systematic review and meta-analysis.** Expert Rev. Respir. Med. 2021; Dmytriw AA, Chibbar R, Chen PPY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882768>
30. **The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya.** E1000Res 2021; 10:113Asmarawati TP, Rosyid AN, Suryantoro SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868645>
31. **Construction and Performance Testing of a Fast-Assembly COVID-19 (FALCON) Emergency Ventilator in a Model of Normal and Low-Pulmonary Compliance Conditions.** Front. Physiol. 2021; 12:642353White LA, Mackay RP, Solitro GF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868006>
32. **Case Study use of high-flow nasal cannula in COVID-19 has improved effectiveness, safety and tolerability when applied in lateral position compared with prone positioning.** Intensive Crit Care Nurs 2021:103061Sanz-Moncusí M, Rosselló-Sancho J, Garcia-Alamino JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875340>
33. **SIADH and severe COVID-19 pneumonia in elderly patients: a therapeutic challenge in developing countries.** Intern Emerg Med 2021:1-3Concepción Zavaleta MJ, Ildefonso Najarro SP, Moreno Marreros DM, Concepción Urteaga LA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893977>
34. **Thromboembolic Disease in COVID-19.** J. Clin. Imaging Sci. 2021; 11:16Tarmey T, Cullen G, Patel TY, Tandon YK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880241>
35. **SARS-CoV-2 and Burkholderia cenocepacia infection in a patient with Cystic Fibrosis: An unfavourable conjunction?** J Cyst Fibros 2021; Olcese C, Casciaro R, Pirlo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883098>
36. **Quantitative fit testing of filtering face-piece respirators during the COVID-19 pandemic reveals anthropometric deficits in most respirators available in Iran.** J Environ Health Sci Eng 2021:1-13Fakherpour A, Jahangiri M, Seif M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875931>
37. **Covid-19-triggered sarcoidal granulomas mimicking scar sarcoidosis.** J Eur Acad Dermatol Venereol 2021; Polat Ekinci A, Büyükbabani N, Meşe S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871106>
38. **The Incidence, Diagnosis, and Outcomes of COVID-19-associated Pulmonary Aspergillosis (CAPA): A Systematic Review.** J Hosp Infect 2021; Chong WH, Neu KP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891985>
39. **A fatal case of COVID-19-associated invasive pulmonary aspergillosis.** J Infect Chemother 2021; Iwanaga Y, Kawanami T, Yamasaki K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867266>
40. **The Pulsatile Modification Improves Hemodynamics and Attenuates Inflammatory Responses in Extracorporeal Membrane Oxygenation.** J Inflamm Res 2021; 14:1357-1364Li G, Zeng J, Liu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880051>
41. **Neurosensory dysphagia in a COVID-19 patient.** J. Neurol. 2021:1-3Zanon A, Cacciaguerra L, Martelli G, Filippi M. <http://www.ncbi.nlm.nih.gov/pubmed/>

term=33876325

42. **Unexpected worsening of progressive multifocal leucoencephalopathy following COVID-19 pneumonia.** J. Neurovirol. 2021;1-4Borrelli S, Dachy B, Gazagnes MD, Du Pasquier R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876412>
43. **Multisystem Inflammatory Syndrome in Children (MIS-C) and the Prothrombotic State: Coagulation Profiles and Rotational Thromboelastometry in a MIS-C Cohort.** J Thromb Haemost 2021; Al-Ghafry M, Vagreich A, Malik M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872443>
44. **Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).** J Thromb Haemost 2021; Thaler J, Ay C, Gleixner KV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877735>
45. **Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid.** J. Thromb. Thrombolysis 2021;1-8Paredes-Ruiz D, Gómez-Cuervo C, Gómez-Martín C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890200>
46. **Underlying conditions and risk of hospitalisation, ICU admission and mortality among those with COVID-19 in Ireland: A national surveillance study.** Lancet Reg Health Eur 2021; 5:100097Bennett KE, Mullooly M, O'Loughlin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880459>
47. **Silent hypoxia in COVID-19: pathomechanism and possible management strategy.** Mol. Biol. Rep. 2021;1-7Rahman A, Tabassum T, Araf Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891272>
48. **Incidence and Mortality of COVID-19-associated Pulmonary Aspergillosis: A Systematic Review and Meta-analysis.** Mycoses 2021; Mitaka H, Kuno T, Takagi H, Patrawalla P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33896063>
49. **A Case of Severe Acute Respiratory Syndrome Coronavirus 2 Treatment With Remdesivir in a Hepatitis C-Coinfected Patient Resulting in Temporary Viral Control and Posttreatment Flare.** Open Forum Infect Dis 2021; 8:ofab100da Cunha MR, Rodrigues IC, Trigueiros F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880393>
50. **Co-infection of hepatitis E virus and Plasmodium falciparum malaria: A genuine risk in sub-Saharan Africa.** Parasit Vectors 2021; 14:215Sahra S, Jahangir A, Iqbal QZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879247>
51. **The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan)** 2021; 13:5Feldman C, Anderson R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894790>
52. **Pholcodine-induced Stevens-Johnson syndrome in a patient with COVID-19.** Postgrad. Med. J. 2021; Bulat V, Likic R, Pondelj N, Azdajic MD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879549>
53. **Hypothesis: AA amyloidosis is a factor causing systemic complications after coronavirus disease.** Prion 2021; 15:53-55Galkin AP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876719>
54. **Fatal Retroperitoneal Hematoma Associated with Covid-19 Prophylactic Anticoagulation Protocol.** Radiol Case Rep 2021; Teta M, Drabkin MJ.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880136>

55. **An evaluation of venous thromboembolism by whole-body enhanced CT scan for critical COVID-19 pneumonia with markedly rises of coagulopathy related factors: a case series study.** *Thromb J* 2021; 19:26Ogawa F, Oi Y, Nakajima K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879177>
56. **Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy.** *Thromb Res* 2021; 203:1-4Rhoades R, Leong R, Kopenitz J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894473>
57. **COVID-19 and thrombotic microangiopathies.** *Thromb Res* 2021; 202:191-198Tiwari NR, Phatak S, Sharma VR, Agarwal SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894421>
58. **The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients.** *Turk J Med Sci* 2021; Karataş A, Malkan Ü Y, Velet M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878857>

Cured – Recovered (17 articles)

1. **Eight-month follow-up of olfactory and gustatory dysfunctions in recovered COVID-19 patients.** *Am. J. Otolaryngol.* 2021; 42:103065Biadsee A, Dagan O, Ormianer Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894627>
2. **Incidence of COVID-19 recurrence among large cohort of healthcare employees.** *Ann. Epidemiol.* 2021; Veronica F, Anne R, Christopher B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895245>
3. **Study protocol medical rehabilitation after COVID-19 disease: an observational study with a comparison group with obstructive airway disease / Re_Co.** *BMC Health Serv. Res.* 2021; 21:373Rutsch M, Frommhold J, Buhr-Schinner H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888104>
4. **'Long COVID' syndrome.** *BMJ Case Rep.* 2021; 14Taribagil P, Creer D, Tahir H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875508>
5. **Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory Testing.** *Clin Infect Dis* 2021; Qureshi AI, Baskett WI, Huang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895814>
6. **Severe Acute Respiratory Syndrome Coronavirus 2 P.2 Lineage Associated with Reinfection Case, Brazil, June-October 2020.** *Emerg Infect Dis* 2021; 27Resende PC, Bezerra JF, Teixeira Vasconcelos RH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883059>
7. **Persistent Antiphospholipid Antibodies, Mast Cell Activation Syndrome, Postural Orthostatic Tachycardia Syndrome and Post-COVID Syndrome: 1 Year On.** *Eur J Case Rep Intern Med* 2021; 8:002378Schofield JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869099>
8. **COVID-19: Is reinfection possible?** *Excli j.* 2021; 20:522-536Costa AOC, de Carvalho Aragão Neto H, Lopes Nunes AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883981>
9. **Vascular Inflammation as a Therapeutic Target in COVID-19 "Long Haulers": HIITing the Spot?** *Front Cardiovasc Med* 2021; 8:643626Christensen RH, Berg

RMG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869305>

10. **Recovery From Coronavirus Disease 2019 Among Older Adults in Post-acute Skilled Nursing Facilities.** J. Am. Med. Dir. Assoc. 2021; Shi S, Lo OY, Newmeyer N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894176>
11. **New-onset Diabetes in "Long COVID".** J. Diabetes 2021; Sathish T, Anton MC, Sivakumar T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893710>
12. **A Multidisciplinary NHS COVID-19 Service to Manage Post-COVID-19 Syndrome in the Community.** J. Prim. Care Community Health 2021; 12:21501327211010994Parkin A, Davison J, Tarrant R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880955>
13. **Speech-Language Pathologists' Role in the Multi-Disciplinary Management and Rehabilitation of Patients with Covid-19.** J Rehabil Med Clin Commun 2020; 3:1000037Mohapatra B, Mohan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884139>
14. **Parkinson's Disease and Post-COVID-19 Syndrome: The Parkinson's Long-COVID Spectrum.** Mov Disord 2021; Leta V, Rodríguez-Violante M, Abundes A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890344>
15. **Persistent Symptoms in Patients Recovering From COVID-19 in Denmark.** Open Forum Infect Dis 2021; 8:ofab042Leth S, Gunst JD, Mathiasen V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875970>
16. **[Post-COVID syndrome: A reflection and opinion paper].** Rev. Esp. Quimioter. 2021; Bouza E, Cantón Moreno R, De Lucas Ramos P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878844>
17. **Post COVID-19 MSSA pneumonia.** SAGE Open Med Case Rep 2021; 9:2050313x211005996Chaudhry B, Alekseyev K, Didenko L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889412>

Cardiovascular disease (44 articles)

1. **Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.** Aging (Albany NY) 2021; 13Ma Z, Wang MP, Liu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886504>
2. **Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) Admitted to Hospital: Rationale and Design of the ACTION (AntiCoagulaTion cOroNavirus)-Coalition IV Trial.** Am. Heart J. 2021; Lopes RD, de Barros ESPGM, Furtado RHM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891907>
3. **The effect of cardiovascular disease and acute cardiac injury on fatal COVID-19: a meta-analysis.** Am J Emerg Med 2021; 48:128-139Long J, Luo Y, Wei Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895644>
4. **An international perspective of out-of-hospital cardiac arrest and cardiopulmonary resuscitation during the COVID-19 pandemic.** Am J Emerg Med 2021; 47:192-197Ong J, O'Connell F, Mazer-Amirshahi M, Pourmand A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894661>
5. **Cardiac Complications and Pertaining Mortality Rate in COVID-19 Patients; a Systematic Review and Meta-Analysis.** Arch Acad Emerg Med 2021; 9:e18Toloui

- A, Moshrefiaraghi D, Madani Neishaboori A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33870205>
6. **Emergency department admissions for myocardial infarction and stroke in France during the first wave of the COVID-19 pandemic: National temporal trends and regional disparities.** Arch Cardiovasc Dis 2021; Olié V, Carcaillon-Bentata L, Thiam MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893038>
 7. **Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19.** Atherosclerosis 2021; Scoccia A, Gallone G, Cereda A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883086>
 8. **Case of right ventricular and aortic thrombi in a patient with severe COVID-19.** BMJ Case Rep. 2021; 14Afari H, Tefera L, Rosovsky RP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875503>
 9. **Cardiorenal syndrome in COVID-19.** BMJ Case Rep. 2021; 14Ali UA, Sadiq MS, Yunus MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893131>
 10. **How has technology been used to deliver cardiac rehabilitation during the COVID-19 pandemic? An international cross-sectional survey of healthcare professionals conducted by the BACPR.** BMJ Open 2021; 11:e046051O'Doherty AF, Humphreys H, Dawkes S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879492>
 11. **Incidence of Kawasaki disease before and during the COVID-19 pandemic: a retrospective cohort study in Japan.** BMJ Paediatr Open 2021; 5:e001034Iio K, Matsubara K, Miyakoshi C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884312>
 12. **Classical and Counter-regulatory Renin-angiotensin System: potential key roles in COVID-19 pathophysiology.** CJC Open 2021; Almutlaq M, Alamro AA, Alroqi F, Barhoumi T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875979>
 13. **Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.** Clin. Appl. Thromb. Hemost. 2021; 27:10760296211008999Moonla C, Sosothikul D, Chiasakul T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874753>
 14. **Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?** Clin Sci (Lond) 2021; 135:1009-1014Simko F, Baka T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881142>
 15. **A Case of Isolated SARS-CoV-2 Fulminant Myopericarditis Without Respiratory Failure.** Cureus 2021; 13:e14003Afriyie F, Fohle E, Dekowski SS, Kumar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884244>
 16. **Submassive Pulmonary Embolism in Mild COVID-19 Without Lung Infiltrates.** Cureus 2021; 13:e13978Manek G, Gupta M, Congrete S, Datta D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880305>
 17. **Cardiovascular Complications in Major 21st Century Viral Epidemics and Pandemics: an Insight into COVID-19.** Curr. Cardiol. Rev. 2021; Hussain M, Collier P, Moudgil R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874873>
 18. **Myocardial Involvement in COVID-19: an Interaction Between Comorbidities and Heart Failure with Preserved Ejection Fraction. A Further Indication of the**

- Role of Inflammation.** Curr. Heart Fail. Rep. 2021;1-8Zaccone G, Tomasoni D, Italia L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890193>
19. **Marantic Endocarditis Associated with COVID-19: A Rare Case Report of a Potentially Deadly Disease.** Eur J Case Rep Intern Med 2021; 8:002409Chan KH, Joseph O, Ahmed E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869101>
 20. **Chronic use of Renin-Angiotensin-Aldosterone-System blockers and mortality in COVID-19: a multicenter prospective cohort and literature review.** Fundam. Clin. Pharmacol. 2021; Gault N, Esposito-Farese M, Revest M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876439>
 21. **Characteristics of the 24-hour ambulatory blood pressure monitoring in a COVID-19 survivor.** Future Cardiol 2021; Wasim D, Alme B, Jordal S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876965>
 22. **Early Detection and Successful Management of Acute Mesenteric Ischaemia in Symptomatic COVID-19 Patient.** Indian J Surg 2021;1-3Balani P, Bhuiyan AS, Dalal VN, Maheshwari GS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867749>
 23. **Kawasaki disease recurrence in the COVID-19 era: a systematic review of the literature.** Ital. J. Pediatr. 2021; 47:95Medaglia AA, Siracusa L, Gioè C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874991>
 24. **Initial Findings From the North American COVID-19 Myocardial Infarction Registry.** J Am Coll Cardiol 2021; 77:1994-2003Garcia S, Dehghani P, Grines C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888249>
 25. **The Clinical Challenge of ST-Segment Elevation Myocardial Infarction and COVID-19.** J Am Coll Cardiol 2021; 77:2004-2006Kornowski R, Orvin K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888250>
 26. **Left ventricular free wall rupture as a result of delayed presentation of an inferior ST-elevation myocardial infarction due to fear of COVID-19: case report.** J. Cardiothorac. Surg. 2021; 16:106Nasr GH, Glovaci D, Mikhail A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888133>
 27. **Outcomes and Risk Factors for Cardiovascular Events in Hospitalized COVID-19 Patients.** J Cardiothorac Vasc Anesth 2021; Xu Q, Samanapally H, Nathala P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867235>
 28. **Letter regarding 'Neurointervention for emergent large vessel occlusion strokes during the COVID-19 pandemic'.** J. Neurointerv. Surg. 2021; Hamidianjahromi A, Mowla A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875553>
 29. **Central nervous system vasculopathy associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a novel case report from Iran.** J. Neurovirol. 2021;1-3Hosseini MJ, Halaji M, Nejad JH, Ranjbar R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876411>
 30. **Characteristics and outcomes of COVID-19-Positive Individuals Admitted for Inpatient Rehabilitation in Toronto, Canada.** J Rehabil Med Clin Commun 2021; 4:1000053Journey WS, Robinson LR, Titman R, Macdonald SL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884155>
 31. **COVID-19 Associated Reversible Cerebral Vasoconstriction Syndrome Successfully Treated with Nimodipine and Aspirin.** J. Stroke Cerebrovasc. Dis. 2021; 30:105822Mansoor T, Alsarrah AA, Mousavi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895426>

32. **Outcomes of COVID-19 Complications and their Possibilities as Potential Triggers of Stroke.** J. Stroke Cerebrovasc. Dis. 2021; 30:105805 Patel U, Malik P, Mehta D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892314>
33. **Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid.** J. Thromb. Thrombolysis 2021;1-8 Paredes-Ruiz D, Gómez-Cuervo C, Gómez-Martín C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890200>
34. **Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms.** J Transl Autoimmun 2021; 4:100100 Wallukat G, Hohberger B, Wenzel K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880442>
35. **Coronary artery bypass graft surgery outcomes in the United States: Impact of the coronavirus disease 2019 (COVID-19) pandemic.** JTCVS Open 2021; Parcha V, Kalra R, Glenn AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870234>
36. **Microvascular thrombosis and clinical implications.** Med Clin (Barc) 2021; Páramo JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875227>
37. **Angiotensin-converting enzyme 2 (ACE2): role in the pathogenesis of diseases outside of COVID-19.** Nephrologie 2021; Mülling N, Rohn H.
38. **Risk stratification of adults with congenital heart disease during the COVID-19 pandemic: insights from a multinational survey among European experts.** Open Heart 2021; 8 Rupert-Repilado FJ, Tobler D, Greutmann M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883228>
39. **Clinical features of hypertensive patients with COVID-19 compared with a normotensive group: Single-center experience in China.** Open Med (Wars) 2021; 16:367-374 Wang S, Zhang Q, Wang P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869774>
40. **Arrhythmias and Electrocardiographic findings in Coronavirus disease 2019: a systematic review and meta-analysis.** Pacing Clin. Electrophysiol. 2021; Garcia-Zamora S, Lee S, Haseeb S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890684>
41. **Knowledge levels, attitudes, and perceptions of individuals with different demographic characteristics on COVID-19: The case of Turkey.** Perspect. Psychiatr. Care 2021; Ates E, Ok E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884642>
42. **Ambient air pollution and cardiovascular disease: learnt from the COVID-19 pandemic.** Postgrad. Med. 2021; Ejaz A, Malik AO, Lopez-Candales A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888043>
43. **The impact of the COVID-19 pandemic on acute coronary syndrome admissions to a tertiary care hospital in Portugal.** Rev. Port. Cardiol. 2021; Calvão J, Amador AF, Costa CMD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892971>
44. **COVID-19 and thrombotic microangiopathies.** Thromb Res 2021; 202:191-198 Tiwari NR, Phatak S, Sharma VR, Agarwal SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894421>

Diagnosis (6 articles)

1. **Missed diagnosis in the COVID-19 era: Are we losing ourselves?** Adv Respir Med 2021; M A, Mohan A, Madan K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881164>
2. **Mortality attributable to COVID-19 in nursing home residents: a retrospective study.** Aging Clin. Exp. Res. 2021;1-7Veronese N, Koyanagi A, Stangherlin V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893989>
3. **Diagnostic Value of Hematological and Biochemical Parameters Combinations for Predicting Coronavirus Disease 2019 (COVID-19) in Suspected Patients.** Am. J. Med. Sci. 2021; Huang D, Yang H, Yu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894184>
4. **End-to-End AI-Based Point-of-Care Diagnosis System for Classifying Respiratory Illnesses and Early Detection of COVID-19: A Theoretical Framework.** Front Med (Lausanne) 2021; 8:585578Belkacem AN, Ouhbi S, Lakas A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869239>
5. **The Diagnostic Yield of the Multidisciplinary Discussion in Patients With COVID-19 Pneumonia.** Front Med (Lausanne) 2021; 8:637872Calabrese F, Pezzuto F, Giraudo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869252>
6. **Central nervous system vasculopathy associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a novel case report from Iran.** J. Neurovirol. 2021;1-3Hosseini MJ, Halaji M, Nejad JH, Ranjbar R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876411>

DM-MS-Obesity (13 articles)

1. **[Obesity and COVID-19: Present and Future].** Acta Med Port 2021; Gregório MJ, Santos A, Graça P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877962>
2. **SARS-CoV-2 proteins regulate inflammatory, thrombotic and diabetic responses in human arterial fibroblasts.** Clin Immunol 2021; 227:108733Freda CT, Yin W, Ghebrehwet B, Rubenstein DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895357>
3. **A Retrospective Study Assessing the Effect of Diabetes on Mortality in Patients With COVID-19 at a Teaching Hospital in the United Kingdom.** Cureus 2021; 13:e13902Ahmed FW, Kirresh OZ, Robinson AV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880258>
4. **Diabetic Ketoacidosis at Onset of Pediatric Type-1 Diabetes Triggered by Covid-19: An Original Case Report.** Cureus 2021; 13:e13958Benyakhlef S, Abdellaoui W, Tahri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880293>
5. **COVID-19 may increase the risk of insulin resistance in adult patients without diabetes: A 6-month prospective study.** Endocr. Pract. 2021; Chen M, Zhu B, Chen D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887468>
6. **The complex combination of COVID-19 and diabetes: pleiotropic changes in glucose metabolism.** Endocrine 2021;1-9Mahrooz A, Muscogiuri G, Buzzetti R, Maddaloni E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886062>
7. **The Impact of COVID-19 Pandemic Lockdown on the Incidence of New-Onset Type 1 Diabetes and Ketoacidosis Among Saudi Children.** Front. Endocrinol.

- ([Lausanne](#))_2021; 12:669302Alaqeel A, Aljuraibah F, Alsuhaibani M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868185>
8. **Type 2 Diabetes Mellitus and COVID-19: A Narrative Review.** [Front. Endocrinol.](#) ([Lausanne](#))_2021; 12:609470Corrao S, Pinelli K, Vacca M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868163>
 9. **New-onset Diabetes in "Long COVID".** [J. Diabetes](#) 2021; Sathish T, Anton MC, Sivakumar T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893710>
 10. **Treatment of Severe Hypertriglyceridemia With Insulin Infusions in Severe COVID-19: A Case Series.** [J. Pharm. Pract.](#) 2021:8971900211010473Thomas CM, Vicent M, Moore S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882724>
 11. **Does higher Body Mass Index increase COVID-19 severity?: a systematic review and meta-analysis.** [Obes Med](#) 2021:100340Chowdhury AI, Alam MR, Rabbi MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875972>
 12. **Outpatient Clinic in Obesity Care During COVID-19 Outbreak: Physically Far, Virtually Near. Brief Correspondence on a Single Center Experience: Cohort Study.** [Obes. Surg.](#) 2021:1-5Pizza F, D'Antonio D, Dell'Isola C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33877505>
 13. **Alphabet strategy for diabetes care: A checklist approach in the time of COVID-19 and beyond.** [World J. Diabetes](#) 2021; 12:407-419Upreti R, Lee JD, Kotecha S, Patel V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889287>

Education and training and science (69 articles)

1. **Using Dynamic Virtual Microscopy to Train Pathology Residents During the Pandemic: Perspectives on Pathology Education in the Age of COVID-19.** [Acad Pathol](#) 2021; 8:23742895211006819Christian RJ, VanSandt M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33884292>
2. **Impact of COVID-19 Pandemic on Training and Well-Being in Radiology Residency: A National Survey of Diagnostic Radiology Trainees in Saudi Arabia.** [Acad Radiol](#) 2021; Alhasan AS, Alahmadi SM, Altayeb YA, Daqqaq TS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33893029>
3. **COVID-19 pandemic preparation: using simulation for systems-based learning to prepare the largest healthcare workforce and system in Canada.** [Adv Simul \(Lond\)](#) 2020; 5:22Dubé M, Kaba A, Cronin T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33875011>
4. **A REVIEW ON EMERGING PATHOGENESIS OF COVID-19 AND POINTS OF CONCERN FOR RESEARCH COMMUNITIES IN NIGERIA.** [Afr J Infect Dis](#) 2021; 15:36-43Muhammad M, Ibrahim SA, Yarube IU, Bello B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33889801>
5. **The impact of COVID-19 on women surgeons and trainees: The transformation of medical students, surgical residents, and attending surgeons.** [Am. J. Surg.](#) 2021; Guetter CR, Nosanov LB, Henry MCW, Oropallo A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33892923>
6. **Medical Student Attitudes Toward Blood Donation in Times of Increased Need.** [Am. Surg.](#) 2021:31348211011083Khatun R, Otaibi BW, Ssentongo A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33877939>

7. **Working in Creative Partnership with Students to Co-Produce Neuroanatomy e-Learning Resources in a new era of Blended Learning.** *Anat Sci Educ* 2021; Border S, Woodward C, Kurn O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871948>
8. **Body donation, teaching and research in dissection rooms in Spain in times of Covid-19.** *Anat Sci Educ* 2021; Manzanares-Céspedes MC, Dalmau-Pastor M, Simon de Blas C, Vázquez-Osorio MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891806>
9. **COVID-19 and Comparative Health Policy Learning; the Experience of 10 Countries.** *Arch Iran Med* 2021; 24:260-272 Raoofi A, Takian A, Haghighi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878884>
10. **NewsMeSH: A new classifier designed to annotate health news with MeSH headings.** *Artif. Intell. Med.* 2021; 114:102053 Pita Costa J, Rei L, Stopar L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875160>
11. **Knowledge, Attitude, and Practice in Indonesian Health Care Workers Regarding COVID-19.** *Asia Pac. J. Public Health* 2021:10105395211011017 Rizki SA, Kurniawan J, Budimulia P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870724>
12. **Online medical conference became favorite in China during COVID-19, will it become a routine model in the future?** *Asian J. Surg.* 2021; Peng D, Cheng YX, Liu XY, Wang CY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879360>
13. **COVID-19 and the Need for Global Critical Care Training. Why Ventilators Alone Are Not the Answer.** *ATS Sch* 2020; 2:13-18 Brotherton BJ, Mbugua E, Halestrap P, Lee BW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870319>
14. **ATS Core Curriculum 2020. Adult Pulmonary Medicine.** *ATS Sch* 2020; 1:416-435 Channick CL, Garrison G, Huie TJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870311>
15. **Training and Deployment of Medical Students as Respiratory Therapist Extenders during COVID-19.** *ATS Sch* 2020; 1:145-151 Hester TB, Cartwright JD, DiGiovine DG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870278>
16. **The Fast Literature Assessment and Review (FLARE) Initiative. A Collaborative Effort for Timely Literature Appraisal during the Coronavirus Disease Pandemic.** *ATS Sch* 2020; 1:186-193 Petri CR, Brenner LN, Calhoun TF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870283>
17. **Determinants of COVID-19-related knowledge and preventive behaviours among students in reopened secondary schools: cross-sectional study.** *BMJ Open* 2021; 11:e050189 Handebo S, Adugna A, Kassie A, Shitu K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895723>
18. **Crisis within a crisis, COVID-19 knowledge and awareness among the Syrian population: a cross-sectional study.** *BMJ Open* 2021; 11:e043305 Mohsen F, Bakkar B, Armashi H, Aldaheer N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879483>
19. **Conducting an ongoing HIV clinical trial during the COVID-19 pandemic in Uganda: a qualitative study of research team and participants' experiences and lessons learnt.** *BMJ Open* 2021; 11:e048825 Muwanguzi PA, Kutyabami P, Osingada CP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883157>

20. **Rethinking the role of Research Ethics Committees in the light of Regulation (EU) No 536/2014 on Clinical Trials and the COVID-19 pandemic.** Br. J. Clin. Pharmacol. 2021; Tusino S, Furfaro M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891323>
21. **Evidence-based primary prevention and health promotion: methods and procedures in 5 research consortia.** Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2021; Brandes M, Muellmann S, Allweiss T *et al.*
22. **COVID-19: A call for mentorship in radiology.** Clin Imaging 2021; 79:48-51 Perry R, Parikh J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872916>
23. **COVID-19: A call for mentorship in radiology.** Clin Imaging 2021; 79:48-51 Perry R, Parikh JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872916>
24. **Comparative analysis of Student's live online learning readiness during the coronavirus (COVID-19) pandemic in the higher education sector.** Comput Educ 2021; 168:104211 Tang YM, Chen PC, Law KMY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879955>
25. **Conducting conservation social science surveys online.** Conserv. Biol. 2021; Wardropper CB, Dayer AA, Goebel MS, Martin VY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887800>
26. **Considerations for assessing physical function and physical activity in clinical trials during the COVID-19 pandemic.** Contemp Clin Trials 2021; 105:106407 Moon SJE, Dabbs AD, Hergenroeder AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887443>
27. **Online examination course instead of classroom teaching: adaptation of medical student teaching during the COVID-19 pandemic.** Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2021; Wiedenmann C, Wacker K, Böhringer D *et al.*
28. **Knowledge, attitude and practice of patients with chronic diseases towards COVID-19 pandemic in Dessie town hospitals, Northeast Ethiopia.** Diabetes Metab Syndr 2021; 15:847-856 Addis SG, Nega AD, Miretu DG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33873054>
29. **Comparison of students' use and acceptance of emergency online learning due to COVID-19 in the USA, Mexico, Peru, and Turkey.** Educ Inf Technol (Dordr) 2021:1-23 Aguilera-Hermida AP, Quiroga-Garza A, Gómez-Mendoza S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867810>
30. **Environmental health research and the COVID-19 pandemic: A turning point towards sustainability.** Environ. Res. 2021; 197:111157 Yang X, Lo K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887273>
31. **Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquine.** Epidemiol. Prev. 2021; 45:28-36 Lilli C, Biggeri A, Zingaretti C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884840>
32. **The influence of the COVID-19 outbreak on European trainees in obstetrics and gynaecology: A survey of the impact on training and trainee.** Eur. J. Obstet. Gynecol. Reprod. Biol. 2021; 261:52-58 Boekhorst F, Khattak H, Topcu EG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892209>

33. **The impact of COVID-19 on obstetrics and gynaecology trainees; how do we move on?** Facts Views Vis Obgyn 2021; 13:9-14Mallick R, Odejinmi F, Sideris M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889856>
34. **The Urgent Need for Management of Biological Samples and Data Accessibility in Latin America.** Front. Pharmacol. 2021; 12:620043Vargas RJ, Cobar OM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867983>
35. **Mental Health, Social and Emotional Well-Being, and Perceived Burdens of University Students During COVID-19 Pandemic Lockdown in Germany.** Front Psychiatry 2021; 12:643957Kohls E, Baldofski S, Moeller R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889102>
36. **Gender Differences in Digital Learning During COVID-19: Competence Beliefs, Intrinsic Value, Learning Engagement, and Perceived Teacher Support.** Front. Psychol. 2021; 12:637776Korlat S, Kollmayer M, Holzer J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868109>
37. **How E-Learning Environmental Stimuli Influence Determinates of Learning Engagement in the Context of COVID-19? SOR Model Perspective.** Front. Psychol. 2021; 12:584976Yang J, Peng MY, Wong S, Chong W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868072>
38. **The Importance of Understanding COVID-19: The Role of Knowledge in Promoting Adherence to Protective Behaviors.** Front Public Health 2021; 9:581497Miller LMS, Gee PM, Katz RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889557>
39. **A Glimpse of the First Eight Months of the COVID-19 Literature on Microsoft Academic Graph: Themes, Citation Contexts, and Uncertainties.** Front Res Metr Anal 2020; 5:607286Chen C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870064>
40. **Intellectual Structure of Coronavirus Research: A Perspective From an Author Cocitation Analysis.** Front Res Metr Anal 2020; 5:595370Mei J, Zhao D, Strotmann A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870058>
41. **Decolonizing Science Diplomacy: A Case Study of the Dominican Republic's COVID-19 Response.** Front Res Metr Anal 2021; 6:637187Mencía-Ripley A, Paulino-Ramírez R, Jiménez JA, Camilo O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870069>
42. **Tracking and Mining the COVID-19 Research Literature.** Front Res Metr Anal 2020; 5:594060Porter AL, Zhang Y, Huang Y, Wu M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870056>
43. **Knowledge, attitudes, practices and fear of COVID-19 among Iranians: A quick online survey.** Health Soc Care Community 2021; Ghaderi E, Mahmoodi H, Sharifi Saqqezi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891794>
44. **Information Needs of Pregnant Women in the COVID-19 Pandemic from Experts' Point of View: A Qualitative Study.** Int J Community Based Nurs Midwifery 2021; 9:139-151Rezaei F, Masaeli Z, Atighechian G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875966>
45. **Web-based Medical Education During COVID-19 Lockdown: A Step Back or a Leap to the Future?** Int. J. Low. Extrem. Wounds 2021:15347346211011848Eleftheriou A, Rokou A, Argyriou C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890811>

46. **Senior BSN students' confidence, comfort, and perception of readiness for clinical practice: the impacts of COVID-19.** Int. J. Nurs. Educ. Scholarsh. 2021; 18Musallam E, B AF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882201>
47. **Telemental health policies for college students during COVID-19.** J. Am. Coll. Health 2021;1-5Huilgol YS, Torous J, Gold JA, Goldman ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891526>
48. **COVID-19 Trial Graph: A Linked Graph for COVID-19 Clinical Trials.** J Am Med Inform Assoc 2021; Du J, Wang Q, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895839>
49. **A fusion of data science and feed-forward neural network-based modelling of COVID-19 outbreak forecasting in IRAQ.** J. Biomed. Inform. 2021; 118:103766Aljaaf AJ, Mohsin TM, Al-Jumeily D, Alloghani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895377>
50. **Reimagining the pipeline: Saturday Academy at New York University College of Dentistry goes virtual.** J. Dent. Educ. 2021; Burns LE, Pezzullo C, Dief S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893653>
51. **Pandemics and education: A historical review.** J. Dent. Educ. 2021; Spielman AI, Sunavala-Dossabhoy G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876429>
52. **Endoscopy Training in COVID-19: Challenges and Hope for a Better Age.** J Gastroenterol Hepatol 2021; Koo CS, Siah KTH, Koh CJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871079>
53. **Association Between Perceived Resilience and Mental Well-Being of Saudi Nursing Students During COVID-19 Pandemic: A Cross-Sectional Study.** J. Holist. Nurs. 2021:8980101211009063Grande RAN, Berdida DJE, Villagrancia HN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876982>
54. **Clinical course, radiological findings and late outcome in preterm infant with suspected vertical transmission born to a mother with severe COVID-19 pneumonia: a case report.** J Med Case Rep 2021; 15:213Farhadi R, Mehrpisheh S, Ghaffari V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892788>
55. **Implementing the National Incident Management System at schools of nursing in response to COVID-19.** J. Prof. Nurs. 2021; 37:255-260de Tantillo L, Christopher R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867077>
56. **Development and Utilization of a Medical Student Surgery Podcast During COVID-19.** J. Surg. Res. 2021; 265:95-99Anteby R, Amiel I, Cordoba M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894454>
57. **Pretesting a poster that communicates principles of COVID-19 prevention at educational institutions in Depok City, Indonesia.** J. Vis. Commun. Med. 2021:1-9Rachmawati A, Artini NNA, Mukaromah Y, Pratomo H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876713>
58. **Teaching Telemedicine: The Next Frontier for Medical Educators.** JMIR Med Educ 2021; 7:e29099Alcocer Alkureishi M, Lenti G, Choo ZY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878011>
59. **One Year of Pandemic Learning Response: Benefits of Massive Online Delivery of the World Health Organization's Technical Guidance.** JMIR Public Health Surveill 2021; 7:e28945Utunen H, Van Kerkhove MD, Tokar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881404>

60. **Coordinating a Postgraduate Orthopaedic Exam During the COVID-19 Pandemic.** Malays Orthop J 2021; 15:16-20Mohamed-Hafiah NH, Abdullah S, Abdul-Rani R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880143>
61. **Self-Illusion and Medical Expertise in the Era of COVID-19.** Open Forum Infect Dis 2021; 8:ofab058Claessens A, Keita-Perse O, Berthier F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880387>
62. **Knowledge levels, attitudes, and perceptions of individuals with different demographic characteristics on COVID-19: The case of Turkey.** Perspect. Psychiatr. Care 2021; Ates E, Ok E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884642>
63. **What are the main areas of research on COVID-19?** Postgrad. Med. J. 2021; Cifuentes-Faura J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883253>
64. **Complexities of COVID-19 Demonstrate the Need for More Interdisciplinary Research Training in Graduate School.** Public Health Rep. 2021:333549211013320Benavidez GA, Mandelbaum J, Fisk CE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882745>
65. **Home education for children with autism spectrum disorder during the COVID-19 pandemic: Indonesian mothers experience.** Res. Dev. Disabil. 2021; 114:103954Daulay N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882385>
66. **Undergraduate palliative care teaching in times of COVID-19.** Schmerz 2021; Scherg A, Ilse B, Elsner F.
67. **Risk Perception and Behavioral Response to COVID-19: A Survey of University Students and Staff in the Iraqi Kurdistan Region.** Soc Work Public Health 2021:1-12Shabu SA, K MA, Mahmood KI, Shabila NP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33866952>
68. **COVID-19 Impact in Neurosurgery Residency: Grit in the Face of Pandemic.** World Neurosurg 2021; Algattas H, Roy S, Agarwal N, Maroon J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894398>
69. **[Annual meeting of the German Society for Rheumatology going virtual-successfully defying the pandemic].** Z. Rheumatol. 2021:1-7Richter JG, Chehab G, Knitza J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877456>

Elderly (16 articles)

1. **Maximal aerobic capacity exercise testing protocols for elderly individuals in the era of COVID-19.** Aging Clin. Exp. Res. 2021:1-5Venturelli M, Cè E, Paneroni M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881755>
2. **Mortality attributable to COVID-19 in nursing home residents: a retrospective study.** Aging Clin. Exp. Res. 2021:1-7Veronese N, Koyanagi A, Stangherlin V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893989>
3. **Aging and emotion regulation during the COVID-19 pandemic.** Aging Ment. Health 2021:1-8Wolfe HE, Isaacowitz DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870771>
4. **Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients.** Alzheimers Dement 2021; Tahira AC, Verjovski-Almeida S, Ferreira ST. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881211>

5. **The multidimensional prognostic index (MPI) for the prognostic stratification of older inpatients with COVID-19: A multicenter prospective observational cohort study.** *Arch. Gerontol. Geriatr.* 2021; 95:104415Pilotto A, Azzini M, Cella A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882420>
6. **COVID-19 as the sole cause of death is uncommon in frail home healthcare individuals: a population-based study.** *BMC Geriatr.* 2021; 21:262Nilsson L, Andersson C, Sjö Dahl R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879078>
7. **The impact of frailty on survival in elderly intensive care patients with COVID-19: the COVIP study.** *Crit Care* 2021; 25:149Jung C, Flaatten H, Fjølner J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874987>
8. **Measuring the outsized impact of COVID-19 in the evolving setting of aged care facilities.** *EClinicalMedicine* 2021; 34:100825Cassone M, Mody L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880439>
9. **Covid-19: a call for mobilizing geriatric expertise.** *Eur. Geriatr. Med.* 2021:1-4O'Hanlon S, Dhessi J, Aronson L, Inouye SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891278>
10. **The presence of care homes and excess deaths during the COVID-19 pandemic: Evidence from Italy.** *Health Econ.* 2021; Alacevich C, Cavalli N, Giuntella O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884695>
11. **Combined predictive performance of age and neutrophilic percentage on admission for severe novel coronavirus disease 2019.** *Int J Clin Pract* 2021:e14257Chen Y, Zhi H, Zhang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884718>
12. **Resilience in Older Adults during the COVID-19 Pandemic: A Socioecological Approach.** *J. Gerontol. B Psychol. Sci. Soc. Sci.* 2021; Igarashi H, Kurth ML, Lee HS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881504>
13. **Digital Inclusion of Older Adults during COVID-19: Lessons from a Case Study of Older Adults Technology Services (OATS).** *J Gerontol Soc Work* 2021:1-13Weil J, Kamber T, Glazebrook A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882782>
14. **The Effect of Loneliness on Death Anxiety in the Elderly During the COVID-19 Pandemic.** *Omega (Westport)* 2021:302228211010587Guner TA, Erdogan Z, Demir I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878967>
15. **[COVID-19 and elderly people in nursing homes: Impact according to the modality of residence].** *Rev Esp Geriatr Gerontol* 2021; Barrera-Algarín E, Estepa-Maestre F, Sarasola-Sánchez-Serrano JL, Malagón-Siria JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892992>
16. **[Covid-19 infectious disease is also a psychogeriatric disease].** *Soins Gerontol.* 2021; 26:37-39Thomas P, Hazif-Thomas C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894913>

Epidemiology (85 articles)

1. **-fuzzy measure model for COVID-19 disease.** *Adv Differ Equ* 2021; 2021:202Ghaffari A, Saadati R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880117>

2. **A REVIEW ON EMERGING PATHOGENESIS OF COVID-19 AND POINTS OF CONCERN FOR RESEARCH COMMUNITIES IN NIGERIA.** Afr J Infect Dis 2021; 15:36-43 Muhammad M, Ibrahim SA, Yarube IU, Bello B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33889801>
3. **100 DAYS OF COVID-19: RISK FACTORS AND CONFIRMED CASES IN 19 AFRICAN COUNTRIES.** Afr J Infect Dis 2021; 15:31-35 Shallie PD, Haffeejee F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33889800>
4. **Dynamics of the COVID-19 epidemic in urban and rural areas in the United States.** Ann. Epidemiol. 2021; Cuadros DF, Branscum AJ, Mukandavire Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894385>
5. **Assessment of Contact Tracing for COVID-19 among People Experiencing Homelessness, Salt Lake County Health Department, March-May 2020.** Ann. Epidemiol. 2021; Fields VL, Kiphibane T, Eason JT *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894384>
6. **A swaying between successive pandemic waves and pandemic fatigue: Where does Jordan stand?** Ann Med Surg (Lond) 2021; 65:102298 Al-Tammemi AB, Tarhini Z, Akour A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880181>
7. **Crowd management COVID-19.** Annu Rev Control 2021; Polanco LD, Siller M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33867812>
8. **The Impact of COVID-19 on First Nations People Health Assessments in Australia.** Asia Pac. J. Public Health 2021:10105395211011012 Robertson R, Mian M, Sreedharan S, Lau P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870726>
9. **[Proposal for territorial analysis to face the SARS-CoV-2 pandemic based on the Profile of pneumonia and Influenza in Ecuador 2016-2018].** Aten. Primaria 2021; 53:102021 Ríos Quituizaca P, Calderón L, Piedra S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33887602>
10. **Epidemiological and virological characteristics of respiratory tract infections in children during COVID-19 outbreak.** BMC Pediatr. 2021; 21:195 Zhu Y, Li W, Yang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888063>
11. **Modelling the impact of the tier system on SARS-CoV-2 transmission in the UK between the first and second national lockdowns.** BMJ Open 2021; 11:e050346 Laydon DJ, Mishra S, Hinsley WR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33888533>
12. **Lack of cross-transmission of SARS-CoV-2 between passenger's cabins on the Diamond Princess cruise ship.** Build. Environ. 2021; 198:107839 Xu P, Jia W, Qian H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875902>
13. **COVID-19 pandemic and its average recovery time in Indian states.** Clin Epidemiol Glob Health 2021; 11:100740 George N, Tyagi NK, Prasad JB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33875974>
14. **Not all COVID-19 pandemic waves are alike.** Clin Microbiol Infect 2021; Domingo P, Pomar V, Mur I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887469>
15. **Analysis and Prediction of COVID-19 Pandemic in Bangladesh by Using ANFIS and LSTM Network.** Cognit. Comput. 2021:1-10 Chowdhury AA, Hasan KT, Hoque KKS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868501>
16. **South African Jewish Responses to COVID-19.** Contemp Jew 2021:1-18 Gilbert S, Gilbert L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867601>

17. **The Novel Coronavirus (COVID-19) Pandemic and the Response in Low-to-Middle Income Countries.** Curr. Breast Cancer Rep. 2021;1-6Shahzad H, Mubarik F, Sattar AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880139>
18. **Unknown uncertainties in the COVID-19 pandemic: Multi-dimensional identification and mathematical modelling for the analysis and estimation of the casualties.** Digit Signal Process 2021; 114:103058Tutsoy O, Balikci K, Ozdil NF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879984>
19. **COVID-19 resurgence: lessons learnt to inform the South African response.** Disaster Med Public Health Prep 2021;1-17Dzobo M, Hlongwa M, Denhere K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867001>
20. **Respiratory Viral Shedding in Healthcare Workers Reinfected with SARS-CoV-2, Brazil, 2020.** Emerg Infect Dis 2021; 27Amorim MR, Souza WM, Barros ACG, Jr. *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871331>
21. **Investigation of the urbanization contribution to the COVID-19 outbreak in Iran and the MECA countries.** Environ Dev Sustain 2021;1-22Bijari NB, Mahdinia MH, Mansouri Daneshvar MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880075>
22. **Effect of Large-Scale Social Restriction (PSBB) during COVID-19 on Outdoor Air Quality: Evidence from Five Cities in DKI Jakarta Province, Indonesia.** Environ. Res. 2021;111164Rizky Anugerah A, Suksessanno Muttaqin P, Purnama DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872645>
23. **Simple quantitative assessment of the outdoor versus indoor airborne transmission of viruses and COVID-19.** Environ. Res. 2021;111189Rowe BR, Canosa A, Drouffe JM, Mitchell JBA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872644>
24. **Meteorological conditions are heterogeneous factors for COVID-19 risk in China.** Environ. Res. 2021;111182Xiao S, Qi H, Ward MP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872647>
25. **Epidemiologic Characteristics of a COVID-19 Outbreak Caused by Religious Activities in Daegu, Korea.** Epidemiol Health 2021:e2021024Kim JY, Lee YM, Lee H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872485>
26. **Transmission of SARS-CoV-2 before and after symptom onset: impact of nonpharmaceutical interventions in China.** Eur. J. Epidemiol. 2021; 36:429-439Bushman M, Worby C, Chang HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881667>
27. **Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel.** Eur. J. Epidemiol. 2021;1-8Reicher S, Ratzon R, Ben-Sahar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884542>
28. **Corona and Coffee on your commute: A spatial analysis of COVID-19 mortality and commuting flows in England in 2020.** Eur. J. Public Health 2021; Francetic I, Munford L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871592>
29. **Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.** Euro Surveill 2021; 26Funk T, Pharris A, Spiteri G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890566>
30. **COVID-19: Is reinfection possible?** Excli j 2021; 20:522-536Costa AOC, de Carvalho Aragão Neto H, Lopes Nunes AP *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33883981>

31. **Mutations in the SARS-CoV-2 spike protein modulate the virus affinity to the human ACE2 receptor, an in silico analysis.** Excli j 2021; 20:585-600Ortega JT, Pujol FH, Jastrzebska B, Rangel HR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883984>
32. **First Report on the Latvian SARS-CoV-2 Isolate Genetic Diversity.** Front Med (Lausanne) 2021; 8:626000Zrelavs N, Ustinova M, Silamikelis I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889583>
33. **Reopening America's Schools During the COVID-19 Pandemic: Protecting Asian Students From Stigma and Discrimination.** Front Sociol 2020; 5:588936Akiba D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869517>
34. **The Role Played by Public Universities in Mitigating the Coronavirus Catastrophe in Brazil: Solidarity, Research and Support to Local Governments Facing the Health Crisis.** Front Sociol 2021; 6:610297Arrais CA, Corcioli G, Medina GDS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869552>
35. **Haplotype Explorer: an infection cluster visualization tool for spatiotemporal dissection of the COVID-19 pandemic.** G3 (Bethesda) 2021; Kawano-Sugaya T, Yatsu K, Sekizuka T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892501>
36. **Mutation rates and selection on synonymous mutations in SARS-CoV-2.** Genome Biol. Evol. 2021; De Maio N, Walker CR, Turakhia Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895815>
37. **Population-level mortality burden from novel coronavirus (COVID-19) in Europe and North America.** Genus 2021; 77:7Soneji S, Beltrán-Sánchez H, Yang JW, Mann C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879923>
38. **Contact tracing apps for the COVID-19 pandemic: a systematic literature review of challenges and future directions for neo-liberal societies.** Health Inf Sci Syst 2021; 9:18Akinbi A, Forshaw M, Blinkhorn V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868671>
39. **Examining spatial inequality in COVID-19 positivity rates across New York City ZIP codes.** Health Place 2021; 69:102574Yang TC, Kim S, Zhao Y, Choi SE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895489>
40. **Predictive Modeling of Covid-19 Data in the US: Adaptive Phase-Space Approach.** IEEE Open J Eng Med Biol 2020; 1:207-213Marmarelis VZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870202>
41. **Effectiveness of potential antiviral treatments in COVID-19 transmission control: a modelling study.** Infect Dis Poverty 2021; 10:53Lin SN, Rui J, Chen QP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874998>
42. **Virological COVID-19 surveillance in Bavaria, Germany suggests no SARS-CoV-2 spread prior to the first German case in January 2020.** Infection 2021;1-4Eberle U, Heinzinger S, Konrad R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891281>
43. **Assessment of global asymptomatic SARS-CoV-2 infection and management practices from China.** Int J Biol Sci 2021; 17:1119-1124Chen Z, Wang B, Mao S, Ye Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867834>
44. **First COVID-19 Cases with High Secondary Infection among Health Workers, Sana'a Capital, April 2020: Lessons Learned and Future Opportunities.** Int J

- Infect Dis 2021; Al-Sakkaf E, Ghaleb Y, Al-Dabis E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895407>
45. **Dramatic Rise of Seroprevalence Rates of SARS-CoV-2 Antibodies among Healthy Blood Donors: The evolution of a Pandemic.** Int J Infect Dis 2021; Sughayer MA, Mansour A, Al Nuirat A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892190>
 46. **On the fractional SIRD mathematical model and control for the transmission of COVID-19: The first and the second waves of the disease in Iran and Japan.** ISA Trans. 2021; Mohammadi H, Rezapour S, Jajarmi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867134>
 47. **COVID-19 pandemic and air transportation: Successfully navigating the paper hurricane.** J Air Transp Manag 2021; 94:102062 Sun X, Wandelt S, Zheng C, Zhang A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875908>
 48. **A fusion of data science and feed-forward neural network-based modelling of COVID-19 outbreak forecasting in IRAQ.** J. Biomed. Inform. 2021; 118:103766 Aljaaf AJ, Mohsin TM, Al-Jumeily D, Alloghani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895377>
 49. **Epidemiological observations on breaking COVID-19 transmission: from the experience of Taiwan.** J. Epidemiol. Community Health 2021; MacDonald I, Hsu JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893185>
 50. **Policy Disparities in Response to COVID-19 between China and South Korea.** J Epidemiol Glob Health 2021; Chen H, Shi L, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876595>
 51. **COVID-19: The Second Wave is not due to Cooling-down in Autumn.** J Epidemiol Glob Health 2021; Langel W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876601>
 52. **Comparison of Predictive Models and Impact Assessment of Lockdown for COVID-19 over the United States.** J Epidemiol Glob Health 2021; Makinde OS, Adeola AM, Abiodun GJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876598>
 53. **Role of Ascertainment Bias in Determining Case Fatality Rate of COVID-19.** J Epidemiol Glob Health 2021; Smith MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876593>
 54. **Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units - a high risk community-hospital interface.** J Infect 2021; Li KK, Woo YM, Stirrup O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895226>
 55. **COVID-19 transmission in Hong Kong despite universal masking.** J Infect 2021; Martín-Sánchez M, Lim WW, Yeung A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895227>
 56. **COVID-19 outbreak at a reception centre for asylum seekers in Espoo, Finland.** J Migr Health 2021; 3:100043 Turunen T, Kontunen K, Sugulle K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880457>
 57. **Negative Effects of COVID-19 Stay-at-Home Mandates on Physical Intervention Outcomes: A Preliminary Study.** J Parkinsons Dis. 2021; Templeton JM, Poellabauer C, Schneider S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867363>
 58. **State estimation-based control of COVID-19 epidemic before and after vaccine development.** J Process Control 2021; 102:1-14 Rajaei A, Raeiszadeh M, Azimi V,

Sharifi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867698>

59. **Utilizing the ACCESS Model to Understand Communication With the Ultraorthodox Community in Beit Shemesh During the First Wave of COVID-19.** J. Transcult. Nurs. 2021;10436596211009575Romem A, Pinchas-Mizrachi R, Zalcman BG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882735>
60. **JUE Insight: Migration, Transportation Infrastructure, and the Spatial Transmission of COVID-19 in China.** J Urban Econ 2021;103351Li B, Ma L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879932>
61. **A Recursive Model of the Spread of COVID-19: Modelling Study.** JMIR Public Health Surveill 2021; 7:e21468Ilyin SO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871381>
62. **Epidemiology, clinical characteristics, and virologic features of COVID-19 patients in Kazakhstan: A nation-wide retrospective cohort study.** Lancet Reg Health Eur 2021; 4:100096Yegorov S, Goremykina M, Ivanova R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880458>
63. **Sexual Minority Disparities in Health and Well-being as a Consequence of the COVID-19 Pandemic Differ by Sexual Identity.** LGBT Health 2021; Fish JN, Salerno J, Williams ND *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887160>
64. **Modelling and predicting the spread of COVID-19 cases depending on restriction policy based on mined recommendation rules.** Math Biosci Eng 2021; 18:2789-2812Yakovyna V, Shakhovska N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892572>
65. **SARS-CoV-2 Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020.** mSphere 2021; 6Han H, Yi J, Cheng G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883260>
66. **COVID-19 Pandemic in Lebanon: One Year Later, What Have We Learnt?** mSystems 2021; 6Koweyes J, Salloum T, Haidar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879497>
67. **Estimation of COVID-19 outbreak size in Harbin, China.** Nonlinear Dyn 2021;1-9Song H, Jia Z, Jin Z, Liu S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867676>
68. **Social distancing mediated generalized model to predict epidemic spread of COVID-19.** Nonlinear Dyn 2021;1-9Yasir KA, Liu WM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867677>
69. **SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020.** PeerJ 2021; 9:e11210Díaz-Vélez C, Failoc-Rojas VE, Valladares-Garrido MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868828>
70. **A random walk Monte Carlo simulation study of COVID-19-like infection spread.** Physica A 2021; 574:126014Triambak S, Mahapatra DP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875903>
71. **Multifaceted strategies for the control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada.** Prev. Med. 2021; 148:106564Vilches TN, Nourbakhsh S, Zhang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878351>
72. **The Impact of COVID-19 on the Latinx Population: A Scoping Literature Review.** Public Health Nurs. 2021; Moore KS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876506>

73. **Decision support system for ranking relevant indicators for reopening strategies following COVID-19 lockdowns.** Qual Quant 2021;1-29Almulhim TS, Barahona I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867586>
74. **A renewal equation model to assess roles and limitations of contact tracing for disease outbreak control.** R Soc Open Sci 2021; 8:202091Scarabel F, Pellis L, Ogden NH, Wu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868698>
75. **Investigation of fractal-fractional order model of COVID-19 in Pakistan under Atangana-Baleanu Caputo (ABC) derivative.** Results Phys 2021; 24:104046Arfan M, Alrabaiah H, Rahman MU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868907>
76. **A COVID-19 outbreak on board ship: Analysis of the sociotechnical system of epidemiological management in the French Navy.** Saf Sci 2021; 140:105296Chassery L, Texier G, Pommier De Santi V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875906>
77. **Evaluating the presence of SARS-CoV-2 RNA in the particulate matters during the peak of COVID-19 in Padua, northern Italy.** Sci Total Environ 2021; 784:147129Pivato A, Amoroso I, Formenton G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894607>
78. **Understanding the Geographical Spread of COVID-19 in Relation with Goods Regional Routes and Governmental Decrees: The Lombardy Region Case Study.** SN Comput Sci 2021; 2:203Tosi D, Chiappa M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870214>
79. **Quantifying the small-area spatio-temporal dynamics of the Covid-19 pandemic in Scotland during a period with limited testing capacity.** Spat Stat 2021:100508Lee D, Robertson C, Marques D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868908>
80. **COVID-19 related callback in blood donors; Outcomes in blood donors and patients.** Transfus. Apher. Sci. 2021:103129Balaghali S, Maghsudlu M, Amini-Kafiabad S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879420>
81. **Assessing regional risk of COVID-19 infection from Wuhan via high-speed rail.** Transp Policy (Oxf) 2021; 106:226-238Li T, Rong L, Zhang A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867701>
82. **SARS-CoV-2 in animals: potential for unknown reservoir hosts and public health implications.** Vet. Q. 2021:1-31Sharun K, Dhama K, Pawde AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892621>
83. **Epidemiological and clinical characteristics of 65 hospitalized patients with COVID-19 in Liaoning, China.** World J Clin Cases 2021; 9:2205-2217Zhang W, Ban Y, Wu YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869596>
84. **COVID-19 pandemic: Are hard lockdowns ineffective?: Why the Bendavid et al. Study does not provide sufficient evidence for this Assumption.** Z. Allgemeinmed. 2021; 97:103-107Glechner A, Stratil JM, Bombana M *et al.*
85. **Sönnichsen A. One year of COVID - An end in sight? Editorial ZFA 1/2021. Z Allg Med 2021; 97: 1. Kochen MM, Kaduszkiewicz H, Niebling W, Rabady S. Trivialization or denial? Comment on the editorial "One year of COVID - An end in sight?" by Andreas Sönnichsen. Z Allg Med 2021; 97: B1-B2. Z. Allgemeinmed. 2021; 97:127Schwabe N.**

Gastro-enterology (10 articles)

1. **Gastrointestinal manifestations related to infection with SARS-COV-2: Appendicular syndrome (A case report).** Ann Med Surg.(Lond). 2021;102288Elbakouri A, El Azhary A, Bouali M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868674>
2. **COVID-19 in patients with hepatobiliary and pancreatic diseases: a single-centre cross-sectional study in East London.** BMJ Open 2021; 11:e045077Dayem Ullah AZM, Sivapalan L, Kocher HM, Chelala C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875444>
3. **COVID-19-Induced Bile Duct Casts and Cholangitis: A Case Report.** Cureus 2021; 13:e14560Sanders D, Bomman S, Irani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889467>
4. **An Unusual Case of Gastrointestinal Bleeding in a Patient With COVID-19.** Cureus 2021; 13:e13901Sanku K, Siddiqui AH, Paul V, Ali M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880257>
5. **Fulminant hepatic failure in a patient testing re-positive for SARS-CoV-2: a case report.** Int. J. Emerg. Med. 2021; 14:24Aldossary B, Hassan A, Moussa M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882839>
6. **DECREASE IN VIRAL HEPATITIS DIAGNOSES DURING THE COVID-19 PANDEMIC IN THE NETHERLANDS.** J Hepatol 2021; Sonneveld MJ, Veldhuijzen IK, van de Laar T *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887356>
7. **A Case of Severe Acute Respiratory Syndrome Coronavirus 2 Treatment With Remdesivir in a Hepatitis C-Coinfected Patient Resulting in Temporary Viral Control and Posttreatment Flare.** Open Forum Infect Dis 2021; 8:ofab100da Cunha MR, Rodrigues IC, Trigueiros F *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880393>
8. **Co-infection of hepatitis E virus and Plasmodium falciparum malaria: A genuine risk in sub-Saharan Africa.** Parasit Vectors 2021; 14:215Sahra S, Jahangir A, Iqbal QZ *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879247>
9. **The impact of the novel coronavirus pandemic on gastrointestinal operative volume in the United States.** Surg. Endosc. 2021;1-7Purdy AC, Smith BR, Hohmann SF, Nguyen NT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871720>
10. **High Child-Pugh and CRUB65 scores predict mortality of decompensated cirrhosis patients with COVID-19: A 23-center, retrospective study.** Virulence 2021; 12:1199-1208Xiao Y, Wu D, Shi X *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870852>

Guidelines (8 articles)

1. **GOLD 2021 guidelines for COPD - what's new and why.** Adv Respir Med 2021; Gupta N, Malhotra N, Ish P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881161>
2. **Systematic review of international guidelines for head and neck oncology management in COVID-19 patients.** Eur Arch Otorhinolaryngol 2021;1-37Gascon L, Fournier I, Chiesa-Estomba C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891167>

3. **Guidelines for clinical management of SARS-CoV-2 infection.** Gac Med Mex 2020; 156:576-583 García-Álvarez JL, García-Vigil JL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33877121>
4. **Development of a Resource Guide to Support the Engagement of Mental Health Providers and Patients With Digital Health Tools: Multimethod Study.** J Med Internet Res 2021; 23:e25773 Strudwick G, McLay D, Lo B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33885374>
5. **One Year of Pandemic Learning Response: Benefits of Massive Online Delivery of the World Health Organization's Technical Guidance.** JMIR Public Health Surveill 2021; 7:e28945 Utunen H, Van Kerkhove MD, Tokar A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33881404>
6. **Fatal Retroperitoneal Hematoma Associated with Covid-19 Prophylactic Anticoagulation Protocol.** Radiol Case Rep 2021; Teta M, Drabkin MJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880136>
7. **Statement from the Japanese Respiratory Society: Working diagnosis and initial management of COPD during the COVID-19 pandemic.** Respir Investig 2021; Shibata Y, Muro S, Yokoyama A, Hashimoto S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33893068>
8. **Guidance for the clinical management of infants born to mothers with suspected/confirmed COVID-19 in Singapore.** Singapore Med J 2021; Yeo KT, Biswas A, Ho SKY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33866749>

Imaging (20 articles)

1. **Echocardiographic Abnormalities as Independent Prognostic Factors of In-Hospital Mortality among COVID-19 Patients.** Arch Acad Emerg Med 2021; 9:e21 Pishgahi M, Karimi Toudeshki K, Safari S, Yousefifard M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33870208>
2. **Artificial intelligence (AI) for medical imaging to combat coronavirus disease (COVID-19): a detailed review with direction for future research.** Artif Intell Rev 2021; 1-31 Soomro TA, Zheng L, Afifi AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875900>
3. **Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19.** Atherosclerosis 2021; Scoccia A, Gallone G, Cereda A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883086>
4. **DenseCapsNet: Detection of COVID-19 from X-ray images using a capsule neural network.** Comput. Biol. Med. 2021; 133:104399 Quan H, Xu X, Zheng T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33892307>
5. **High-Resolution CT Chest Findings in Suspected COVID-19 Pneumonia Patients With Negative Real-Time Polymerase Chain Reaction Assay.** Cureus 2021; 13:e14023 Yusuf S, Ahmad H, Zeb R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33889463>
6. **Lung ultrasound may be a valuable aid in decision making for patients admitted with COVID-19 disease.** Eur Clin Respir J 2021; 8:1909521 Falster C, Jacobsen N, Wulff Madsen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889342>

7. **Efficacy of chest CT scan for COVID-19 diagnosis in a low prevalence and incidence region.** Eur Radiol 2021;1-6Thomas C, Naudin M, Tasu JP *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33871709>
8. **Chest CT Images for COVID-19: Radiologists and Computer-Based Detection.** Front Mol Biosci 2021; 8:614207Dou Q, Liu J, Zhang W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33869276>
9. **Chest radiography patterns of COVID-19 pneumonia in Kumasi, Ghana.** Ghana Med. J. 2020; 54:264-268Badu-Pepurah A, Anyitey-Kokor I, Ackon A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33883775>
10. **Point-of-care ultrasound (PoCUS) in the early diagnosis of novel coronavirus 2019 disease (COVID-19) in a first-level emergency department during a SARS-CoV-2 outbreak in Italy: a real-life analysis.** Intern Emerg Med 2021;1-12Bianchi S, Savinelli C, Paolucci E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881727>
11. **Comparing Visual Scoring of Lung Injury with a Quantifying AI-Based Scoring in Patients with COVID-19.** J Belg Soc Radiol 2021; 105:16Biebau C, Dubbeldam A, Cockmartin L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870080>
12. **Chest CT Diagnosis of COVID-19: Accuracy using CO-RADS and CT-Involvement Scoring.** J Belg Soc Radiol 2021; 105:17Van Berkel B, Vandevenne J, Coursier K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870081>
13. **Ultrasonography as a diagnostic aid for a neonate with gingival swelling in a COVID-19 neonatal intensive care unit.** J. Indian Soc. Pedod. Prev. Dent. 2021; 39:101-103Kakade A, Deshmukh B, Agarwal A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33885396>
14. **Cost benefit analysis of portable chest radiography through glass: Initial experience at a tertiary care centre during COVID-19 pandemic.** J Med Imaging Radiat Sci 2021; Liu TY, Rai A, Ditkofsky N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33875400>
15. **REPLY TO LETTER TO THE EDITOR: POTENTIAL USE OF RADIOLABELED ANTIBODIES FOR IMAGING AND TREATMENT OF COVID-19.** J Nucl Med 2021; Pillarsetty N, Carter L, Lewis JS, Reiner T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893187>
16. **The role of PoCUS in the assessment of COVID-19 patients.** J Ultrasound 2021;1-9Karp J, Burke K, Daubaras SM, McDermott C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33870480>
17. **Smart access development for classifying lung disease with chest x-ray images using deep learning.** Mater Today Proc 2021; Kumaraguru T, Abirami P, Darshan KM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880332>
18. **Detection of COVID-19 from CT scan images: A spiking neural network-based approach.** Neural Comput Appl 2021;1-14Garain A, Basu A, Giampaolo F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33879976>
19. **SARS-CoV-2 serology increases diagnostic accuracy in CT-suspected, PCR-negative COVID-19 patients during pandemic.** Respir Res 2021; 22:119Schneider J, Mijočević H, Ulm K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892720>

20. **An evaluation of venous thromboembolism by whole-body enhanced CT scan for critical COVID-19 pneumonia with markedly rises of coagulopathy related factors: a case series study.** Thromb J 2021; 19:26 Ogawa F, Oi Y, Nakajima K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=3387917>

Immune response (31 articles)

1. **Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19.** Allergy 2021; Adamo S, Chevrier S, Cervia C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884644>
2. **Emerging roles of coronavirus in autoimmune diseases.** Arch Med Res 2021; Zhou SY, Zhang C, Shu WJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875273>
3. **Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes by disease-related blood biomarkers.** Arthritis Rheumatol 2021; Kessel C, Vollenberg R, Masjosthusmann K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880885>
4. **Seroprevalence of SARS-CoV-2 Antibodies Among Health Care Personnel at a Health Care System in Pakistan.** Asia Pac. J. Public Health 2021;1010539521101101010 Abbas S, Raza A, Iftikhar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880961>
5. **Adult multisystem inflammatory syndrome in a patient who recovered from COVID-19 postvaccination.** BMJ Case Rep. 2021; 14 Uwaydah AK, Hassan NMM, Abu Ghoush MS, Shahin KMM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883119>
6. **A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.** Cell Host Microbe 2021; Liu H, Yuan M, Huang D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894127>
7. **Beware of traumatic anosmia in COVID-19 pandemic.** Cjem 2021;1-2 Nagamine T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881763>
8. **Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application.** Clin Immunol 2021; 227:108727 Zuo W, Zhao X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887436>
9. **Prevalence of SARS-CoV-2 antibodies among market and city bus depot workers in Lima, Peru.** Clin Infect Dis 2021; Tovar M, Peinado J, Palomino S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881476>
10. **Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort study.** Crit Care 2021; 25:148 Bhatraju PK, Morrell ED, Zelnick L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874973>
11. **Clinical Performance of SARS-CoV-2 IgG and IgM Tests Using an Automated Chemiluminescent Assay.** Curr Med Sci 2021; 41:318-322 Zhou JA, Zeng HL, Deng LY, Li HJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877548>
12. **Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients.** EBioMedicine

2021:103341Balestrieri E, Minutolo A, Petrone V *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33867312>

13. **Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses.** Emerg Microbes Infect 2021:1-28Yang Y, Wang X, Du RH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870851>
14. **SARS-CoV-2 antibodies: comparison of three high-throughput immunoassays versus the neutralization test.** Eur. J. Clin. Invest. 2021:e13573Laterza R, Schirinzi A, Bruno R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870493>
15. **Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel.** Eur. J. Epidemiol. 2021:1-8Reicher S, Ratzon R, Ben-Sahar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884542>
16. **Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index in patients with COVID-19-associated pneumonia.** Gac Med Mex 2020; 156:527-531Carpio-Orantes LD, García-Méndez S, Hernández-Hernández SN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877106>
17. **IFN- γ and TNF- α drive a CXCL10⁺ CCL2⁺ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation.** Genome Med. 2021; 13:64Zhang F, Mears JR, Shakib L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879239>
18. **Dramatic Rise of Seroprevalence Rates of SARS-CoV-2 Antibodies among Healthy Blood Donors: The evolution of a Pandemic.** Int J Infect Dis 2021; Sughayer MA, Mansour A, Al Nuirat A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892190>
19. **Head-to-head validation of six immunoassays for SARS-CoV-2 in hospitalized patients.** J Clin Virol 2021; 139:104821Zonneveld R, Jurriaans S, van Gool T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882373>
20. **Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.** J Hepatol 2021; Rabinowich L, Grupper A, Baruch R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892006>
21. **Development of in-house ELISAs for the detection of anti-SARS-CoV-2 RBD and N IgG and IgM antibodies in biological samples.** J King Saud Univ Sci 2021; 33:101439Ibrahim EH, Ghramh HA, Kilany M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879983>
22. **Multisystem Inflammatory Syndrome in Children (MIS-C) and the Prothrombotic State: Coagulation Profiles and Rotational Thromboelastometry in a MIS-C Cohort.** J Thromb Haemost 2021; Al-Ghafry M, Vagreicha A, Malik M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872443>
23. **Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms.** J Transl Autoimmun 2021; 4:100100Wallukat G, Hohberger B, Wenzel K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880442>
24. **SARS-CoV-2-reactive cellular and humoral immunity in hemodialysis population.** Kidney Int 2021; Anft M, Blazquez-Navarro A, Paniskaki K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887319>

25. **Low immunization rates among kidney transplant recipients who received two doses of the mRNA-1273 SARS-CoV-2 vaccine.** *Kidney Int* 2021; Benotmane I, Gautier-Vargas G, Cognard N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887315>
26. **Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients on haemodialysis. A call to arms.** *Kidney Int* 2021; Billany RE, Selvaskandan H, Adenwalla SF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887316>
27. **COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions.** *mBio* 2021; 12Adeniji OS, Giron LB, Purwar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879594>
28. **Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.** *mBio* 2021; 12Natarajan H, Crowley AR, Butler SE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879585>
29. **SARS-CoV-2 Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020.** *mSphere* 2021; 6Han H, Yi J, Cheng G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883260>
30. **The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives.** *Pulmonology* 2021; Boechat JL, Chora I, Morais A, Delgado L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867315>
31. **Prolonged humoral and cellular immunity in COVID-19-recovered patients.** *Saudi J. Biol. Sci.* 2021; Alsayb MA, Dakhilallah DAA, Makhdoom HQ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867805>

Management miscellaneous diseases (56 articles)

1. **The impact of the COVID-19 pandemic and governor mandated stay at home order on emergency department super utilizers.** *Am J Emerg Med* 2021; 48:114-119Alwood S, Musso MW, Jones GN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892402>
2. **The impact of the COVID-19 pandemic on the utilization of emergency department services for the treatment of injuries.** *Am J Emerg Med* 2021; 47:187-191Harmon KJ, Fliss MD, Marshall SW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892334>
3. **Increased complications in patients who test COVID-19 positive after elective surgery and implications for pre and postoperative screening.** *Am. J. Surg.* 2021; Prasad NK, Lake R, Englum BR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894979>
4. **Medical Student Attitudes Toward Blood Donation in Times of Increased Need.** *Am. Surg.* 2021;31348211011083Khatun R, Otaibi BW, Ssentongo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877939>
5. **COVID-19 pandemic: pain, quality of life and impact on public health in the confinement in Spain.** *Ann Palliat Med* 2021; Iglesias-López E, García-Isidoro S, Castellanos-Sánchez VO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894721>
6. **The impact of distance cataract surgical wet laboratory training on cataract surgical competency of ophthalmology residents.** *BMC Med. Educ.* 2021;

21:219Geary A, Wen Q, Adrianzén R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874941>

7. **Paediatric emergency department dog bite attendance during the COVID-19 pandemic: an audit at a tertiary children's hospital.** *BMJ Paediatr Open* 2021; 5:e001040Tulloch JSP, Minford S, Pimblett V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884313>
8. **Did COVID-19 related delays in surgical management lead to patient morbidity in the orthopaedic oncological population?** *Bone Jt Open* 2021; 2:236-242Fitzgerald MJ, Goodman HJ, Kenan S, Kenan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870729>
9. **Insights into patient preferences for elective surgery during the COVID-19 pandemic.** *Bone Jt Open* 2021; 2:261-270Hotchen AJ, Khan SA, Khan MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882713>
10. **Management of odontogenic cervicofacial infections presenting to oral and maxillofacial units during the first wave of the COVID-19 pandemic in the United Kingdom.** *Br. J. Oral Maxillofac. Surg.* 2021; Puglia FA, Ubhi H, Dawoud B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892990>
11. **Challenges and future directions in breast cancer care in Fukushima prefecture in Japan: correspondence to "A survey on the current status of clinical resources for diagnosis and treatment of breast cancer in rural hospitals of the Tohoku region in Japan".** *Breast Cancer* 2021:1-2Ozaki A, Tachibana K, Ohtake T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880708>
12. **Prostate cancer survivorship, deaths, and health care management.** *Cancer* 2021; Bauer JE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882148>
13. **Impact of COVID-19 on the Children with Cancer in 6 Pediatric Oncology Units (POU's) of Pakistan-a Multi-Center Study.** *Cancer Invest.* 2021:1-11Raza MR, Maqsood S, Rana ZA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33866889>
14. **E-Handover in Surgery Improves Clinical Efficiency and Adherence to COVID-19 Infection Control Measures.** *Cureus* 2021; 13:e13967Jacob N, Chaudhary O, Darwish NM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880300>
15. **Dental team and infection control for the COVID-19: (A short review of the current guidelines).** *Dent. Res. J. (Isfahan)* 2020; 17:409-411Torabinia N, Nilchian F, Razavi SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889344>
16. **Graft-Versus-Host Disease-Like Reactions in the Gastrointestinal Tract in a Patient with SARS-CoV-2 Infection.** *Dig Endosc* 2021; Ozawa N, Yamazaki K, Kushima R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876462>
17. **The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects.** *Drug Discov Today* 2021; Qiu T, Wang Y, Liang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892148>
18. **National approaches to managing cancer care: responses of countries in the MENA region to the COVID-19 pandemic.** *Ecancermedicalscience* 2021; 15:1189Benbrahim Z, Mula-Hussain L, Al-Shamsi HO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889198>
19. **Silver linings: a qualitative study of desirable changes to cancer care during the COVID-19 pandemic.** *Ecancermedicalscience* 2021; 15:1202Lombe D, Sullivan R, Caduff C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889211>

20. **Systematic review of international guidelines for head and neck oncology management in COVID-19 patients.** Eur Arch Otorhinolaryngol 2021;1-37 Gascon L, Fournier I, Chiesa-Estomba C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891167>
21. **Breast Cancer Management During the COVID-19 Pandemic: The Senologic International Society Survey.** Eur J Breast Health 2021; 17:188-196 Mathelin C, Ame S, Anyanwu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870120>
22. **Psoriasis care during the time of COVID-19: real-world data on changes in treatments and appointments from a German university hospital.** Eur. J. Dermatol. 2021; Ninosu N, Roehrich F, Diehl K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871361>
23. **Impact of the COVID-19 pandemic on access to health care services among patients with Multiple Sclerosis in the Lazio region, Italy.** Eur. J. Neurol. 2021; Colais P, Cascini S, Balducci M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33896086>
24. **The cost of living with cancer during the second wave of COVID-19: A mixed methods study of Danish cancer patients' perspectives.** Eur. J. Oncol. Nurs. 2021; 52:101958 Dieperink KB, Ikander T, Appiah S, Tolstrup LK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878634>
25. **Impact of the first COVID-19 shutdown on patient volumes and surgical procedures of a Level I trauma center.** Eur. J. Trauma Emerg. Surg. 2021;1-11 Kreis CA, Ortmann B, Freistuehler M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881555>
26. **Can we safely use systemic treatment in atopic dermatitis during the COVID-19 pandemic? Overview of selected conventional and biologic systemic therapies.** Expert Rev. Clin. Immunol. 2021; Marko M, Pawliczak R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33866905>
27. **Deep Brain Stimulation for Parkinson's Disease During the COVID-19 Pandemic: Patient Perspective.** Front. Hum. Neurosci. 2021; 15:628105 Zhang C, Zhang J, Qiu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867957>
28. **Outcomes of COVID-19 Negative Hip Fracture Patients During the Acute and Subacute Pandemic.** Geriatr Orthop Surg Rehabil 2021; 12:21514593211006692 Onizuka N, Topor LN, Schroder LK, Switzer JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868768>
29. **The role of community pharmacists in increasing access and use of self-care interventions for sexual and reproductive health in the Eastern Mediterranean Region: examples from Egypt, Jordan, Lebanon and Somalia.** Health Res. Policy Syst. 2021; 19:49 El Bizri L, Jarrar LG, Ali WKA, Omar AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882956>
30. **Community-led HIV self-testing for men who have sex with men in Lebanon: lessons learned and impact of COVID-19.** Health Res. Policy Syst. 2021; 19:50 Maatouk I, Nakib ME, Assi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882944>
31. **COVID-19 Management in Clinical Dental Care. Part I: Epidemiology, Public Health Implications, and Risk Assessment.** Int. Dent. J. 2021; Melo P, Barbosa JM, Jardim L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879353>

32. **Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: A national qualitative assessment in Canada.** Int. J. Drug Policy 2021;103237Ali F, Russell C, Nafeh F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893026>
33. **Learning from organisational changes in the management of breast cancer patients during the COVID-19 pandemic: Preparing for a second wave at a breast unit in northern Italy.** Int. J. Health Plann. Manage. 2021; Ferro A, Cristofolini P, Garcia-Etienne CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890324>
34. **Oral isotretinoin treatment in patients with acne vulgaris during the COVID-19 pandemic: A retrospective cohort study in a tertiary care hospital.** J Cosmet Dermatol 2021; Demirel Ögüt N, Kutlu Ö, Erbağcı E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884755>
35. **Management of patients with X-linked hypophosphatemic rickets during Covid-19 pandemic lockdown.** J. Pediatr. Endocrinol. Metab. 2021; Baroncelli GI, Bertelloni S, Cosci ODCM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887813>
36. **Cancer survivors' perceived vulnerability to COVID-19 and impacts on cognitive, affective, and behavioral responses to the pandemic.** J. Psychosoc. Oncol. 2021;1-19Slivjak Et MA, Fishbein Jn MA, Nealis M MPH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886442>
37. **COVID-19 - Changes in Workload and Clinical Practice in Trauma and Orthopaedics in a District General Hospital in the United Kingdom.** Malays Orthop J 2021; 15:100-104Faria G, Virani S, Tadros BJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880155>
38. **Impact of COVID-19 on Clinical Practices during Lockdown: A pan India Survey of Orthopaedic Surgeons.** Malays Orthop J 2021; 15:55-62Jain VK, Upadhyaya GK, Iyengar KP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880149>
39. **Orthopaedic Practices and Surgeries during COVID-19 in Pakistan - A Survey Based Study.** Malays Orthop J 2021; 15:72-78Saad-Ilyas M, Zehra U, Khan UU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880151>
40. **Increased dispensing of prescription medications in Australia early in the COVID-19 pandemic.** Med. J. Aust. 2021; Mian M, Sreedharan S, Giles S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884634>
41. **Evaluation of Parents' Knowledge and Attitudes Towards Pediatric Dental Practice during the COVID-19 Pandemic.** Oral Health Prev Dent 2021; 19:271-277Surme K, Akman H, Cime Akbaydogan L, Akin M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881290>
42. **Orthopaedic surgeons' perceptions and attitudes on COVID-19 related changes in practice: an international cross-sectional survey.** Pan Afr. Med. J. 2021; 38:96Meraghni N, Bouyoucef H, Larbi RS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889262>
43. **Effects of COVID -19 pandemic and lockdown on people with multiple system atrophy participating in a therapeutic education program.** Parkinsonism Relat.

- Disord. 2021; 86:78-80Cámara A, Compta Y, Pérez-Soriano A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33873000>
44. **Online action planning forums to develop a roadmap to mitigate the impact of COVID-19 on the delivery of global children's surgical care.** Pediatr. Surg. Int. 2021;1-13Abbas A, Samad L, Ozgediz D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880597>
 45. **Integrated management is effective in the prevention and control of COVID-19 in the blood purification center: joint efforts from multiple departments.** Ren Replace Ther 2021; 7:19Yin J, Yin J, Tian Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868717>
 46. **Hospitalization and Mortality from COVID-19 of Patients with Rheumatic Inflammatory Diseases in Andalusia.** Reumatol. Clin. 2021; Mena-Vázquez N, Manrique Arija S, Rojas-Giménez M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895100>
 47. **Knowledge, awareness, attitude and practice of dental practitioners regarding Covid-19 pandemic and infection control: a cross sectional study in Kolkata metropolitan region.** Rocz. Panstw. Zakl. Hig. 2021; 72:95-101Bera R, Kalia P, Hiremath S, Jaiswal D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883104>
 48. **Management of colorectal cancer in the era of COVID-19: Challenges and suggestions.** Sci. Prog. 2021; 104:368504211010626Alam W, Bouferraa Y, Haibe Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878982>
 49. **Prevention and control measures of the coronavirus disease 2019 (COVID-19) in low-risk departments: The spine surgery department example.** Sci. Prog. 2021; 104:368504211009670Zheng Y, Zhang X, Fang S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33878962>
 50. **Surgical volume reduction and the announcement of triage during the 1st wave of the COVID-19 pandemic in Japan: a cohort study using an interrupted time series analysis.** Surg. Today 2021;1-8Okuno T, Takada D, Shin JH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33881619>
 51. **Multicenter study of US trauma centers examining the effect of the COVID-19 pandemic on injury causes, diagnoses and procedures.** Trauma Surg Acute Care Open 2021; 6:e000655Salottolo K, Caiafa R, Mueller J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33884307>
 52. **Almost one year of COVID-19 pandemic: how radiotherapy centers have counteracted its impact on cancer treatment in Lombardy, Italy. CODRAL/AIRO-L study.** Tumori 2021:3008916211009974Jereczek-Fossa BA, Palazzi MF, Tonoli S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33885350>
 53. **Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: A model based analysis.** Vaccine 2021; Daniels V, Saxena K, Roberts C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875269>
 54. **[Examination of patients with glaucoma during the COVID-19 pandemic].** Vestn. Oftalmol. 2021; 137:75-83Kuryshcheva NI, Pechenkina AA, Goncharova AS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33881266>
 55. **Long-term control of melanoma brain metastases with co-occurring intracranial infection and involuntary drug reduction during COVID-19**

- pandemic: A case report.** World J Clin Cases 2021; 9:2373-2379Wang Y, Lian B, Cui CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869616>
56. **Colorectal cancer screening in the COVID-19 era.** World. J. Gastrointest. Oncol. 2021; 13:238-251Kadakuntla A, Wang T, Medgyesy K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889276>

Management (45 articles)

1. **Development of a Prone Team and Exploration of Staff Perceptions During COVID-19.** AACN Adv. Crit. Care 2021:e1-e10Miguel K, Snyderman C, Capasso V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878151>
2. **Models will only get us so far: planning for place of care and death.** Age Ageing 2021; Borgstrom E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878163>
3. **Priority Setting of Ventilators in the COVID-19 Pandemic from the Public's Perspective.** AJOB Empir Bioeth 2021:1-13Asghari F, Parsapour A, Shamsi Gooshki E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881385>
4. **Comparative outcomes between COVID-19 and influenza patients placed on veno-venous extracorporeal membrane oxygenation for severe ARDS.** Am. J. Surg. 2021; Raff LA, Reid TD, Johnson D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894980>
5. **Functional electrical stimulation-cycling favours erectus position restoration and walking in patients with critical COVID-19. A proof-of-concept controlled study.** Ann. Phys. Rehabil. Med. 2021; Mateo S, Bergeron V, Cheminon M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895378>
6. **Using CPAP in COVID-19 patients outside of the intensive care setting: a comparison of survival and outcomes between dialysis and non-dialysis dependent patients.** BMC Nephrol. 2021; 22:144Floyd L, Stauss M, Storrar J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882842>
7. **Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?** Clin Sci (Lond) 2021; 135:1009-1014Simko F, Baka T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881142>
8. **Perspectives of Internal Medicine Physicians Regarding Medication Abortion Provision in the Primary Care Setting.** Contraception 2021; Wolgemuth T, Judge-Golden C, Lane K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894250>
9. **Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units.** Crit Care 2021; 25:155Lavinio A, Ercole A, Battaglini D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888132>
10. **Essential Health and Nutrition Service Provision during the COVID-19 Pandemic: Lessons from Select Ethiopian Woredas.** Curr Dev Nutr 2021; 5:nzab024Workicho A, Kershaw MJ, Berhanu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884343>
11. **Deploying Healthcare Providers during COVID-19 Pandemic.** Disaster Med Public Health Prep 2021:1-13Shander A, Mesrobian J, Weiss J, Javidroozi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33866981>

12. **Possible Potential Effects of Honey and Its Main Components Against Covid-19 Infection.** Dose Response 2021; 19:1559325820982423Abedi F, Ghasemi S, Farkhondeh T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867892>
13. **Transmission of SARS-CoV-2 before and after symptom onset: impact of nonpharmaceutical interventions in China.** Eur. J. Epidemiol. 2021; 36:429-439Bushman M, Worby C, Chang HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881667>
14. **COVID-SCORE Spain: Public perceptions of key government COVID-19 control measures.** Eur. J. Public Health 2021; White TM, Cash-Gibson L, Martin-Moreno JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872348>
15. **Can single-use bronchoscopes help prevent nosocomial COVID-19 infections?** Expert Rev. Med. Devices 2021; Barron S, Kennedy MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891519>
16. **Rationales and uncertainties for aspirin use in COVID-19: a narrative review.** Fam Med Community Health 2021; 9Sayed Ahmed HA, Merrell E, Ismail M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879541>
17. **Cooking at Home and Adherence to the Mediterranean Diet During the COVID-19 Confinement: The Experience From the Croatian COVIDiet Study.** Front Nutr 2021; 8:617721Pfeifer D, Rešetar J, Gajdoš Kljusurić J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869262>
18. **Construction and Performance Testing of a Fast-Assembly COVID-19 (FALCON) Emergency Ventilator in a Model of Normal and Low-Pulmonary Compliance Conditions.** Front. Physiol. 2021; 12:642353White LA, Mackay RP, Solitro GF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868006>
19. **The Effect of Persuasive Messages in Promoting Home-Based Physical Activity During COVID-19 Pandemic.** Front. Psychol. 2021; 12:644050Carfora V, Catellani P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868116>
20. **Who Gets Cured? COVID-19 and Developing a Critical Medical Sociology and Anthropology of Cure.** Front Sociol 2020; 5:613548Berghs M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869531>
21. **In Search of Wise Management of Medical Resources and Personnel in the Long Combat With Coronavirus.** Front Sociol 2020; 5:40Hu YR, Wang M, Zhang B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869447>
22. **Chronic use of Renin-Angiotensin-Aldosterone-System blockers and mortality in COVID-19: a multicenter prospective cohort and literature review.** Fundam. Clin. Pharmacol. 2021; Gault N, Esposito-Farese M, Revest M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876439>
23. **Guidelines for clinical management of SARS-CoV-2 infection.** Gac Med Mex 2020; 156:576-583García-Álvarez JL, García-Vigil JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877121>
24. **Nonpharmaceutical interventions contribute to the control of COVID-19 in China based on a pairwise model.** Infect Dis Model 2021; 6:643-663Luo XF, Feng S, Yang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869909>
25. **Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: a randomized clinical trial.** Int J Infect Dis

- 2021; Siami Z, Aghajanian S, Mansouri S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33878462>
26. **Acceptability of COVID-19 Vaccine in Africa.** Int J MCH AIDS 2021; 10:134-138Wirsiy FS, Nkfusai CN, Ako-Arrey DE *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868778>
 27. **Case Study use of high-flow nasal cannula in COVID-19 has improved effectiveness, safety and tolerability when applied in lateral position compared with prone positioning.** Intensive Crit Care Nurs 2021:103061Sanz-Moncusí M, Rosselló-Sancho J, Garcia-Alamino JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875340>
 28. **The use of direct acting oral anticoagulants in patients with COVID-19 infection.** J Community Hosp Intern Med Perspect 2021; 11:184-186Aly R, Gupta S, Singh B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889317>
 29. **Quantitative fit testing of filtering face-piece respirators during the COVID-19 pandemic reveals anthropometric deficits in most respirators available in Iran.** J Environ Health Sci Eng 2021:1-13Fakherpour A, Jahangiri M, Seif M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33875931>
 30. **The mechanisms between illness representations of COVID-19 and behavioral intention to visit hospitals for scheduled medical consultations in a Chinese general population.** J Health Psychol 2021:13591053211008217She R, Luo S, Lau MM, Lau JTF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878946>
 31. **The Pulsatile Modification Improves Hemodynamics and Attenuates Inflammatory Responses in Extracorporeal Membrane Oxygenation.** J Inflamm Res 2021; 14:1357-1364Li G, Zeng J, Liu Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880051>
 32. **Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications.** J Inflamm Res 2021; 14:1487-1510Rowaiye AB, Okpalefe OA, Onuh Adejoke O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889008>
 33. **Letter regarding 'Neurointervention for emergent large vessel occlusion strokes during the COVID-19 pandemic'.** J. Neurointerv. Surg. 2021; Hamidianjahromi A, Mowla A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875553>
 34. **Chemo-Preventive Effect of Vegetables and Fruits Consumption on the COVID-19 Pandemic.** J Nutr Food Sci 2021; 4Yedjou CG, Alo RA, Liu J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33884222>
 35. **COVID-19 Associated Reversible Cerebral Vasoconstriction Syndrome Successfully Treated with Nimodipine and Aspirin.** J. Stroke Cerebrovasc. Dis. 2021; 30:105822Mansoor T, Alsarrah AA, Mousavi H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895426>
 36. **Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).** J Thromb Haemost 2021; Thaler J, Ay C, Gleixner KV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877735>
 37. **Recommendations for ethical decision making regarding hospital visitation during the COVID-19 pandemic.** Medizinische Klinik - Intensivmedizin und Notfallmedizin 2021; Rogge A, Naeve-Nydahl M, Nydahl P *et al.*

38. **Silent hypoxia in COVID-19: pathomechanism and possible management strategy.** Mol. Biol. Rep. 2021:1-7Rahman A, Tabassum T, Araf Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33891272>
39. **Challenges facing nurse managers during and beyond COVID-19 pandemic in relation to perceived organizational support.** Nurs. Forum 2021; Gab Allah AR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33870510>
40. **A nutraceutical strategy for downregulating TGF β signalling: prospects for prevention of fibrotic disorders, including post-COVID-19 pulmonary fibrosis.** Open Heart 2021; 8DiNicolantonio JJ, McCarty MF, Barroso-Aranda J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33879509>
41. **Promoting Population Behavioral Health in a Safety-Net Health System During the COVID-19 Pandemic.** Psychiatr. Serv. 2021:appips202000546Lim CT, Fulwiler CE, Carson NJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882680>
42. **Probiotics/ prebiotics in viral respiratory infections: implication for emerging pathogens.** Recent Pat Biotechnol 2021; Heidari Z, Tajbakhsh A, Gheibi-Hayat SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874878>
43. **Rapid Response System Adaptations at 40 US Hospitals During the COVID-19 Pandemic.** Resusc Plus 2021:100121Mitchell OJL, Doran O, Yuriditsky E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33870236>
44. **Guidance for the clinical management of infants born to mothers with suspected/confirmed COVID-19 in Singapore.** Singapore Med J 2021; Yeo KT, Biswas A, Ho SKY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33866749>
45. **Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy.** Thromb Res 2021; 203:1-4Rhoades R, Leong R, Kopenitz J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894473>

Mental – public health (104 articles)

1. **Battling Burnout at the Frontlines of Health Care Amid COVID-19.** AACN Adv. Crit. Care 2021:e1-e9Howell BAM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882576>
2. **The associations of life quality, depression, and cognitive impairment with mortality in older adults with COVID-19: a prospective, observational study.** Acta Clin. Belg. 2021:1-8Bayrak M, Çadirci K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870876>
3. **Severe mental illness is associated with increased mortality and severe course of COVID-19.** Acta Psychiatr. Scand. 2021; Barcella CA, Polcwiartek C, Mohr GH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894064>
4. **Effects of social support on mental health for critical care nurses during the coronavirus disease 2019 (COVID-19) pandemic in Japan: A web-based cross-sectional study.** Acute Med Surg 2021; 8:e645Tatsuno J, Unoki T, Sakuramoto H, Hamamoto M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868689>
5. **KNOWLEDGE AND REASONS FOR ANXIETY AMONG NURSES TOWARDS COVID -19 IN NIGERIA.** Afr J Infect Dis 2021; 15:16-23Odikpo LC, Abazie HO, Emon D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889798>

6. **Aging and emotion regulation during the COVID-19 pandemic.** Aging Ment. Health 2021;1-8Wolfe HE, Isaacowitz DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870771>
7. **COVID-19 in oncology palliative care: psychological stress from the perspective of psychodynamics at work.** Ann Palliat Med 2021; de Azeredo Siqueira AS, Teixeira ER, de Oliveira da Cunha DA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894722>
8. **COVID-19 pandemic: pain, quality of life and impact on public health in the confinement in Spain.** Ann Palliat Med 2021; Iglesias-López E, García-Isidoro S, Castellanos-Sánchez VO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894721>
9. **The effect of prohibiting outside food during COVID-19 pandemic on the body weight of schizophrenic patients taking olanzapine or clozapine: a retrospective self-controlled study.** Ann Palliat Med 2021; Zhang C, Wang X, Hu C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894724>
10. **Impact of COVID-19 pandemic related lockdown on Suicide: Analysis of newspaper reports during pre-lockdown and lockdown period in Bangladesh and India.** Asian J Psychiatr 2021; 60:102649Kar SK, Menon V, Arafat SMY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887672>
11. **Investigating smoking and nicotine dependence among people with severe mental illness during the COVID-19 pandemic: analysis of linked data from a UK Closing the Gap cohort.** BJPsych Open 2021; 7:e86Peckham E, Allgar V, Crosland S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888178>
12. **A qualitative study of physician perceptions and experiences of caring for critically ill patients in the context of resource strain during the first wave of the COVID-19 pandemic.** BMC Health Serv. Res. 2021; 21:374Parsons Leigh J, Kemp LG, de Grood C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888096>
13. **Anxiety and facial self-contacts: possible impact on COVID-19 transmission in dental practice.** BMC Oral Health 2021; 21:200Carrillo-Diaz M, Lacomba-Trejo L, Del Valle-González A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879144>
14. **The impact of the COVID-19 pandemic on mental health in the general population: a comparison between Germany and the UK.** BMC Psychol 2021; 9:60Knolle F, Ronan L, Murray GK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892807>
15. **Attitudes, behaviours and barriers to public health measures for COVID-19: a survey to inform public health messaging.** BMC Public Health 2021; 21:765Lang R, Benham JL, Atabati O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882896>
16. **How do Canadian public health agencies respond to the COVID-19 emergency using social media: a protocol for a case study using content and sentiment analysis.** BMJ Open 2021; 11:e041818Kothari A, Foisey L, Donelle L, Bauer M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888527>
17. **Remote care for mental health: qualitative study with service users, carers and staff during the COVID-19 pandemic.** BMJ Open 2021; 11:e049210Liberati E, Richards N, Parker J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888531>
18. **Fears of compassion magnify the harmful effects of threat of COVID-19 on mental health and social safeness across 21 countries.** Clin. Psychol.

- Psychother. 2021; Matos M, McEwan K, Kanovský M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880832>
19. **Excited Catatonia - A Delayed Neuropsychiatric Complication of COVID-19 Infection.** Cureus 2021; 13:e13891Zain SM, Muthukanagaraj P, Rahman N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880247>
 20. **The 5-factor model of psychological response to COVID-19: its correlation with anxiety and depression.** Curr. Psychol. 2021:1-13Aboul-Ata MA, Qonsua FT.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33875911>
 21. **Frequency and perceived effectiveness of mental health providers' coping strategies during COVID-19.** Curr. Psychol. 2021:1-10Reilly SE, Soulliard ZA, McCuddy WT, Mahoney JJ, 3rd. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867779>
 22. **How are OCD patients and their families coping with the COVID-19 pandemic? A qualitative study.** Curr. Psychol. 2021:1-11Tandt HLN, Van Parys H, Leyman L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867778>
 23. **Internet-Related Behaviors and Psychological Distress Among Schoolchildren During the COVID-19 School Hiatus.** Cyberpsychol Behav Soc Netw 2021; Chen CY, Chen IH, Pakpour AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877905>
 24. **Addressing Pediatric Mental Health during COVID-19 and other Disasters: A National Tabletop Exercise.** Disaster Med Public Health Prep 2021:1-13Gupta S, Schreiber M, McGuire T, Newton C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867004>
 25. **Pre-pandemic cognitive function and COVID-19 mortality: prospective cohort study.** Eur. J. Epidemiol. 2021:1-6Batty GD, Deary IJ, Gale CR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33893922>
 26. **Spiritual Well-Being and Mental Health During the COVID-19 Pandemic in Italy.** Front Psychiatry 2021; 12:626944Coppola I, Rania N, Parisi R, Lagomarsino F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868047>
 27. **Psychological Health, Sleep Quality, Behavior, and Internet Use Among People During the COVID-19 Pandemic: A Cross-Sectional Study.** Front Psychiatry 2021; 12:632496Elhadi M, Alsoufi A, Msherghi A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868049>
 28. **Prevalence of Mental Health Problems and Its Associated Factors Among Recovered COVID-19 Patients During the Pandemic: A Single-Center Study.** Front Psychiatry 2021; 12:602244Khademi M, Vaziri-Harami R, Shams J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868043>
 29. **Mental Health, Social and Emotional Well-Being, and Perceived Burdens of University Students During COVID-19 Pandemic Lockdown in Germany.** Front Psychiatry 2021; 12:643957Kohls E, Baldofski S, Moeller R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33889102>
 30. **Correlates of Psychological Distress Among Pakistani Adults During the COVID-19 Outbreak: Parallel and Serial Mediation Analyses.** Front. Psychol. 2021; 12:647821Ashraf F, Zareen G, Nusrat A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868122>

31. **An Exploratory Study of Police Officers' Perceptions of Health Risk, Work Stress, and Psychological Distress During the COVID-19 Outbreak in China.** Front. Psychol. 2021; 12:632970Huang Q, Bodla AA, Chen C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868096>
32. **COVID-19: Are School Counseling Services Ready? Students' Psychological Symptoms, School Counselors' Views, and Solutions.** Front. Psychol. 2021; 12:647740Karaman MA, Eşici H, Tomar İ H, Aliyev R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868121>
33. **Psychological Differences Among Healthcare Workers of a Rehabilitation Institute During the COVID-19 Pandemic: A Two-Step Study.** Front. Psychol. 2021; 12:636129Panzeri A, Rossi Ferrario S, Cerutti P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868105>
34. **Prolonged COVID 19 Outbreak and Psychological Response of Nurses in Italian Healthcare System: Cross-Sectional Study.** Front. Psychol. 2021; 12:608413Ranieri J, Guerra F, Perilli E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889106>
35. **Culturally Grounded Scapegoating in Response to Illness and the COVID-19 Pandemic.** Front. Psychol. 2021; 12:632641Yang Q, Young IF, Wan J, Sullivan D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33889110>
36. **Cultural Sources of Strength and Resilience: A Case Study of Holistic Wellness Boxes for COVID-19 Response in Indigenous Communities.** Front Sociol 2021; 6:612637Aulandez KMW, Walls ML, Weiss NM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33869563>
37. **Commentary: COVID-19 and mental health equity in the United States.** Front Sociol 2020; 5:584390Condon EM, Dettmer AM, Gee DG *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33869513>
38. **Understanding Grief During the First-Wave of COVID-19 in the United Kingdom-A Hypothetical Approach to Challenges and Support.** Front Sociol 2021; 6:607645Fang C, Comery A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869550>
39. **Impact of coronaphobia on treatment and follow-up compliance of cancer patients.** Future Oncol 2021; Akagunduz B, Ozer M, Karacin C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880932>
40. **Mental disorder prevalence among populations impacted by coronavirus pandemics: A multilevel meta-analytic study of COVID-19, MERS & SARS.** Gen. Hosp. Psychiatry 2021; 70:124-133Boden M, Cohen N, Froelich JM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894561>
41. **Public Health Crises In Comparison: China's Epidemic Response Policies From SARS To COVID-19.** Glob Public Health 2021:1-14Li M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33891518>
42. **Cyberbullying, social stigma, and self-esteem: the impact of COVID-19 on students from East and Southeast Asia at the University of Jordan.** Heliyon 2021; 7:e06711Alsawalqa RO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869877>
43. **Does 'COVID-19 phobia' stimulate career anxiety?: Experience from a developing country.** Heliyon 2021; 7:e06346Mahmud MS, Rahman MM, Masud-UI-

- Hasan M, Islam MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869821>
44. **Psychological pressure and changes in food consumption: the effect of COVID-19 crisis.** *Heliyon* 2021; 7:e06607Russo C, Simeone M, Demartini E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869860>
 45. **Tsunami of economic turmoil to hit the healthcare in 2021-2022: COVID-19 pandemic is just an earthquake.** *Hosp Pract (1995)* 2021:1-8Arredondo E, Kashyap R, Surani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33866912>
 46. **Perceived quarantine competence, attitudes, and practices among the public during the coronavirus pandemic: A Saudi descriptive study.** *Int J Clin Pract* 2021:e14242Almarwani AM, Aljohani MS, Eweda G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884727>
 47. **About Anxiety levels and Anti-anxiety drugs among quarantined Undergraduate Jordanian Students during COVID-19 Pandemic.** *Int J Clin Pract* 2021:e14249Alqudah A, Al-Smadi A, Oqal M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884714>
 48. **Impact of COVID-19 on post-traumatic stress symptoms in the general population: An integrative review.** *Int. J. Ment. Health Nurs.* 2021; Hong S, Kim H, Park MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884723>
 49. **Association between resilience and burnout of front-line nurses at the peak of the COVID-19 pandemic: Positive and negative affect as mediators in Wuhan.** *Int. J. Ment. Health Nurs.* 2021; Zhang X, Jiang X, Ni P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893718>
 50. **Senior BSN students' confidence, comfort, and perception of readiness for clinical practice: the impacts of COVID-19.** *Int. J. Nurs. Educ. Scholarsh.* 2021; 18Musallam E, B AF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882201>
 51. **The quality of life, resources, and coping during the first weeks of the COVID-19 pandemic in people seeking psychological counselling before the pandemic.** *Int. J. Occup. Med. Environ. Health* 2021; Chwaszcz J, Palacz-Chrisidis A, Wiechetek M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33885045>
 52. **COVID-19: The future of nursing will determine the fate of our health services.** *Int Nurs Rev* 2021; 68:9-11Catton H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891771>
 53. **Factors affecting frontline Korean nurses' mental health during the COVID-19 pandemic.** *Int Nurs Rev* 2021; Cho M, Kim O, Pang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894067>
 54. **Nurses' experiences in response to COVID-19 in a psychiatric ward in Singapore.** *Int Nurs Rev* 2021; Gao Z, Tan FPL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894062>
 55. **Clinician mental health, nursing shortages and the COVID-19 pandemic: Crises within crises.** *Int Nurs Rev* 2021; 68:12-14Turale S, Nantsupawat A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891772>
 56. **Drawing on emotions: the evolving role of art therapy.** *Ir. J. Psychol. Med.* 2021:1-3Cheng C, Elamin ME, May H, Kennedy M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870885>
 57. **Cannabis withdrawal induced brief psychotic disorder: a case study during the national lockdown secondary to the COVID-19 pandemic.** *J. Addict. Dis.*

- 2021:1-8Marín J, Pérez de Mendiola X, Fernández S, Chart JP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33884940>
58. **Letters from the pandemic: Nursing student narratives of change, challenges and thriving at the outset of COVID-19.** J. Adv. Nurs. 2021; Heilferty CM, Phillips LJ, Mathios R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871891>
 59. **Mental health services in primary care: Evidence for the feasibility of telehealth during the COVID-19 pandemic.** J Affect Disord Rep 2021; 5:100146Frank HE, Grumbach NM, Conrad SM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33870261>
 60. **Mental health services in primary care: Evidence for the feasibility of telehealth during the COVID-19 pandemic.** J Affect Disord Rep 2021; 5:100146Frank HE, Grumbach NM, Conrad SM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33870261>
 61. **Custodial Grandparent's Job Loss During the COVID-19 Pandemic and Its Relationship With Parenting Stress and Mental Health.** J. Appl. Gerontol. 2021:7334648211006222Wu Q, Xu Y, Jedwab M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33870739>
 62. **Impact of COVID-19 pandemic and related isolation measures on violence against children in Egypt.** J. Egypt. Public Health Assoc. 2021; 96:11AboKresha SA, Abdelkreem E, Ali RAE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880660>
 63. **Association Between Perceived Resilience and Mental Well-Being of Saudi Nursing Students During COVID-19 Pandemic: A Cross-Sectional Study.** J. Holist. Nurs. 2021:8980101211009063Grande RAN, Berdida DJE, Villagrancia HN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876982>
 64. **"It's ok, mom. I got it!": Exploring the experiences of young adults with intellectual disabilities in a postsecondary program affected by the COVID-19 pandemic from their perspective and their families' perspective.** J Intellect Disabil 2021:17446295211002346Spencer P, Van Haneghan JP, Baxter A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33878973>
 65. **Intimate Partner Violence Experiences During COVID-19 Among Male Couples.** J Interpers Violence 2021:8862605211005135Walsh AR, Sullivan S, Stephenson R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33866839>
 66. **Development of a Resource Guide to Support the Engagement of Mental Health Providers and Patients With Digital Health Tools: Multimethod Study.** J Med Internet Res 2021; 23:e25773Strudwick G, McLay D, Lo B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33885374>
 67. **Impact of the COVID-19 Pandemic on Health Care Utilization in a Large Integrated Health Care System: Retrospective Cohort Study.** J Med Internet Res 2021; 23:e26558Xu S, Glenn S, Sy L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882020>
 68. **Impact of the COVID-19 lockdown on screen media use in patients referred for ADHD to child and adolescent psychiatry: an introduction to problematic use of the internet in ADHD and results of a survey.** J Neural Transm (Vienna) 2021:1-11Werling AM, Walitza S, Drechsler R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33885969>

69. **Survey of attitudes of individuals who underwent remote prenatal check-ups and consultations in response to the COVID-19 pandemic.** J. Obstet. Gynaecol. Res. 2021; Nakagawa K, Umazume T, Mayama M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880830>
70. **Negative Effects of COVID-19 Stay-at-Home Mandates on Physical Intervention Outcomes: A Preliminary Study.** J. Parkinsons Dis. 2021; Templeton JM, Poellabauer C, Schneider S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867363>
71. **Anxiety and COVID-19: A study of online content readability.** J Prev Interv Community 2021:1-9 Seidel EJ, Hillyer GC, Basch CH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33871313>
72. **Psychosocial impact of the COVID-19 pandemic on cancer patients, survivors and caregivers.** J. Psychosoc. Oncol. 2021:1-7 Amaniera I, Bach C, Vachani C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33870877>
73. **The impact of COVID-19 on the professional and personal lives of pediatric oncology social workers.** J. Psychosoc. Oncol. 2021:1-15 Wiener L, Fry A, Pelletier W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886433>
74. **Spiritual Support During COVID-19 in England: A Scoping Study of Online Sources.** J Relig Health 2021:1-22 Papadopoulos I, Lazzarino R, Wright S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33871782>
75. **State health disparities research in Rural America: Gaps and future directions in an era of COVID-19.** J Rural Health 2021; Cacari Stone L, Roary MC, Diana A, Grady PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881778>
76. **Mobile Sensing Apps and Self-management of Mental Health During the COVID-19 Pandemic: Web-Based Survey.** JMIR Form Res 2021;
5:e24180 Suruliraj B, Bessenyei K, Bagnell A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33872181>
77. **Learning the Mental Health Impact of COVID-19 in the United States With Explainable Artificial Intelligence: Observational Study.** JMIR Ment Health 2021;
8:e25097 Jha IP, Awasthi R, Kumar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877051>
78. **Loneliness, worries, anxiety, and precautionary behaviours in response to the COVID-19 pandemic: A longitudinal analysis of 200,000 Western and Northern Europeans.** Lancet Reg Health Eur 2021; 2:100020 Varga TV, Bu F, Dissing AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870246>
79. **A mental health informatics study on the mediating effect of the regulatory emotional self-efficacy.** Math Biosci Eng 2021; 18:2775-2788 Xu Z, Du J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33892571>
80. **Experiences of critical care nurses fighting against COVID-19: A qualitative phenomenological study.** Nurs. Forum 2021; Chegini Z, Arab-Zozani M, Rajabi MR, Kakemam E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895986>
81. **The psychosocial impact on frontline nurses of caring for patients with COVID-19 during the first wave of the pandemic in New York City.** Nurs. Outlook 2021; Kovner C, Raveis VH, Van Devanter N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894986>
82. **Associations between COVID-19 perceptions, anxiety, and depressive symptoms among adults living in the United States.** Nurs. Outlook 2021;

Wierenga KL, Moore SE, Pressler SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894985>

83. **The Effect of Loneliness on Death Anxiety in the Elderly During the COVID-19 Pandemic.** Omega (Westport) 2021;302228211010587Guner TA, Erdogan Z, Demir I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878967>
84. **It's a conspiracy: Covid-19 conspiracies link to psychopathy, Machiavellianism and collective narcissism.** Pers. Individ. Dif. 2021; 171:110559Hughes S, Machan L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867616>
85. **Investigation of psychiatric symptoms in individuals in Turkey during the COVID-19 outbreak.** Perspect. Psychiatr. Care 2021; Kök Eren H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33896012>
86. **Adolescent psychopathological profiles and the outcome of the COVID-19 pandemic: Longitudinal findings from the UK Millennium Cohort Study.** Prog. Neuropsychopharmacol. Biol. Psychiatry 2021;110330Essau CA, de la Torre-Luque A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887389>
87. **Supporting the Mental Health Workforce During and After COVID-19.** Psychiatr. Serv. 2021:appips202000509Druss BG, Cohen AN, Brister T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882690>
88. **OCD during COVID-19: Understanding clinical and non-clinical anxiety in the community.** Psychiatry Res 2021; 300:113910Acenowr CP, Coles ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872852>
89. **Longitudinal changes in psychological distress in the UK from 2019 to September 2020 during the COVID-19 pandemic: Evidence from a large nationally representative study.** Psychiatry Res 2021; 300:113920Daly M, Robinson E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882397>
90. **Predictors and consequences of loneliness during the COVID-19 Pandemic.** Psychiatry Res 2021; 300:113934Rumas R, Shamblaw AL, Jagtap S, Best MW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882398>
91. **The role of the COVID-19 pandemic in altered psychological well-being, mental health and sleep: an online cross-sectional study.** Psychol Health Med 2021;1-9Allen SF, Stevenson J, Lazuras L, Akram U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878999>
92. **Follow-up to a randomized controlled trial of the effect of self-affirmation on anxiety during the COVID-19 pandemic.** Psychol Health Med 2021;1-6Li S, Xu Q, Zhou A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882760>
93. **Effects of group psychological intervention combined with pulmonary rehabilitation exercises on anxiety and sleep disorders in patients with mild coronavirus disease 2019 (COVID-19) infections in a Fangcang hospital.** Psychol Health Med 2021;1-11Liu Y, Yang YQ, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877926>
94. **Using social media data to assess the impact of COVID-19 on mental health in China.** Psychol. Med. 2021;1-8Zhu Y, Cao L, Xie J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875036>
95. **Home education for children with autism spectrum disorder during the COVID-19 pandemic: Indonesian mothers experience.** Res. Dev. Disabil. 2021; 114:103954Daulay N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882385>

96. **Sleep deficit in COVID-19 health-care workers may increase the infection risk.** Scand J Public Health 2021;14034948211007679Ishikura IA, Rosa DS, Hachul H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870776>
97. **Maternal insomnia during the COVID-19 pandemic: associations with depression and anxiety.** Soc. Psychiatry Psychiatr. Epidemiol. 2021;1-9Wang J, Zhou Y, Qian W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891160>
98. **When public health messages become stressful: Managing chronic disease during COVID-19.** Soc Sci Humanit Open 2021; 4:100150Coupet S, Nicolas G, Louder CN, Meyer M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880443>
99. **Social factors and worry associated with COVID-19: Evidence from a large survey in China.** Soc. Sci. Med. 2021; 277:113934Zhou M, Guo W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878665>
100. **[Covid-19 infectious disease is also a psychogeriatric disease].** Soins Gerontol. 2021; 26:37-39Thomas P, Hazif-Thomas C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894913>
101. **Psychological assessment and lived experiences of recovered COVID-19 patients who presented for convalescent plasma donation.** Transfus. Clin. Biol. 2021; Maheshwari A, Varshney M, Gupta K, Bajpai M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895379>
102. **Global health disparities in vulnerable populations of psychiatric patients during the COVID-19 pandemic.** World J Psychiatry 2021; 11:94-108Diaz A, Baweja R, Bonatakis JK, Baweja R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889535>
103. **[Predictors of process-related and structuring parental support during distance learning due to Corona-pandemic].** Z Erziehungswiss 2021;1-24Sander A, Schäfer L, van Ophuysen S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875915>
104. **Predicted impacts of government policies and actions on the SARS-CoV-2 disease in the northwestern Himalayan region, India.** Z Gesundh Wiss 2021;1-9Haq SM, Yaqoob U, Hassan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880322>

Meta-analyses - systematic reviews (15 articles)

1. **Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.** Aging (Albany NY) 2021; 13Ma Z, Wang MP, Liu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886504>
2. **Hospital-Level Variation in Death for Critically Ill Patients with COVID-19.** Am J Respir Crit Care Med 2021; Churpek MM, Gupta S, Spicer AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891529>
3. **Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.** Clin. Appl. Thromb. Hemost. 2021; 27:10760296211008999Moonla C, Sosothikul D, Chiasakul T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874753>
4. **Kidney disease and COVID-19 disease severity-systematic review and meta-analysis.** Clin. Exp. Med. 2021;1-11Singh J, Malik P, Patel N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891214>

5. **The Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis.** Cureus 2021; 13:e13894 Menon T, Sharma R, Kataria S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880250>
6. **Outcomes of acute respiratory distress syndrome in COVID-19 patients compared to the general population: A systematic review and meta-analysis.** Expert Rev. Respir. Med. 2021; Dmytriw AA, Chibbar R, Chen PPY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33882768>
7. **Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis.** Front Med (Lausanne) 2021; 8:660688 Barreira DF, Lourenço RA, Calisto R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33889590>
8. **Mental disorder prevalence among populations impacted by coronavirus pandemics: A multilevel meta-analytic study of COVID-19, MERS & SARS.** Gen. Hosp. Psychiatry 2021; 70:124-133 Boden M, Cohen N, Froelich JM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894561>
9. **Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis.** Intensive Care Med 2021; 1-17 Chaudhuri D, Sasaki K, Karkar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876268>
10. **Distinct cytokine profiles associated with COVID-19 severity and mortality.** J Allergy Clin Immunol 2021; Dorgham K, Quentric P, Gökkaya M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894209>
11. **Incidence and Mortality of COVID-19-associated Pulmonary Aspergillosis: A Systematic Review and Meta-analysis.** Mycoses 2021; Mitaka H, Kuno T, Takagi H, Patrawalla P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33896063>
12. **Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials.** Nepal J Epidemiol 2021; 11:959-982 Sathian B, Asim M, Banerjee I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868742>
13. **Does higher Body Mass Index increase COVID-19 severity?: a systematic review and meta-analysis.** Obes Med 2021; 100340 Chowdhury AI, Alam MR, Rabbi MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875972>
14. **Arrhythmias and Electrocardiographic findings in Coronavirus disease 2019: a systematic review and meta-analysis.** Pacing Clin. Electrophysiol. 2021; Garcia-Zamora S, Lee S, Haseeb S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890684>
15. **Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis.** Sleep Med. 2021; 82:47-53 Hariyanto TI, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892451>

Mortality (32 articles)

1. **Severe mental illness is associated with increased mortality and severe course of COVID-19.** Acta Psychiatr. Scand. 2021; Barcella CA, Polcwiartek C, Mohr GH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894064>

2. **Mortality attributable to COVID-19 in nursing home residents: a retrospective study.** Aging Clin. Exp. Res. 2021;1-7Veronese N, Koyanagi A, Stangherlin V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893989>
3. **Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients.** Alzheimers Dement 2021; Tahira AC, Verjovski-Almeida S, Ferreira ST. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881211>
4. **Hospital-Level Variation in Death for Critically Ill Patients with COVID-19.** Am J Respir Crit Care Med 2021; Churpek MM, Gupta S, Spicer AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891529>
5. **Determinants of mortality of patients with COVID-19 in Wuhan, China: a case-control study.** Ann Palliat Med 2021; Li J, Yang L, Zeng Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894714>
6. **Risk factors for mortality of coronavirus disease 2019 (COVID-19) patients during the early outbreak of COVID-19: a systematic review and meta-analysis.** Ann Palliat Med 2021; Wu Y, Li H, Zhang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894729>
7. **Cardiac Complications and Pertaining Mortality Rate in COVID-19 Patients; a Systematic Review and Meta-Analysis.** Arch Acad Emerg Med 2021; 9:e18Toloui A, Moshrefiaraghi D, Madani Neishaboori A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870205>
8. **Lupus anticoagulant single positivity at acute phase is not associated with venous thromboembolism or in-hospital mortality in COVID-19.** Arthritis Rheumatol 2021; Gendron N, Dragon-Durey MA, Chocron R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881229>
9. **ABO blood groups, COVID-19 infection and mortality.** Blood Cells Mol. Dis. 2021; 89:102571Lehrer S, Rheinstein PH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894687>
10. **COVID-19 as the sole cause of death is uncommon in frail home healthcare individuals: a population-based study.** BMC Geriatr. 2021; 21:262Nilsson L, Andersson C, Sjö Dahl R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879078>
11. **The impact of frailty on survival in elderly intensive care patients with COVID-19: the COVIP study.** Crit Care 2021; 25:149Jung C, Flaatten H, Fjølner J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874987>
12. **A Retrospective Study Assessing the Effect of Diabetes on Mortality in Patients With COVID-19 at a Teaching Hospital in the United Kingdom.** Cureus 2021; 13:e13902Ahmed FW, Kirresh OZ, Robinson AV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880258>
13. **The Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis.** Cureus 2021; 13:e13894Menon T, Sharma R, Kataria S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880250>
14. **Development of a multivariable model predicting mortality risk from comorbidities in an Italian cohort of 18,286 confirmed COVID-19 cases aged 40 years or older.** Epidemiol. Prev. 2021; 45:100-109Andreano A, Murtas R, Tunesi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884848>

15. **Pre-pandemic cognitive function and COVID-19 mortality: prospective cohort study.** Eur. J. Epidemiol. 2021;1-6Batty GD, Deary IJ, Gale CR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33893922>
16. **Corona and Coffee on your commute: A spatial analysis of COVID-19 mortality and commuting flows in England in 2020.** Eur. J. Public Health 2021; Francetic I, Munford L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871592>
17. **The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19.** Front Med (Lausanne) 2021; 8:637647Rose L, Graham L, Koenecke A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869251>
18. **Poverty and Covid-19: Rates of Incidence and Deaths in the United States During the First 10 Weeks of the Pandemic.** Front Sociol 2020; 5:47Finch WH, Hernández Finch ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869454>
19. **Association of neutrophil-to-lymphocyte and lymphocyte-to-C-reactive protein ratios with COVID-19-related mortality.** Gac Med Mex 2020; 156:553-558Albarrán-Sánchez A, González-Ríos RD, Alberti-Minutti P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33877103>
20. **Population-level mortality burden from novel coronavirus (COVID-19) in Europe and North America.** Genus 2021; 77:7Soneji S, Beltrán-Sánchez H, Yang JW, Mann C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879923>
21. **The presence of care homes and excess deaths during the COVID-19 pandemic: Evidence from Italy.** Health Econ. 2021; Alacevich C, Cavalli N, Giuntella O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884695>
22. **Fatalities of COVID-19 are rather attributable to multisystem inflammatory syndrome than infectious meningitis or sepsis.** Indian J. Med. Microbiol. 2021; Finsterer J, Scorza FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867206>
23. **The role of hemogram parameters and CRP in predicting mortality in COVID-19 infection.** Int J Clin Pract 2021:e14256Acar E, Demir A, Yıldırım B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33887100>
24. **Predictive value of d-dimer/albumin ratio and fibrinogen/albumin ratio for in-hospital mortality in patients with COVID-19.** Int J Clin Pract 2021:e14263Küçükceran K, Ayranci MK, Girişgin AS, Koçak S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33891337>
25. **Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI).** Intern Emerg Med 2021;1-11Corradini E, Ventura P, Ageno W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893976>
26. **Role of Ascertainment Bias in Determining Case Fatality Rate of COVID-19.** J Epidemiol Glob Health 2021; Smith MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876593>
27. **Cause of death based on systematic postmortem studies in patients with positive SARS-CoV2 tissue PCR during the COVID-19 pandemic.** J Intern Med 2021; Romanova ES, Vasilyev VV, Startseva G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33872433>
28. **A Clinical Risk Score to Predict In-hospital Mortality from COVID-19 in South Korea.** J Korean Med Sci 2021; 36:e108Her AY, Bhak Y, Jun EJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33876588>

29. **Predictors of Length of Hospital Stay, Mortality, and Outcomes Among Hospitalised COVID-19 Patients in Saudi Arabia: A Cross-Sectional Study.** J Multidiscip Healthc 2021; 14:839-852 Alwafi H, Naser AY, Qanash S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883900>
30. **Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain.** Lancet Reg Health Eur 2021; 3:100041 Garcia-Vidal C, Cózar-Llistó A, Meira F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870249>
31. **Incidence and Mortality of COVID-19-associated Pulmonary Aspergillosis: A Systematic Review and Meta-analysis.** Mycoses 2021; Mitaka H, Kuno T, Takagi H, Patrawalla P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33896063>
32. **Factors influencing the COVID-19 daily deaths' peak across European countries.** Public Health 2021; 194:135-142 Jabłońska K, Aballéa S, Toumi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=3389235>

Online – IT – Apps (96 articles)

1. **Using Dynamic Virtual Microscopy to Train Pathology Residents During the Pandemic: Perspectives on Pathology Education in the Age of COVID-19.** Acad Pathol 2021; 8:23742895211006819 Christian RJ, VanSandt M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884292>
2. **Effects of social support on mental health for critical care nurses during the coronavirus disease 2019 (COVID-19) pandemic in Japan: A web-based cross-sectional study.** Acute Med Surg 2021; 8:e645 Tatsuno J, Unoki T, Sakuramoto H, Hamamoto M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868689>
3. **Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial.** Addict. Sci. Clin. Pract. 2021; 16:24 Hser YI, Ober AJ, Dopp AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879260>
4. **Working in Creative Partnership with Students to Co-Produce Neuroanatomy e-Learning Resources in a new era of Blended Learning.** Anat Sci Educ 2021; Border S, Woodward C, Kurn O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871948>
5. **NewsMeSH: A new classifier designed to annotate health news with MeSH headings.** Artif. Intell. Med. 2021; 114:102053 Pita Costa J, Rei L, Stopar L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875160>
6. **Mass Media Influence on Changing Healthy Lifestyle of Community People During COVID-19 Pandemic in Bangladesh: A Cross-Sectional Survey.** Asia Pac. J. Public Health 2021:10105395211011030 Islam MN, Islam A, Hossain MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870719>
7. **Online medical conference became favorite in China during COVID-19, will it become a routine model in the future?** Asian J. Surg. 2021; Peng D, Cheng YX, Liu XY, Wang CY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879360>
8. **Making a Traditional Spine Surgery Clinic Telemedicine-Ready in the "New Normal" of Coronavirus Disease 2019.** Asian Spine J 2021; 15:164-171 Liu KG,

Tan WLB, Yip WLJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33866765>

9. **Commitment, Collaboration, and Problem Resolution to Promote and Sustain Access to Multifaceted Applied Behavior-Analytic Services Utilizing Telepractice.** Behav Anal Pract 2021;1-23Frederick JK, Rogers VR, Raabe GR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875928>
10. **A longitudinal and geospatial analysis of COVID-19 tweets during the early outbreak period in the United States.** BMC Public Health 2021; 21:793Cuomo RE, Purushothaman V, Li J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894745>
11. **Remote care for mental health: qualitative study with service users, carers and staff during the COVID-19 pandemic.** BMJ Open 2021; 11:e049210Liberati E, Richards N, Parker J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888531>
12. **How has technology been used to deliver cardiac rehabilitation during the COVID-19 pandemic? An international cross-sectional survey of healthcare professionals conducted by the BACPR.** BMJ Open 2021; 11:e046051O'Doherty AF, Humphreys H, Dawkes S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879492>
13. **Patient satisfaction scores with telemedicine in the neurosurgical population.** Clin. Neurol. Neurosurg. 2021; 205:106605Porche K, Vaziri S, Mehkri Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894681>
14. **Comparative analysis of Student's live online learning readiness during the coronavirus (COVID-19) pandemic in the higher education sector.** Comput Educ 2021; 168:104211Tang YM, Chen PC, Law KMY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879955>
15. **Conducting conservation social science surveys online.** Conserv. Biol. 2021; Wardropper CB, Dayer AA, Goebel MS, Martin VY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887800>
16. **E-Handover in Surgery Improves Clinical Efficiency and Adherence to COVID-19 Infection Control Measures.** Cureus 2021; 13:e13967Jacob N, Chaudhary O, Darwish NM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880300>
17. **Assessment of the Efficacy of Telephone Medicine Consultations in Trauma and Orthopaedics During COVID-19 Using the Ashford Clinic Letter Score.** Cureus 2021; 13:e13871Raad M, Ndlovu S, Neen D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868835>
18. **Internet-Related Behaviors and Psychological Distress Among Schoolchildren During the COVID-19 School Hiatus.** Cyberpsychol Behav Soc Netw 2021; Chen CY, Chen IH, Pakpour AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877905>
19. **Online examination course instead of classroom teaching: adaptation of medical student teaching during the COVID-19 pandemic.** Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2021; Wiedenmann C, Wacker K, Böhringer D *et al.*
20. **Telephonic Triage in Times of COVID-19: Experiences at a Telemedicine Centre in India.** Disaster Med Public Health Prep 2021:1-5Ray A, Sharma S, Sadasivam B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888174>
21. **'I'm just ringing to get a repeat prescription for my contraceptive pill, doctor': developing authentic simulated telephone consultations for medical students.**

- Educ. Prim. Care 2021;1-5Beddows J, Abdalla M, Blanchard D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33890545>
22. **Participatory syndromic surveillance as a tool for tracking COVID-19 in Bangladesh.** Epidemics 2021; 35:100462Mahmud AS, Chowdhury S, Sojib KH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887643>
 23. **Behaviours and attitudes in response to the COVID-19 pandemic: insights from a cross-national Facebook survey.** EPJ Data Sci 2021; 10:17Perrotta D, Grow A, Rampazzo F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880320>
 24. **End-to-End AI-Based Point-of-Care Diagnosis System for Classifying Respiratory Illnesses and Early Detection of COVID-19: A Theoretical Framework.** Front Med (Lausanne) 2021; 8:585578Belkacem AN, Ouhbi S, Lakas A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869239>
 25. **Humor in Times of COVID-19 in Spain: Viewing Coronavirus Through Memes Disseminated via WhatsApp.** Front. Psychol. 2021; 12:611788Cancelas-Ouviña LP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868083>
 26. **Gender Differences in Digital Learning During COVID-19: Competence Beliefs, Intrinsic Value, Learning Engagement, and Perceived Teacher Support.** Front. Psychol. 2021; 12:637776Korlat S, Kollmayer M, Holzer J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868109>
 27. **How E-Learning Environmental Stimuli Influence Determinates of Learning Engagement in the Context of COVID-19? SOR Model Perspective.** Front. Psychol. 2021; 12:584976Yang J, Peng MY, Wong S, Chong W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868072>
 28. **A Glimpse of the First Eight Months of the COVID-19 Literature on Microsoft Academic Graph: Themes, Citation Contexts, and Uncertainties.** Front Res Metr Anal 2020; 5:607286Chen C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870064>
 29. **Youth Networks' Advances Toward the Sustainable Development Goals During the COVID-19 Pandemic.** Front Sociol 2020; 5:589539Barber K, Mostajo-Radji MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869518>
 30. **Influences of digital media use on children and adolescents with ADHD during COVID-19 pandemic.** Global Health 2021; 17:48Shuai L, He S, Zheng H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874977>
 31. **Contact tracing apps for the COVID-19 pandemic: a systematic literature review of challenges and future directions for neo-liberal societies.** Health Inf Sci Syst 2021; 9:18Akinbi A, Forshaw M, Blinkhorn V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868671>
 32. **Cyberbullying, social stigma, and self-esteem: the impact of COVID-19 on students from East and Southeast Asia at the University of Jordan.** Heliyon 2021; 7:e06711Alsawalqa RO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869877>
 33. **The role of nanotechnology in current COVID-19 outbreak.** Heliyon 2021; 7:e06841Tavakol S, Zahmatkeshan M, Mohammadinejad R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880422>
 34. **CRISPR/Cas-New Molecular Scissors in Diagnostics and Therapeutics of COVID-19.** Indian J. Clin. Biochem. 2021;1-9Gadwal A, Roy D, Khokhar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879980>

35. **Contribution of machine learning approaches in response to SARS-CoV-2 infection.** Inform Med Unlocked 2021; 23:100526Mottaqi MS, Mohammadipanah F, Sajedi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869730>
36. **Web-based Medical Education During COVID-19 Lockdown: A Step Back or a Leap to the Future?** Int. J. Low. Extrem. Wounds 2021:15347346211011848Eleftheriou A, Rokou A, Argyriou C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890811>
37. **Emergency upscaling of video consultation during the COVID-19 pandemic: Contrasting user experience with data insights from the electronic health record in a large academic hospital.** Int. J. Med. Inform. 2021; 150:104463Barsom EZ, Meijer HAW, Blom J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872824>
38. **Information seeking behavior and COVID-19 pandemic: A snapshot of young, middle aged and senior individuals in Greece.** Int. J. Med. Inform. 2021; 150:104465Skarpa PE, Garoufallou E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887589>
39. **Comparing telehealth with office-based visits for common pediatric otolaryngology complaints.** Int J Pediatr Otorhinolaryngol 2021; 145:110712Kolb CM, Born K, Banker K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887549>
40. **COVID-19 in the Age of Artificial Intelligence: A Comprehensive Review.** Interdiscip Sci 2021:1-23Rasheed J, Jamil A, Hameed AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886097>
41. **Mental health services in primary care: Evidence for the feasibility of telehealth during the COVID-19 pandemic.** J Affect Disord Rep 2021; 5:100146Frank HE, Grumbach NM, Conrad SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870261>
42. **Mental health services in primary care: Evidence for the feasibility of telehealth during the COVID-19 pandemic.** J Affect Disord Rep 2021; 5:100146Frank HE, Grumbach NM, Conrad SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870261>
43. **Impact of Rapid Transition to Telemedicine-Based Delivery on Allergy/Immunology Care during COVID-19.** J Allergy Clin Immunol Pract 2021; Tsao LR, Villanueva SA, Pines DA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894393>
44. **From the Cochrane Library: Tele dermatology for Diagnosing Skin Cancer in Adults.** J Am Acad Dermatol 2021; Sivesind TE, Szeto MD, Matin RN, Dellavalle RP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894319>
45. **Tele mental health policies for college students during COVID-19.** J. Am. Coll. Health 2021:1-5Huigol YS, Torous J, Gold JA, Goldman ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891526>
46. **A fusion of data science and feed-forward neural network-based modelling of COVID-19 outbreak forecasting in IRAQ.** J. Biomed. Inform. 2021; 118:103766Aljaaf AJ, Mohsin TM, Al-Jumeily D, Alloghani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895377>
47. **Building An OMOP Common Data Model-Compliant Annotated Corpus for COVID-19 Clinical Trials.** J. Biomed. Inform. 2021:103790Sun Y, Butler A, Stewart LA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887457>

48. **Reimagining the pipeline: Saturday Academy at New York University College of Dentistry goes virtual.** J. Dent. Educ. 2021; Burns LE, Pezzullo C, Dief S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893653>
49. **Digital Inclusion of Older Adults during COVID-19: Lessons from a Case Study of Older Adults Technology Services (OATS).** J Gerontol Soc Work 2021;1-13Weil J, Kamber T, Glazebrook A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882782>
50. **Evaluation of an Intrahospital Telemedicine Program for Patients Admitted With COVID-19: Mixed Methods Study.** J Med Internet Res 2021; 23:e25987Legler S, Diehl M, Hilliard B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872187>
51. **Development and Utilization of a Medical Student Surgery Podcast During COVID-19.** J. Surg. Res. 2021; 265:95-99Anteby R, Amiel I, Cordoba M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894454>
52. **Conducting Internet-Based Visits for Onboarding Populations With Limited Digital Literacy to an mHealth Intervention: Development of a Patient-Centered Approach.** JMIR Form Res 2021; 5:e25299Hernandez-Ramos R, Aguilera A, Garcia F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872184>
53. **Mobile Sensing Apps and Self-management of Mental Health During the COVID-19 Pandemic: Web-Based Survey.** JMIR Form Res 2021; 5:e24180Suruliraj B, Bessenyei K, Bagnell A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872181>
54. **Teaching Telemedicine: The Next Frontier for Medical Educators.** JMIR Med Educ 2021; 7:e29099Alcocer Alkureishi M, Lenti G, Choo ZY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878011>
55. **One Year of Pandemic Learning Response: Benefits of Massive Online Delivery of the World Health Organization's Technical Guidance.** JMIR Public Health Surveill 2021; 7:e28945Utunen H, Van Kerkhove MD, Tokar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881404>
56. **Digital innovation in medicine: the COVID-19 pandemic as an accelerator of “digital health”.** Journal fur Urologie und Urogynakologie 2021; 28Mumm JN, Rodler S, Mumm ML *et al.*
57. **Curricular response to COVID-19: real-time interactive telehealth experience (RITE) program.** Med. Educ. Online 2021; 26:1918609Safdieh JE, Lee JI, Prasad L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886434>
58. **Telemedicine review in neuro-oncology: comparative experiential analysis for Barrow Neurological Institute and Geisinger Health during the 2020 COVID-19 pandemic.** Neurooncol Pract 2021; 8:109-116Fonkem E, Gatson NTN, Tadipatri R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889416>
59. **Uptake of telehealth in Parkinson's disease clinical care and research during the COVID-19 pandemic.** Parkinsonism Relat. Disord. 2021; 86:97-100Shivkumar V, Subramanian T, Agarwal P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895540>
60. **It's a conspiracy: Covid-19 conspiracies link to psychopathy, Machiavellianism and collective narcissism.** Pers. Individ. Dif. 2021; 171:110559Hughes S, Machan L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867616>

61. **Automated, multiparametric monitoring of respiratory biomarkers and vital signs in clinical and home settings for COVID-19 patients.** Proc Natl Acad Sci U S A 2021; 118: Ni X, Ouyang W, Jeong H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893178>
62. **Using social media data to assess the impact of COVID-19 on mental health in China.** Psychol. Med. 2021;1-8: Zhu Y, Cao L, Xie J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875036>
63. **Experience, experts, statistics, or just science? Predictors and consequences of reliance on different evidence types during the COVID-19 infodemic.** Public Underst Sci 2021;9636625211009685: Lu H, Chu H, Ma Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892612>
64. **Feasibility of tele-rehabilitation in survivors of COVID-19 pneumonia.** Pulmonology 2021; Paneroni M, Vitacca M, Bernocchi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893061>
65. **Creative social media use for Covid-19 prevention in Bangladesh: a structural equation modeling approach.** Soc Netw Anal Min 2021; 11:38: Islam MM, Islam MM, Ahmed F, Rumana AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868509>
66. **The Content and Accessibility of Spine Surgery Fellowship Websites and the North American Spine Surgery (NASS) Fellowship Directory.** Spine J 2021; Gerlach EB, Plantz MA, Swiatek PR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895376>
67. **Organizational and External Factors Associated with Video Telehealth Use in the Veterans Health Administration Before and During the COVID-19 Pandemic.** Telemed J E Health 2021; Jacobs J, Ferguson JM, Van Campen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887166>
68. **Implementation and Monitoring of a Telemedicine Model in Acromegalic Outpatients in a Low-Income Country During the COVID-19 Pandemic.** Telemed J E Health 2021; Naves LA, Rosa IN, Lima TAS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877890>
69. **[Annual meeting of the German Society for Rheumatology going virtual- successfully defying the pandemic].** Z. Rheumatol. 2021;1-7: Richter JG, Chehab G, Knitza J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877456>

Other – Miscellaneous (105 articles)

1. **Ambient temperature and COVID-19 outcomes.** Adv Respir Med 2021; Madan M, Pahuja S, Tyagi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881162>
2. **Convicted drinking and driving offenders: Comparing alcohol use before and after the pandemic outbreak.** Alcohol. Clin. Exp. Res. 2021; Manning AR, Romano E, Diebold J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871077>
3. **New Year.** Anesthesiologie und Intensivmedizin 2021; 62:2: Geldner G.
4. **Crowd management COVID-19.** Annu Rev Control 2021; Polanco LD, Siller M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867812>
5. **Reciprocal Trust as an Ethical Response to the COVID-19 Pandemic.** Asian Bioeth Rev 2021;1-20: Chan HY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875921>

6. **COVID-19: challenges faced by Nepalese migrants living in Japan.** BMC Public Health 2021; 21:752Bhandari D, Kotera Y, Ozaki A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33874937>
7. **Lifestyle habits of adults during the COVID-19 pandemic lockdown in Cyprus: evidence from a cross-sectional study.** BMC Public Health 2021; 21:786Kolokotroni O, Mosquera MC, Quattrocchi A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33892688>
8. **Impact of COVID-19 on household food insecurity and interlinkages with child feeding practices and coping strategies in Uttar Pradesh, India: a longitudinal community-based study.** BMJ Open 2021; 11:e048738Nguyen PH, Kachwaha S, Pant A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883156>
9. **Impact of COVID-19 on Migrants' Access to Primary Care and Implications for Vaccine Roll Out: A National Qualitative Study.** Br. J. Gen. Pract. 2021; Knights F, Carter J, Deal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875420>
10. **COVID-19, Seignorage, Quantitative Easing and the Fiscal-Monetary Nexus.** Comp Econ Stud 2021:1-19Cukierman A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867661>
11. **Safe Distance-Based Vehicle Routing Problem: Medical Waste Collection Case Study in COVID-19 Pandemic.** Comput Ind Eng 2021:107328Eren E, Rifat Tuzkaya U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879956>
12. **Letter to the editor regarding article: Impact of COVID-19 outbreak on lifestyle behaviour: A review of studies published in India (Rawat et al.).** Diabetes Metab Syndr 2021; Mirzaei F, Tavilani A, Abbasi-Oshaghi E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895088>
13. **The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects.** Drug Discov Today 2021; Qiu T, Wang Y, Liang S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892148>
14. **Infectious disease, the climate, and the future.** Environ Epidemiol 2021; 5:e133Tong S, Ebi K, Olsen J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870009>
15. **Effect of large-scale social restriction (PSBB) during COVID-19 on outdoor air quality: Evidence from five cities in DKI Jakarta Province, Indonesia.** Environ. Res. 2021; 197:111164Anugerah AR, Muttaqin PS, Purnama DA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33872645>
16. **The impact of COVID-19 lockdown on atmospheric CO(2) in Xi'an, China.** Environ. Res. 2021; 197:111208Wu S, Zhou W, Xiong X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895110>
17. **Characterization of littered face masks in the southeastern part of Turkey.** Environ. Sci. Pollut. Res. Int. 2021:1-11Akarsu C, Madenli Ö, Deveci E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895953>
18. **COVID-19 and municipal solid waste (MSW) management: a review.** Environ. Sci. Pollut. Res. Int. 2021:1-16Das AK, Islam MN, Billah MM, Sarker A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33877522>
19. **Effect of COVID-19 lockdown on noise pollution levels in an Indian city: a case study of Kanpur.** Environ. Sci. Pollut. Res. Int. 2021:1-13Mishra A, Das S, Singh D, Maurya AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884552>

20. **Threshold effects of COVID-19-confirmed cases on change in pollutants changes: evidence from the Chinese top ten cities.** Environ. Sci. Pollut. Res. Int. 2021;1-9Wang Q, Wang X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876371>
21. **Ethical challenges of nurses related covid-19 pandemic in inpatient wards: an integrative review.** Ethics Med Public Health 2021;100669Firouzkouhi M, Alimohammadi N, Kako M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869710>
22. **Estimating Employment Gains of the Proposed Infrastructure Stimulus Plan in Post-Covid-19 South Africa.** Eur J Dev Res 2021;1-28Habiyaemye A, Molewa O, Lekomanyane P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879979>
23. **Ethical Challenges Related to the Novel Coronavirus (COVID-19) Outbreak: Interviews With Professionals From Saudi Arabia.** Front Med (Lausanne) 2021; 8:620444Alahmad G, Richi H, BaniMustafa A, Almutairi AF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869243>
24. **The Impact of COVID-19 Pandemic and Lockdown on Alcohol Consumption: A Perspective From Hair Analysis.** Front Psychiatry 2021; 12:632519Alladio E, Visintin L, Lombardo T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889098>
25. **Heterogeneity in Risk-Taking During the COVID-19 Pandemic: Evidence From the UK Lockdown.** Front. Psychol. 2021; 12:643653Guenther B, Galizzi MM, Sanders JG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868115>
26. **Dual Careers of Athletes During COVID-19 Lockdown.** Front. Psychol. 2021; 12:657671Izzicupo P, Di Baldassarre A, Abelkalns I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868131>
27. **Save for Safe: Effect of COVID-19 Pandemic on Consumers' Saving and Spending Behavior in China.** Front. Psychol. 2021; 12:636859Jin X, Zhao Y, Song W, Zhao T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868106>
28. **Warning Messages in Crisis Communication: Risk Appraisal and Warning Compliance in Severe Weather, Violent Acts, and the COVID-19 Pandemic.** Front. Psychol. 2021; 12:557178Rahn M, Tomczyk S, Schopp N, Schmidt S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868065>
29. **Not All in the Same Boat. Socioeconomic Differences in Marital Stress and Satisfaction During the Covid-19 Pandemic.** Front. Psychol. 2021; 12:635148Turliuc MN, Candel OS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868101>
30. **From Normal to Viral Body: Death Rituals During Ordinary and Extraordinary Covidian Times in Pakistan.** Front Sociol 2020; 5:619913Ali I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869536>
31. **Predicting the Patriarchal Politics of Pandemics From Mary Shelley to COVID-19.** Front Sociol 2021; 6:624909Botting EH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869576>
32. **War Metaphors in Political Communication on Covid-19.** Front Sociol 2020; 5:583680Castro Seixas E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869509>
33. **The Articulation of the Indigenous Peoples of Brazil in Facing the Covid-19 Pandemic.** Front Sociol 2021; 6:611336da Silva LL, Nascimento PE, Araújo OCG, Pereira TMG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869556>

34. **Credibility Contests: Media Debates on Do-It-Yourself Coronavirus Responses and the Role of Citizens in Health Crises.** *Front Sociol* 2020; 5:592666Erikainen S, Stewart E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869520>
35. **Status Construction During COVID-19: Antibody Positive People's Rising Prestige.** *Front Sociol* 2020; 5:576827Evans MDR, Kelley J, Kelley S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869503>
36. **Covid-19 as a Social Crisis and Justice Challenge for Cities.** *Front Sociol* 2020; 5:583638Haase A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869508>
37. **Case Report: Indigenous Sovereignty in a Pandemic: Tribal Codes in the United States as Preparedness.** *Front Sociol* 2021; 6:617995Hiraldo D, James K, Carroll SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869571>
38. **COVID-19 Pandemic Management Strategies and Outcomes in East Asia and the Western World: The Scientific State, Democratic Ideology, and Social Behavior.** *Front Sociol* 2020; 5:575588Ho HK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869501>
39. **Covid-19 Response From Global Makers: The Careables Cases of Global Design and Local Production.** *Front Sociol* 2021; 6:629587Kieslinger B, Schaefer T, Fabian CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869577>
40. **Unequal and Invisible: A Feminist Political Economy Approach to Valuing Women's Care Labor in the COVID-19 Response.** *Front Sociol* 2020; 5:588279Lokot M, Bhatia A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869516>
41. **The Juggernaut of Modernity Collapses. The Crisis of Social Planification in the Post COVID-19 era.** *Front Sociol* 2020; 5:611885Lusardi R, Tomelleri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869527>
42. **The Covid-19 Pandemics: why Intersectionality Matters.** *Front Sociol* 2021; 6:642662Maestripieri L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869589>
43. **COVID-19: Technology, Social Connections, Loneliness, and Leisure Activities: An International Study Protocol.** *Front Sociol* 2020; 5:574811Marston HR, Ivan L, Fernández-Ardèvol M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869500>
44. **Our Collective Needs and Strengths: Urban AI/ANs and the COVID-19 Pandemic.** *Front Sociol* 2021; 6:611775Maudrie TL, Lessard KH, Dickerson J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869561>
45. **Development and Dissemination of a Strengths-Based Indigenous Children's Storybook: "Our Smallest Warriors, Our Strongest Medicine: Overcoming COVID-19".** *Front Sociol* 2021; 6:611356O'Keefe VM, Maudrie TL, Ingalls A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869558>
46. **Creativity, Resilience and Resistance: Black Birthworkers' Responses to the COVID-19 Pandemic.** *Front Sociol* 2021; 6:636029Oparah JC, James JE, Barnett D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869584>
47. **"Soldiers of the System": Maternity Care in Russia Between Bureaucratic Instructions and the Epidemiological Risks of COVID-19.** *Front Sociol* 2021; 6:611374Ozhiganova A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869559>
48. **Disinformation and Conspiracy Theories in the Age of COVID-19.** *Front Sociol* 2020; 5:560681Pereira PS, Silveira ADS, Pereira A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869496>

49. **Socio-Economic Implications of COVID-19 Pandemic in South Asia: Emerging Risks and Growing Challenges.** Front Sociol 2021; 6:629693Rasul G, Nepal AK, Hussain A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869579>
50. **Born in Captivity: The Experiences of Puerto Rican Birth Workers and Their Clients in Quarantine.** Front Sociol 2021; 6:613831Reyes E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869565>
51. **What Makes Young People Think Positively About Social Distancing During the Corona Crisis in Germany?** Front Sociol 2020; 5:61Rieger MO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869467>
52. **Transitions in Black and Latinx Community-Based Doula Work in the US During COVID-19.** Front Sociol 2021; 6:611350Rivera M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869557>
53. **Pregnancy During the Global COVID-19 Pandemic: Canadian Experiences of Care.** Front Sociol 2021; 6:611324Rudrum S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869555>
54. **On the Outside Looking In: A Global Doula Response to COVID-19.** Front Sociol 2021; 6:613978Searcy JJ, Castañeda AN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869566>
55. **Impact of the COVID-19 Pandemic on Loneliness Among Older Adults.** Front Sociol 2020; 5:590935Seifert A, Hassler B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869519>
56. **The Covid-19 Emergency and the Risk of Social Fragmentation in the Palermo Case.** Front Sociol 2020; 5:624160Siino AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869539>
57. **Tino Rangatiratanga and Well-being: Māori Self Determination in the Face of Covid-19.** Front Sociol 2021; 6:613340Te One A, Clifford C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869564>
58. **The Italian Deaf Community at the Time of Coronavirus.** Front Sociol 2020; 5:612559Tomasuolo E, Gulli T, Volterra V, Fontana S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869529>
59. **Covid-19 Requires a Social Medicine Response.** Front Sociol 2020; 5:579991Trout LJ, Kleinman A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869507>
60. **COVID-19 in New Mexico Tribal Lands: Understanding the Role of Social Vulnerabilities and Historical Racisms.** Front Sociol 2020; 5:610355Yellow Horse AJ, Deschine Parkhurst NA, Huyser KR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869526>
61. **Social policy as an integral component of pandemic response: Learning from COVID-19 in Brazil, Germany, India and the United States.** Glob Public Health 2021;1-14Greer SL, Jarman H, Falkenbach M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876715>
62. **Youth and the COVID-19 crisis: Lessons learned from a human rights-based prevention programme for youths in São Paulo, Brazil.** Glob Public Health 2021;1-14Paiva V, Garcia MRV, França-Jr I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870865>

63. **Addressing COVID-19 vulnerabilities: How do we achieve global health security in an inequitable world.** Glob Public Health 2021:1-11Šehović AB, Govender K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870859>
64. **Unmet health care need and income-Related horizontal equity in use of health care during the COVID-19 pandemic.** Health Econ. 2021; Davillas A, Jones AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890334>
65. **The role of parliamentarians in promoting self-care interventions for sexual and reproductive health and rights: applying COVID-19 lens in the Eastern Mediterranean region.** Health Res. Policy Syst. 2021; 19:45Abou-Taleb H, Mohamed N, Gholbzouri K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882960>
66. **Colliding worlds: Family carers' experiences of balancing work and care in Ireland during the COVID-19 pandemic.** Health Soc Care Community 2021; Lafferty A, Phillips D, Dowling-Hertherington L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891356>
67. **Food insecurity associated with elevated eating disorder symptoms, impairment, and eating disorder diagnoses in an American University student sample before and during the beginning of the COVID-19 pandemic.** Int. J. Eat. Disord. 2021; Christensen KA, Forbush KT, Richson BN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33885180>
68. **Coronavirus Legislation and Obligations of Lessee in Jordan: Some Preliminary Reflections/Considerations.** Int J Semiot Law 2021:1-7El-Haija MIA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867695>
69. **Nurses' stories from Beirut: The 2020 explosive disaster on top of a pandemic and economic crises.** Int Nurs Rev 2021; 68:1-8Jabbour R, Harakeh M, Dakessian Sailan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891770>
70. **'Code-95' rapid response calls for patients under airborne precautions in the COVID-19-era: a cross-sectional survey of healthcare worker perceptions.** Intern. Med. J. 2021; 51:494-505Subramaniam A, Zuberav A, Wengritzky R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890372>
71. **COVID-19 Global Humanitarian Response Plan: An optimal distribution model for high-priority countries.** ISA Trans. 2021; Hezam IM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867131>
72. **"Trying My Best": Sexual Minority Adolescents' Self-Care During the COVID-19 Pandemic.** J. Adolesc. Health 2021; O'Brien RP, Parra LA, Cederbaum JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875330>
73. **Changes in the Health of Adolescent Athletes: A Comparison of Health Measures Collected Before and During the CoVID-19 Pandemic.** J Athl Train 2021; McGuine TA, Biese K, Hetzel SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887766>
74. **Beyond political affiliation: an examination of the relationships between social factors and perceptions of and responses to COVID-19.** J. Behav. Med. 2021:1-12Franz B, Dhanani LY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877532>
75. **Habitat loss and the risk of disease outbreak.** J. Environ. Econ. Manage. 2021; 108:102451Barbier EB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867599>

76. **Identification of behaviour patterns in waste collection and disposal during the first wave of COVID-19 in Regina, Saskatchewan, Canada.** J. Environ. Manage. 2021; 290:112663 Richter A, Ng KTW, Vu HL, Kabir G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887640>
77. **Unequal impact of the COVID-19 crisis on minority ethnic groups: a framework for understanding and addressing inequalities.** J. Epidemiol. Community Health 2021; Katikireddi SV, Lal S, Carrol ED *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883198>
78. **Exploring the Impact of COVID-19 Pandemic on Economic Activities and Well-being of Older Adults in South-eastern Nigeria: Lessons for Gerontological Social Workers.** J Gerontol Soc Work 2021:1-16 Agbawodikeizu PU, Ezulike CD, Ekoh PC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882781>
79. **COVID-19 Blind Spots: A Consensus Statement on the Importance of Competent Political Leadership and the Need for Public Health Cognizance.** J. Glob. Infect. Dis. 2020; 12:167-190 Papadimos TJ, Soghoian SE, Nanayakkara P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888955>
80. **The Economic Impact of COVID-19 Treatment at a Hospital-level: Investment and Financial Registers of Brazilian Hospitals.** J Health Econ Outcomes Res 2021; 8:36-41 Beck da Silva Etges AP, Bertoglio Cardoso R, Marcolino MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889651>
81. **Costs associated with COVID-19 in healthcare personnel in Greece: a cost-of-illness analysis.** J Hosp Infect 2021; Maltezou HC, Giannouchos TV, Pavli A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894306>
82. **Virtual Seminar on Coronavirus 2019 for the US-Mexico Border Region: Building Opportunities for Communication and Collaboration.** J Immigr Minor Health 2021:1-4 Aceves B, Lopez-Galvez N, Rangel G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881680>
83. **Attitude and practices of parents toward their children's oral health care during COVID-19 pandemic.** J. Indian Soc. Pedod. Prev. Dent. 2021; 39:22-28 Goswami M, Grewal M, Garg A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33885383>
84. **"It's ok, mom. I got it!": Exploring the experiences of young adults with intellectual disabilities in a postsecondary program affected by the COVID-19 pandemic from their perspective and their families' perspective.** J Intellect Disabil 2021:17446295211002346 Spencer P, Van Haneghan JP, Baxter A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878973>
85. **Accommodating workers with disabilities in the post-Covid world.** J. Occup. Environ. Hyg. 2021:1-8 McNamara KA, Stanch PM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891510>
86. **Indigenous data sovereignty and COVID-19 data issues for American Indian and Alaska Native Tribes and populations.** J Popul Res (Canberra) 2021:1-5 Yellow Horse AJ, Huyser KR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867817>
87. **Assessing Attitudes Toward COVID-19 Prevention: Defining Two Attitudes Crucial for Understanding Systemic and Social Variables Associated with**

- Disparities.** *J Racial Ethn Health Disparities* 2021:1-10 Rivers AS, Clifton M, Pizzuto AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876408>
88. **Learning to Interpret Pediatric Vocal Fold Mobility: A Laryngeal Ultrasound Training Module.** *Laryngoscope* 2021; Alexander NL, Tran B, Zhu H, Ongkasuwan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890677>
 89. **[COVID-19 and Its Environment: From a History of Human Medicine Towards an Ecological History of Medicine?].** *Ntm* 2021:1-9 Diener L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871662>
 90. **Which lives are worth saving? Biolegitimacy and harm reduction during COVID-19.** *Nurs. Inq.* 2021:e12417 Larocque C, Foth T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886134>
 91. **Understanding effective nurse leadership styles during the COVID-19 pandemic.** *Nurs. Stand.* 2021; Harrington A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884778>
 92. **The risk perception of COVID-19 and practice of precautionary measures amongst healthcare workers in the National Health Insurance Scheme Clinic of a tertiary hospital in Nigeria.** *Pan Afr. Med. J.* 2021; 38:73 Enabulele O, Esther A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889239>
 93. **Assessment of activities of daily living in patients post COVID-19: a systematic review.** *PeerJ* 2021; 9:e11026 Pizarro-Pennarolli C, Sánchez-Rojas C, Torres-Castro R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868804>
 94. **Why Should Natural Principles Be Simple?** *Philosophia (Ramat Gan)* 2021:1-15 Tozzi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879931>
 95. **Ambient air pollution and cardiovascular disease: learnt from the COVID-19 pandemic.** *Postgrad. Med.* 2021; Ejaz A, Malik AO, Lopez-Candales A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888043>
 96. **A qualitative study exploring older smokers' attitudes and motivation toward quitting during the COVID-19 pandemic.** *Prev Med Rep* 2021; 22:101359 Cordon M, Eyestone E, Hutchison S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868901>
 97. **Level of Community Readiness for the Prevention of COVID-19 Pandemic and Associated Factors Among Residents of Awi Zone, Ethiopia: A Community-Based Cross-Sectional Study.** *Risk Manag. Healthc. Policy* 2021; 14:1509-1524 Adane D, Yeshaneh A, Wassihun B, Gasheneit A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883957>
 98. **Epistemic and Political Confrontations Around the Public Policies to Fight COVID-19 Pandemic.** *Sci Educ (Dordr)* 2021:1-25 Moura CB, Nascimento MM, Lima NW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879974>
 99. **Evaluating the presence of SARS-CoV-2 RNA in the particulate matters during the peak of COVID-19 in Padua, northern Italy.** *Sci Total Environ* 2021; 784:147129 Pivato A, Amoroso I, Formenton G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894607>
 100. **The Content and Accessibility of Spine Surgery Fellowship Websites and the North American Spine Surgery (NASS) Fellowship Directory.** *Spine J* 2021; Gerlach EB, Plantz MA, Swiatek PR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895376>

101. **Still ignored and still invisible: the situation of displaced people and people affected by disasters in the COVID-19 pandemic.** Sustain Sci 2021;1-4Abeldaño Zúñiga RA, González Villoria AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868495>
102. **Impact of lockdown due to COVID-19 pandemic on groundwater salinity in Punjab, India: some hydrogeoethics issues.** Sustain Water Resour Manag 2021; 7:27Krishan G, Sudarsan N, Sidhu BS, Vashisth R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869731>
103. **Industry update covering January 2021.** Ther. Deliv. 2021; Simpson I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876655>
104. **Effect of the COVID-19 pandemic on health insurance coverage among trauma patients: a study of six level I trauma centers.** Trauma Surg Acute Care Open 2021; 6:e000640Sercy E, Duane TM, Lieser M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884306>
105. **SARS-CoV-2: Cross-scale Insights from Ecology and Evolution.** Trends Microbiol. 2021; Snedden CE, Makanani SK, Schwartz ST *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893024>
106. **Personal health data in times of a pandemic—legal and ethical aspects.** Wien. Med. Wochenschr. 2021; 171:9-15Schmidhuber M, Stöger K.

Pathology (5 articles)

1. **Using Dynamic Virtual Microscopy to Train Pathology Residents During the Pandemic: Perspectives on Pathology Education in the Age of COVID-19.** Acad Pathol 2021; 8:23742895211006819Christian RJ, VanSandt M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884292>
2. **A Framework for Maintaining a Fully Operational Autopsy Service at a Large Academic Teaching Institution During a Global Pandemic.** Acad Pathol 2021; 8:23742895211006821Fu L, Zak T, Shanes E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884293>
3. **Systematic Review of Microthrombi in COVID-19 Autopsies.** Acta Haematol. 2021;1-8Parra-Medina R, Herrera S, Mejia J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33873184>
4. **Pathological Findings in COVID-19 as a Tool to Define SARS-CoV-2 Pathogenesis. A Systematic Review.** Front. Pharmacol. 2021; 12:614586Mondello C, Roccuzzo S, Malfa O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867981>
5. **Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty®).** Leg. Med. (Tokyo) 2021; 51:101895Edler C, Klein A, Schröder AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895650>

Protection (20 articles)

1. **Skin Reactions to Personal Protective Equipment among First-Line COVID-19 Healthcare Workers: A Survey in Northern Morocco.** Ann Work Expo Health 2021; Marraha F, Al Faker I, Charif F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876214>

2. **Mitigation of Aerosols Generated during Exercise Testing with a Portable High-Efficiency Particulate Air (HEPA) Filter with Fume Hood.** Chest 2021; Garzona-Navas A, Sajgalik P, Ibolya C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895130>
3. **Dental team and infection control for the COVID-19: (A short review of the current guidelines).** Dent. Res. J. (Isfahan) 2020; 17:409-411 Torabinia N, Nilchian F, Razavi SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889344>
4. **Simple quantitative assessment of the outdoor versus indoor airborne transmission of viruses and COVID-19.** Environ. Res. 2021:111189 Rowe BR, Canosa A, Drouffe JM, Mitchell JBA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872644>
5. **Characterization of littered face masks in the southeastern part of Turkey.** Environ. Sci. Pollut. Res. Int. 2021:1-11 Akarsu C, Madenli Ö, Deveci E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895953>
6. **Elective open "Shield Tracheostomy" in patients with COVID-19.** Eur Arch Otorhinolaryngol 2021:1-7 Šifrer R, Benedik J, Aničin A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881578>
7. **Covid-19: a call for mobilizing geriatric expertise.** Eur. Geriatr. Med. 2021:1-4 O'Hanlon S, Dhessi J, Aronson L, Inouye SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891278>
8. **Position paper of the Association for Aerosol Research on the occurrence of SARS-CoV-2 infection.** Gefahrstoffe Reinhaltung der Luft 2021; 81:60 Asbach C.
9. **Effective design of barrier enclosure to contain aerosol emissions from COVID-19 patients.** Indoor Air 2021; Daniel D, Lin M, Luhung I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876847>
10. **Monitoring social distancing through human detection for preventing/reducing COVID spread.** Int J Inf Technol 2021:1-10 Ansari MA, Singh DK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870073>
11. **Pyrolysis kinetic behaviour and TG-FTIR-GC-MS analysis of Coronavirus Face Masks.** J Anal Appl Pyrolysis 2021; 156:105118 Yousef S, Eimontas J, Striūgas N, Abdelnaby MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875899>
12. **COVID-19 transmission in Hong Kong despite universal masking.** J Infect 2021; Martín-Sánchez M, Lim WW, Yeung A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895227>
13. **Suction mask device: a simple, inexpensive, and effective method of reducing spread of aerosolized particles during endoscopic endonasal surgery in the era of COVID-19.** J. Neurosurg. 2021:1-7 Hara T, Zachariah MA, Li R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892478>
14. **COVID-19 related pressure injuries in patients and personnel: A systematic review.** J Tissue Viability 2021; Yu JN, Wu BB, Feng LP, Chen HL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895045>
15. **Protection against COVID-19: How effective are face masks?** Monatsschr. Kinderheilkd. 2021; Kerbl R.
16. **COVID-19 Mitigation With Appropriate Safety Measures in an Essential Workplace: Lessons for Opening Work Settings in the United States During**

- COVID-19.** Open Forum Infect Dis 2021; 8:ofab086Haigh KZ, Gandhi M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880391>
17. **Pandemic Risk Management using Engineering Safety Principles.** Process Saf Environ Prot 2021; Alauddin M, Khan F, Imtiaz S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33879978>
18. **Prevention and control measures of the coronavirus disease 2019 (COVID-19) in low-risk departments: The spine surgery department example.** Sci. Prog. 2021; 104:368504211009670Zheng Y, Zhang X, Fang S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33878962>
19. **Perceptions of healthcare workers in high-risk areas of a Singapore hospital during COVID-19: a cross-sectional study.** Singapore Med J 2021; Au-Yong PA, Peh WM, Koh FH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33866717>
20. **SARS-CoV-2, surgeons and surgical masks.** World J Clin Cases 2021; 9:2170-2180Khalil MI, Banik GR, Mansoor S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869593>

Pulmonary disease (13 articles)

1. **GOLD 2021 guidelines for COPD - what's new and why.** Adv Respir Med 2021; Gupta N, Malhotra N, Ish P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881161>
2. **Dysregulation of ion transport in the lung epithelium infected with SARS-CoV-2.** Am J Physiol Lung Cell Mol Physiol 2021; Dada LA, Vagin O, Sznajder JI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881360>
3. **Pneumatocele after recovering from COVID-19.** BMJ Case Rep. 2021; 14Sugimoto H, Era Y, Sugimoto K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875514>
4. **Pulmonary Fibrosis After COVID-19 Pneumonia.** Cureus 2021; 13:e13923Malik B, Abdelazeem B, Ghatol A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868858>
5. **What good came out of the Covid-19 outbreak for workers with occupational asthma?** Expert Rev. Respir. Med. 2021:1-3Burge S, Moore VC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33866901>
6. **Inhalation dosimetry of nasally inhaled respiratory aerosols in the human respiratory tract with locally remodeled conducting lungs.** Inhal. Toxicol. 2021:1-17Si XA, Talaat M, Su WC, Xi J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870835>
7. **Challenges for asthma units in response to COVID-19: a qualitative group dynamics analysis.** J. Asthma 2021:1-13Martínez Rivera C, Crespo-Lessman A, Arismendi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882776>
8. **Rehabilitation of Patients with Platypnea-Orthodeoxia Syndrome in COVID-19 Pneumonia: Two Case Reports.** J Rehabil Med Clin Commun 2020; 3:1000044Tham SL, Ong PL, Lee AJY, Tay MRJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884145>
9. **Statement from the Japanese Respiratory Society: Working diagnosis and initial management of COPD during the COVID-19 pandemic.** Respir Investig 2021; Shibata Y, Muro S, Yokoyama A, Hashimoto S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893068>

10. **Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation.** Respir. Med. 2021; 182:106401 Maniscalco M, Ambrosino P, Fuschillo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33873099>
11. **Validity of the 6-Minute Walk Test in Patients with End-Stage Lung Diseases Wearing an Oronasal Surgical Mask in Times of the COVID-19 Pandemic.** Respiration 2021;1-6 Just IA, Schoenrath F, Passinger P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878758>
12. **Post COVID-19 MSSA pneumonia.** SAGE Open Med Case Rep 2021; 9:2050313x211005996 Chaudhry B, Alekseyev K, Didenko L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889412>
13. **Pleural complications of Covid-19 pneumonia.** Turk J Med Sci 2021; Şatir Türk M, Akarsu I, Tombul I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890447>

Renal disease (13 articles)

1. **Dialysis circuit clotting in critically ill patients with COVID-19 infection.** BMC Nephrol. 2021; 22:141 Khoo BZE, Lim RS, See YP, Yeo SC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879086>
2. **Cardiorenal syndrome in COVID-19.** BMJ Case Rep. 2021; 14 Ali UA, Sadiq MS, Yunus MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893131>
3. **Kidney disease and COVID-19 disease severity-systematic review and meta-analysis.** Clin. Exp. Med. 2021;1-11 Singh J, Malik P, Patel N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891214>
4. **The Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis.** Cureus 2021; 13:e13894 Menon T, Sharma R, Kataria S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880250>
5. **Continuous renal replacement therapy in intensive care patients with COVID-19; survival and renal recovery.** J Crit Care 2021; 64:125-130 Eriksson KE, Campoccia-Jalde F, Rysz S, Rimes-Stigare C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878517>
6. **Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units - a high risk community-hospital interface.** J Infect 2021; Li KK, Woo YM, Stirrup O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895226>
7. **Successful deceased donor kidney transplantation to a recipient with a history of COVID-19 treatment.** J Infect Chemother 2021; Yoshinaga K, Araki M, Wada K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893036>
8. **SARS-CoV-2-reactive cellular and humoral immunity in hemodialysis population.** Kidney Int 2021; Anft M, Blazquez-Navarro A, Paniskaki K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887319>
9. **Low immunization rates among kidney transplant recipients who received two doses of the mRNA-1273 SARS-CoV-2 vaccine.** Kidney Int 2021; Benotmane I, Gautier-Vargas G, Cognard N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887315>

10. **Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA Covid-19 vaccine. The war is far from being won.** Kidney Int 2021; Torreggiani M, Bianchi S, Fois A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33887320>
11. **Experience with SARS-COV-2 BNT162b2 mRNA vaccine in dialysis patients.** Kidney Int 2021; Yanay NB, Freiman S, Shapira M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33887318>
12. **A patient with end-stage renal disease who recovered from coronavirus disease 2019 then received a kidney transplant.** Transpl. Immunol. 2021:101395 Wang T, Qiu T, Wang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895261>
13. **Recovery of kidney function after AKI due to COVID-19 in kidney transplant recipients.** Transpl Int 2021; Bajpai D, Deb S, Bose S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33884672>

Reviews (23 articles)

1. **An Early Unexpected Immune Thrombotic Thrombocytopenic Purpura Relapse Associated with SARS-CoV-2 Infection: A Case Report and Literature Review.** Acta Haematol. 2021:1-5 Kornowski Cohen M, Sheena L, Shafir Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895748>
2. **Systematic Review of Microthrombi in COVID-19 Autopsies.** Acta Haematol. 2021:1-8 Parra-Medina R, Herrera S, Mejia J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33873184>
3. **Potential "biopeptidal" therapeutics for severe respiratory syndrome coronaviruses: a review of antiviral peptides, viral mechanisms, and prospective needs.** Appl. Microbiol. Biotechnol. 2021:1-14 Ashaolu TJ, Nawaz A, Walayat N, Khalifa I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876282>
4. **Artificial intelligence (AI) for medical imaging to combat coronavirus disease (COVID-19): a detailed review with direction for future research.** Artif Intell Rev 2021:1-31 Soomro TA, Zheng L, Afifi AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875900>
5. **Misleading clinical evidence and systematic reviews on ivermectin for COVID-19.** BMJ Evid Based Med 2021; Garegnani LI, Madrid E, Meza N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33888547>
6. **Trends in Coronavirus Disease 2019 Hospitalization and Prognosis: Gender Effect.** Curr Med Sci 2021; 41:312-317 Shi MJ, Lv JG, Lin L, Guo JY.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33877547>
7. **Potential Candidates against COVID-19 Targeting RNA-Dependent RNA Polymerase: A Comprehensive Review.** Curr. Pharm. Biotechnol. 2021; Agrawal N, Goyal A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882805>
8. **Type 2 Diabetes Mellitus and COVID-19: A Narrative Review.** Front. Endocrinol. (Lausanne) 2021; 12:609470 Corrao S, Pinelli K, Vacca M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868163>
9. **Genetics Insight for COVID-19 Susceptibility and Severity: A Review.** Front. Immunol. 2021; 12:622176 Fricke-Galindo I, Falfán-Valencia R.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868239>

10. **Pathological Findings in COVID-19 as a Tool to Define SARS-CoV-2 Pathogenesis. A Systematic Review.** Front. Pharmacol. 2021; 12:614586Mondello C, Roccuzzo S, Malfa O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867981>
11. **COVID-19: a basic approach to understanding potential treatments.** Gac Med Mex 2020; 156:570-575Cedillo-Alvarez C, Gallardo-Ortiz IA, López LT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877122>
12. **Contact tracing apps for the COVID-19 pandemic: a systematic literature review of challenges and future directions for neo-liberal societies.** Health Inf Sci Syst 2021; 9:18Akinbi A, Forshaw M, Blinkhorn V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868671>
13. **Effectiveness of potential antiviral treatments in COVID-19 transmission control: a modelling study.** Infect Dis Poverty 2021; 10:53Lin SN, Rui J, Chen QP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874998>
14. **COVID-19 in the Age of Artificial Intelligence: A Comprehensive Review.** Interdiscip Sci 2021:1-23Rasheed J, Jamil A, Hameed AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886097>
15. **Kawasaki disease recurrence in the COVID-19 era: a systematic review of the literature.** Ital. J. Pediatr. 2021; 47:95Medaglia AA, Siracusa L, Gioè C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874991>
16. **Pandemics and education: A historical review.** J. Dent. Educ. 2021; Spielman AI, Sunavala-Dossabhoy G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876429>
17. **Association of Guillain-Barre syndrome with COVID-19 infection: An updated systematic review.** J. Neuroimmunol. 2021; 355:577577Sheikh AB, Chourasia PK, Javed N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895700>
18. **An unusual and atypical presentation of the novel coronavirus: A case report and brief review of the literature.** J Taibah Univ Med Sci 2021; Alshoabi SA, Haider KH, Mostafa MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867909>
19. **Myelopathy associated with SARS-COV-2 infection. A systematic review.** Neurol. Res. 2021:1-9Artemiadis A, Liampas A, Hadjigeorgiou L, Zis P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870878>
20. **Assessment of activities of daily living in patients post COVID-19: a systematic review.** PeerJ 2021; 9:e11026Pizarro-Pennarolli C, Sánchez-Rojas C, Torres-Castro R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868804>
21. **Brazilian essential oils as source for the discovery of new anti-COVID-19 drug: a review guided by in silico study.** Phytochem Rev 2021:1-20Amparo TR, Seibert JB, Silveira BM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867898>
22. **The Impact of COVID-19 on the Latinx Population: A Scoping Literature Review.** Public Health Nurs. 2021; Moore KS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876506>
23. **Can vital signs recorded in patients' homes aid decision making in emergency care? A Scoping Review.** Resusc Plus 2021; 6:100116Hamza M, Alsma J, Kellett J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870237>

Risk factors (48 articles)

1. **Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.** Aging (Albany NY) 2021; 13Ma Z, Wang MP, Liu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886504>
2. **Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients.** Alzheimers Dement 2021; Tahira AC, Verjovski-Almeida S, Ferreira ST. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881211>
3. **On-admission anemia predicts mortality in COVID-19 patients: A single center, retrospective cohort study.** Am J Emerg Med 2021; 48:140-147Oh SM, Skendelas JP, Macdonald E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895645>
4. **Hospital-Level Variation in Death for Critically Ill Patients with COVID-19.** Am J Respir Crit Care Med 2021; Churpek MM, Gupta S, Spicer AB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891529>
5. **Determinants of mortality of patients with COVID-19 in Wuhan, China: a case-control study.** Ann Palliat Med 2021; Li J, Yang L, Zeng Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894714>
6. **Risk factors for mortality of coronavirus disease 2019 (COVID-19) patients during the early outbreak of COVID-19: a systematic review and meta-analysis.** Ann Palliat Med 2021; Wu Y, Li H, Zhang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894729>
7. **The multidimensional prognostic index (MPI) for the prognostic stratification of older inpatients with COVID-19: A multicenter prospective observational cohort study.** Arch. Gerontol. Geriatr. 2021; 95:104415Pilotto A, Azzini M, Cella A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882420>
8. **Lupus anticoagulant single positivity at acute phase is not associated with venous thromboembolism or in-hospital mortality in COVID-19.** Arthritis Rheumatol 2021; Gendron N, Dragon-Durey MA, Chocron R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881229>
9. **ABO blood groups, COVID-19 infection and mortality.** Blood Cells Mol. Dis. 2021; 89:102571Lehrer S, Rheinstein PH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894687>
10. **The characteristics of laboratory tests at admission and the risk factors for adverse clinical outcomes of severe and critical COVID-19 patients.** BMC Infect. Dis. 2021; 21:371Wang L, Cheng X, Dong Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879073>
11. **Laboratory predictors of severe Coronavirus Disease 2019 and lung function in followed-up.** Clin. Respir. J. 2021; Pan M, Wang RR, Chen X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33896114>
12. **A Retrospective Study Assessing the Effect of Diabetes on Mortality in Patients With COVID-19 at a Teaching Hospital in the United Kingdom.** Cureus 2021; 13:e13902Ahmed FW, Kirresh OZ, Robinson AV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880258>
13. **Calculating outcome predictors of COVID-19 requires inclusion of multiple determinants.** Disaster Med Public Health Prep 2021:1-4Finsterer J, Scorza FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888177>
14. **Epigenome-wide association study of COVID-19 severity with respiratory failure.** EBioMedicine 2021:103339Castro de Moura M, Davalos V, Planas-Serra L

et al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867313>

15. **Development of a multivariable model predicting mortality risk from comorbidities in an Italian cohort of 18,286 confirmed COVID-19 cases aged 40 years or older.** Epidemiol. Prev. 2021; 45:100-109 Andreano A, Murtas R, Tunesi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884848>
16. **Epigenomics in COVID-19; the link between DNA methylation, histone modifications and SARS-CoV-2 infection.** Epigenomics 2021; Shirvaliloo M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876664>
17. **The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19.** Front Med (Lausanne) 2021; 8:637647 Rose L, Graham L, Koenecke A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869251>
18. **Association of neutrophil-to-lymphocyte and lymphocyte-to-C-reactive protein ratios with COVID-19-related mortality.** Gac Med Mex 2020; 156:553-558 Albarrán-Sánchez A, González-Ríos RD, Alberti-Minutti P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877103>
19. **Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index in patients with COVID-19-associated pneumonia.** Gac Med Mex 2020; 156:527-531 Carpio-Orantes LD, García-Méndez S, Hernández-Hernández SN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877106>
20. **IFN- γ and TNF- α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation.** Genome Med. 2021; 13:64 Zhang F, Mears JR, Shakib L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879239>
21. **Fatalities of COVID-19 are rather attributable to multisystem inflammatory syndrome than infectious meningitis or sepsis.** Indian J. Med. Microbiol. 2021; Finsterer J, Scorza FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867206>
22. **The role of hemogram parameters and CRP in predicting mortality in COVID-19 infection.** Int J Clin Pract 2021:e14256 Acar E, Demir A, Yıldırım B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887100>
23. **Predictive value of d-dimer/albumin ratio and fibrinogen/albumin ratio for in-hospital mortality in patients with COVID-19.** Int J Clin Pract 2021:e14263 Küçükceran K, Ayranci MK, Girişgin AS, Koçak S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891337>
24. **Predictors of severe hypoxemia among COVID-19 patients in Burkina Faso (West Africa): findings from hospital based cross-sectional study.** Int J Infect Dis 2021; Arnaud DE, Apoline SK, Risgou OA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894354>
25. **Serum Calcium and Vitamin D levels correlation with severity of COVID-19 in hospitalized patients in Royal Hospital, Oman.** Int J Infect Dis 2021; Osman W, Al Fahdi F, Khamis F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892191>
26. **Differential alteration trend of white blood cells (WBCs) and monocytes count in severe and non-severe COVID-19 patients within a 7-day follow-up.** Iran J Microbiol 2021; 13:8-16 Pirsalehi A, Salari S, Baghestani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889357>
27. **Distinct cytokine profiles associated with COVID-19 severity and mortality.** J Allergy Clin Immunol 2021; Dorgham K, Quentric P, Gökkaya M *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894209>

28. **Incidence and prognosis of COVID-19 in psoriasis patients on biologic therapy: a multicenter retrospective cohort study.** J Eur Acad Dermatol Venereol 2021; Georgakopoulos JR, Mufti A, Vender R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33872431>
29. **Excessive matrix metalloproteinase-1 and hyperactivation of endothelial cells occurred in COVID-19 patients and were associated with the severity of COVID-19.** J Infect Dis 2021; Syed F, Li W, Relich RF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33885811>
30. **Effect of environmental pollution PM2.5, carbon monoxide, and ozone on the incidence and mortality due to SARS-CoV-2 infection in London, United Kingdom.** J King Saud Univ Sci 2021; 33:101373Ayoub Meo S, Adnan Abukhalaf A, Sami W, Hoang TD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867776>
31. **A Clinical Risk Score to Predict In-hospital Mortality from COVID-19 in South Korea.** J Korean Med Sci 2021; 36:e108Her AY, Bhak Y, Jun EJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33876588>
32. **Predictors of Length of Hospital Stay, Mortality, and Outcomes Among Hospitalised COVID-19 Patients in Saudi Arabia: A Cross-Sectional Study.** J Multidiscip Healthc 2021; 14:839-852Alwafi H, Naser AY, Qanash S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33883900>
33. **Hypothyroidism is associated with prolonged COVID-19-induced anosmia: a case-control study.** J. Neurol. Neurosurg. Psychiatry 2021; Tsivgoulis G, Fragkou PC, Karofylakis E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879534>
34. **Underlying conditions and risk of hospitalisation, ICU admission and mortality among those with COVID-19 in Ireland: A national surveillance study.** Lancet Reg Health Eur 2021; 5:100097Bennett KE, Mullooly M, O'Loughlin M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880459>
35. **D-Dimer and Serum ferritin as an Independent Risk Factor for Severity in COVID-19 Patients.** Mater Today Proc 2021; A MH, Taha ZB, Gailan Malek A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868964>
36. **COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions.** mBio 2021; 12Adeniji OS, Giron LB, Purwar M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33879594>
37. **The role of carbohydrate antigen 125 in COVID-19.** Med. Hypotheses 2021; 151:110590Dökümcü E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33873150>
38. **Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis.** Mult Scler Relat Disord 2021; 52:102922Bose G, Galetta K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895693>
39. **COVID-19 and mutations a threat level assessment.** Nepal J Epidemiol 2021; 11:983-987Robinson J, Banerjee I, Leclézio A, Sathian B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868743>
40. **Angiotensin-converting enzyme 2 (ACE2): role in the pathogenesis of diseases outside of COVID-19.** Nephrologie 2021; Mülling N, Rohn H.
41. **Does higher Body Mass Index increase COVID-19 severity?: a systematic review and meta-analysis.** Obes Med 2021:100340Chowdhury AI, Alam MR, Rabbi MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875972>

42. **Risk stratification of adults with congenital heart disease during the COVID-19 pandemic: insights from a multinational survey among European experts.** Open Heart 2021; 8Ruperti-Repilado FJ, Tobler D, Greutmann M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33883228>
43. **COVID-19 severity in relation to sociodemographics and vitamin D use.** Open Med (Wars) 2021; 16:591-609Abdulateef DS, Rahman HS, Salih JM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33869781>
44. **Factors influencing the COVID-19 daily deaths' peak across European countries.** Public Health 2021; 194:135-142Jabłońska K, Aballéa S, Toumi M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33892351>
45. **Sleep deficit in COVID-19 health-care workers may increase the infection risk.** Scand J Public Health 2021:14034948211007679Ishikura IA, Rosa DS, Hachul H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870776>
46. **Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis.** Sleep Med. 2021; 82:47-53Hariyanto TI, Kurniawan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892451>
47. **High Child-Pugh and CRUB65 scores predict mortality of decompensated cirrhosis patients with COVID-19: A 23-center, retrospective study.** Virulence 2021; 12:1199-1208Xiao Y, Wu D, Shi X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870852>
48. **Burden and prevalence of risk factors for severe COVID-19 in the ageing European population - a SHARE-based analysis.** Z Gesundh Wiss 2021:1-10Ahrenfeldt LJ, Nielsen CR, Möller S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868899>

Safety (13 articles)

1. **Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.** Ann. Rheum. Dis. 2021; Martelli Júnior H, Marques NP, Marques NCT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883160>
2. **Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1.** BMJ Case Rep. 2021; 14Patel SU, Khurram R, Lakhani A, Quirk B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888484>
3. **Adult multisystem inflammatory syndrome in a patient who recovered from COVID-19 postvaccination.** BMJ Case Rep. 2021; 14Uwaydah AK, Hassan NMM, Abu Ghoush MS, Shahin KMM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883119>
4. **Potent Toxic Effects of Taroxaz-104 on the Replication of SARS-CoV-2 Particles.** Chem. Biol. Interact. 2021:109480Rabie AM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33887223>
5. **First dose of BNT162b2 mRNA vaccine in a Health Care Worker cohort is associated with reduced symptomatic and asymptomatic SARS-CoV-2**

- infection.** Clin Infect Dis 2021; Lillie PJ, O'Brien P, Lawtie M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33893480>
6. **Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers.** J Korean Med Sci 2021; 36:e110 Song JY, Cheong HJ, Kim SR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33876589>
 7. **Covid-19 mRNA Vaccination: Age and Immune Status and its Association with Axillary Lymph Node PET/CT Uptake.** J Nucl Med 2021; Eifer M, Tau N, Alhoubani Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893188>
 8. **Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty®).** Leg. Med. (Tokyo) 2021; 51:101895 Edler C, Klein A, Schröder AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895650>
 9. **Toxicity of hydroxychloroquine, a potential treatment for COVID-19, on free-living marine nematodes.** Mar. Pollut. Bull. 2021; 167:112361 Ben Ali M, Hedfi A, Almalki M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33873039>
 10. **Parsonage Turner syndrome after COVID-19 vaccination.** Muscle Nerve 2021; Mahajan S, Zhang F, Mahajan A, Zimnowodzki S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33890680>
 11. **Pandemic Risk Management using Engineering Safety Principles.** Process Saf Environ Prot 2021; Alauddin M, Khan F, Imtiaz S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33879978>
 12. **"Unilateral axillary lymphadenopathy following COVID-19 vaccination: A case report and imaging findings".** Radiol Case Rep 2021; Dominguez JL, Eberhardt SC, Revels JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868525>
 13. **Developing standard safety outcomes for COVID-19 vaccines.** Vaccine 2021; Buttery JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888324>

Treatment options (72 articles)

1. **Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities.** Adv. Appl. Bioinform. Chem. 2021; 14:71-85 Villoutreix BO, Krishnamoorthy R, Tamouza R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33880039>
2. **Pulmonary thromboembolism post-COVID convalescent plasma therapy: adding fuel to a smoldering fire!** Adv Respir Med 2021; Marwah V, Choudhary R, Peter D, Bhati G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33881163>
3. **Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.** Aging (Albany NY) 2021; 13 Wu L, Zheng Y, Liu J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33879634>
4. **Pharmacist outreach Program for COVID-19 monoclonal antibody distribution.** Am. J. Health Syst. Pharm. 2021; Malashock C, Keifer A, Reisbig K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895795>
5. **A narrative review of COVID-19: magnesium isoglycyrrhizinate as a potential adjuvant treatment.** Ann Palliat Med 2021; Tang C, Ding H, Sun Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33894736>

6. **Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study.** Ann Palliat Med 2021; Xu X, Zhang J, Zheng W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894725>
7. **Approach to Sedation and Analgesia in COVID-19 Patients on Venovenous Extracorporeal Membrane Oxygenation.** Ann. Pharmacother. 2021:10600280211010751Dreucean D, Harris JE, Voore P, Donahue KR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882694>
8. **Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.** Ann. Rheum. Dis. 2021; Martelli Júnior H, Marques NP, Marques NCT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883160>
9. **A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.** Antiviral Res 2021; 190:105078Zhao J, Guo S, Yi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894278>
10. **Potential "biopeptidal" therapeutics for severe respiratory syndrome coronaviruses: a review of antiviral peptides, viral mechanisms, and prospective needs.** Appl. Microbiol. Biotechnol. 2021:1-14Ashaolu TJ, Nawaz A, Walayat N, Khalifa I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876282>
11. **Antiviral peptides from aquatic organisms: Functionality and potential inhibitory effect on SARS-CoV-2.** Aquaculture 2021; 541:736783Sumon TA, Hussain MA, Hasan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883784>
12. **Phytochemistry and pharmacological activity of the genus artemisia.** Arch. Pharm. Res. 2021:1-36Bisht D, Kumar D, Kumar D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893998>
13. **Prediction of Anti-COVID 19 Therapeutic Power of Medicinal Moroccan Plants Using Molecular Docking.** Bioinform. Biol. Insights 2021; 15:11779322211009199Nouadi B, Ezaouine A, El Messal M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888980>
14. **Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy.** Biomed. Pharmacother. 2021; 139:111626Kelleni MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894625>
15. **Development of ciclesonide analogues that block SARS-CoV-2 RNA replication.** Bioorg. Med. Chem. Lett. 2021; 43:128052Tsuiji G, Yonemitsu K, Ito T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887440>
16. **Misleading clinical evidence and systematic reviews on ivermectin for COVID-19.** BMJ Evid Based Med 2021; Garegnani LI, Madrid E, Meza N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888547>
17. **Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections.** Br. J. Clin. Pharmacol. 2021; Böhm R, Bulin C, Waetzig V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871897>
18. **Computational Design and Modeling of Nanobodies toward SARS-CoV-2 Receptor Binding Domain.** Chem. Biol. Drug Des. 2021; Yang J, Zhang Z, Yang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894099>

19. **Potent Toxic Effects of Taroxaz-104 on the Replication of SARS-CoV-2 Particles.** Chem. Biol. Interact. 2021;109480Rabie AM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33887223>
20. **A Case of Acute Telogen Effluvium After SARS-CoV-2 Infection.** Clin. Cosmet. Investig. Dermatol. 2021; 14:385-387Lv S, Wang L, Zou X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33889006>
21. **Identification of potential antiviral compounds against SARS-CoV-2 structural and non structural protein targets: A pharmacoinformatics study of the CAS COVID-19 dataset.** Comput. Biol. Med. 2021; 133:104364García R, Hussain A, Koduru P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895457>
22. **SARS-CoV-2 Entry inhibitors targeting virus-ACE2 or virus-TMPRSS2 interactions.** Curr Med Chem 2021; Lin H, Cherukupalli S, Feng D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33881969>
23. **Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: A retrospective study with propensity score matching sensitivity analysis.** Curr. Med. Res. Opin. 2021;1Alamer A, Alrashed AA, Alfaifi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890544>
24. **A Network Pharmacology Study to Uncover the Multiple Molecular Mechanism of the Chinese Patent Medicine Toujiequwen Granules in the Treatment of Corona Virus Disease 2019 (COVID-19).** Curr Med Sci 2021; 41:297-305Yang BY, Wang HZ, Ma ZZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877545>
25. **COVID-19 and Disease-Modifying Anti-rheumatic Drugs.** Curr. Rheumatol. Rep. 2021; 23:28D'Silva KM, Wallace ZS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893890>
26. **Early adoption of non-pharmaceutical interventions and COVID-19 mortality.** Econ. Hum. Biol. 2021; 42:101003Amuedo-Dorantes C, Borra C, Rivera-Garrido N, Sevilla A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894688>
27. **Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquine.** Epidemiol. Prev. 2021; 45:28-36Lilli C, Biggeri A, Zingaretti C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884840>
28. **Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report.** Eur J Hosp Pharm 2021; Kroes JA, Zielhuis SW, Bethlehem C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33883206>
29. **Immunomodulatory Extracellular Vesicles: An alternative to cell therapy for COVID-19.** Expert Opin Biol Ther 2021; Gupta A, Kashte S, Kadam S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33886388>
30. **The role of IL-6 and IL-6 blockade in COVID-19.** Expert Rev. Clin. Immunol. 2021; Potere N, Batticciotto A, Vecchié A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874829>
31. **Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease.** Front Chem 2021; 9:622898Mengist HM, Dilnessa T, Jin T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33889562>
32. **New Roles for Vitamin D Superagonists: From COVID to Cancer.** Front. Endocrinol. (Lausanne) 2021; 12:644298Easty DJ, Farr CJ, Hennessy BT.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868174>

33. **Why Haven't We Found an Effective Treatment for COVID-19?** Front. Immunol. 2021; 12:644850 Spicer AJ, Jalkanen S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868280>
34. **Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis.** Front Med (Lausanne) 2021; 8:660688 Barreira DF, Lourenço RA, Calisto R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889590>
35. **COVID-19: a basic approach to understanding potential treatments.** Gac Med Mex 2020; 156:570-575 Cedillo-Alvarez C, Gallardo-Ortiz IA, López LT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877122>
36. **Inferring molecular mechanisms of dexamethasone therapy in severe COVID-19 from existing transcriptomic data.** Gene 2021; 788:145665 Sharma A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887367>
37. **CRISPR/Cas-New Molecular Scissors in Diagnostics and Therapeutics of COVID-19.** Indian J. Clin. Biochem. 2021:1-9 Gadwal A, Roy D, Khokhar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879980>
38. **Effectiveness of potential antiviral treatments in COVID-19 transmission control: a modelling study.** Infect Dis Poverty 2021; 10:53 Lin SN, Rui J, Chen QP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874998>
39. **The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data.** Infect Drug Resist 2021; 14:1389-1392 Capici S, Sala L, Galimberti S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880043>
40. **Immunopharmacological perspective on zinc in SARS-CoV-2 infection.** Int Immunopharmacol 2021; 96:107630 Asl SH, Nikfarjam S, Majidi Zolbanin N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882442>
41. **Potential Antioxidative, Anti-inflammatory and Immunomodulatory Effects of Ghrelin, an Endogenous Peptide from the Stomach in SARS-CoV2 Infection.** Int. J. Pept. Res. Ther. 2021:1-9 Jafari A, Sadeghpour S, Ghasemnejad-Berenji H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880115>
42. **In Silico Identification of Multi-target Anti-SARS-CoV-2 Peptides from Quinoa Seed Proteins.** Int. J. Pept. Res. Ther. 2021:1-11 Wong FC, Ong JH, Kumar DT, Chai TT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867899>
43. **Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis.** Intensive Care Med 2021:1-17 Chaudhuri D, Sasaki K, Karkar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876268>
44. **High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?** Intern Emerg Med 2021:1-2 Cameli P, Bergantini L, d'Alessandro M, Bargagli E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876321>
45. **Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case-control study.** J. Clin. Pathol. 2021; Klein MN, Wang EW, Zimand P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893156>
46. **Baricitinib: From Rheumatoid Arthritis to COVID-19(5).** J. Clin. Pharmacol. 2021; Assadiasl S, Fatahi Y, Mosharmovahed B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870531>

47. **Experimental therapies under investigation for COVID-19.** *J Community Hosp Intern Med Perspect* 2021; 11:187-193 Golamari R, Kapoor N, Devaraj T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889318>
48. **Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia.** *J Comp Eff Res* 2021; Agirbasli M, Tanrikulu A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887951>
49. **In silico approach for identifying natural lead molecules against SARS-CoV-2.** *J. Mol. Graph. Model.* 2021; 106:107916 Gupta SS, Kumar A, Shankar R, Sharma U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892297>
50. **Structurally modified compounds of hydroxychloroquine, remdesivir and tetrahydrocannabinol against main protease of SARS-CoV-2, a possible hope for COVID-19: Docking and molecular dynamics simulation studies.** *J. Mol. Liq.* 2021; 335:116185 Mishra D, Maurya RR, Kumar K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879934>
51. **Molecular Insights of Hyaluronic Acid-Hydroxychloroquine Conjugate as a Promising Drug in Targeting SARS-CoV-2 Viral Proteins.** *J. Mol. Struct.* 2021:130457 Thirumalaisamy R, Aroulmoji V, Iqbal MN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867575>
52. **REPLY TO LETTER TO THE EDITOR: POTENTIAL USE OF RADIOLABELED ANTIBODIES FOR IMAGING AND TREATMENT OF COVID-19.** *J Nucl Med* 2021; Pillarsetty N, Carter L, Lewis JS, Reiner T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893187>
53. **Virtual screening by targeting proteolytic sites of furin and TMPRSS2 to propose potential compounds obstructing the entry of SARS-CoV-2 virus into human host cells.** *J Tradit Complement Med* 2021; Vardhan S, Sahoo SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868970>
54. **MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreak.** *J Transl Med* 2021; 19:164 Jamalkhah M, Asaadi Y, Azangou-Khyavy M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888147>
55. **Toxicity of hydroxychloroquine, a potential treatment for COVID-19, on free-living marine nematodes.** *Mar. Pollut. Bull.* 2021; 167:112361 Ben Ali M, Hedfi A, Almalki M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33873039>
56. **Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.** *mBio* 2021; 12 Natarajan H, Crowley AR, Butler SE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879585>
57. **Application of intravenous immunoglobulin (IVIG) to modulate inflammation in critical COVID-19 - A theoretical perspective.** *Med. Hypotheses* 2021; 151:110592 Yaqinuddin A, Ambia AR, Elgazzar TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33878626>
58. **Management of COVID-19: Current Status and Future Prospects.** *Microbes Infect* 2021:104832 Kabir MA, Ahmed R, Chowdhury R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872807>
59. **Clinical efficacy of eucaloric ketogenic nutrition in the COVID-19 cytokine storm: A retrospective analysis of mortality and intensive care unit admission.**

- Nutrition 2021; 89:111236Sukkar SG, Cogorno L, Pisciotto L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895559>
60. **Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors.** Open Heart 2021; 8DiNicolantonio JJ, Barroso-Aranda J, McCarty MF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875563>
61. **Role of pirfenidone in TGF- β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.** Pharmacol. Rep. 2021:1-16Hamidi SH, Kadamboor Veethil S, Hamidi SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880743>
62. **Brazilian essential oils as source for the discovery of new anti-COVID-19 drug: a review guided by in silico study.** Phytochem Rev 2021:1-20Amparo TR, Seibert JB, Silveira BM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867898>
63. **Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial.** Porto Biomed J 2021; 6:e134Tavares M, Farraia M, Silva S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869886>
64. **Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).** Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2021; 42:5-18Panovska-Stavridis I, Ridova N, Stojanoska T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894123>
65. **Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases.** Rheumatol Adv Pract 2021; 5:rkab014Pham K, Torres H, Satlin MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875975>
66. **Interactions between SARS coronavirus 2 papain-like protease and immune system: a potential drug target for the treatment of COVID-19.** Scand. J. Immunol. 2021:e13044Mahmoudvand S, Shokri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872387>
67. **Old Treatment for a New Disease: Can Rectal Ozone Insufflation Be Used for COVID-19 Management? A Case Report.** SN Compr Clin Med 2021:1-4Hendawy HA, Mosallam W, Abuelnaga ME, Sabry AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875977>
68. **Combination therapy with plasma exchange and glucocorticoid may be effective for severe COVID-19 infection. -A retrospective observational study.** Ther. Apher. Dial. 2021; Matsushita Y, Kusaoi M, Hiki M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887110>
69. **[Not Available].** Therapie 2021; Billy E, Clarot F, Depagne C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892936>
70. **Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology.** Top Curr Chem (Cham) 2021; 379:23Zhuo LS, Wang MS, Yang JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886017>
71. **Exploring the utility of extracellular vesicles in ameliorating viral infection-associated inflammation, cytokine storm and tissue damage.** Transl. Oncol. 2021; 14:101095Pillalamarri N, Abdullah, Ren G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887552>

72. **A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.** Trials 2021; 22:288McEvoy NL, Clarke JL, McElvaney OJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=3387498>

Trials (16 articles)

1. **Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) Admitted to Hospital: Rationale and Design of the ACTION (AntiCoagulaTion cOroNavirus)-Coalition IV Trial.** Am. Heart J. 2021; Lopes RD, de Barros ESPGM, Furtado RHM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891907>
2. **The multidimensional prognostic index (MPI) for the prognostic stratification of older inpatients with COVID-19: A multicenter prospective observational cohort study.** Arch. Gerontol. Geriatr. 2021; 95:104415Pilotto A, Azzini M, Cella A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882420>
3. **Study protocol medical rehabilitation after COVID-19 disease: an observational study with a comparison group with obstructive airway disease / Re_Co.** BMC Health Serv. Res. 2021; 21:373Rutsch M, Frommhold J, Buhr-Schinner H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888104>
4. **Conducting an ongoing HIV clinical trial during the COVID-19 pandemic in Uganda: a qualitative study of research team and participants' experiences and lessons learnt.** BMJ Open 2021; 11:e048825Muwanguzi PA, Kutwabami P, Osingada CP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883157>
5. **Considerations for assessing physical function and physical activity in clinical trials during the COVID-19 pandemic.** Contemp Clin Trials 2021; 105:106407Moon SJE, Dabbs AD, Hergenroeder AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887443>
6. **Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquine.** Epidemiol. Prev. 2021; 45:28-36Lilli C, Biggeri A, Zingaretti C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33884840>
7. **Deficiencies in Planning Interventional Trial Registration of COVID-19 in China.** Front Med (Lausanne) 2021; 8:618185Li X, Zhang S, Zhou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869242>
8. **Psychological Differences Among Healthcare Workers of a Rehabilitation Institute During the COVID-19 Pandemic: A Two-Step Study.** Front. Psychol. 2021; 12:636129Panzeri A, Rossi Ferrario S, Cerutti P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868105>
9. **COVID-19 Trial Graph: A Linked Graph for COVID-19 Clinical Trials.** J Am Med Inform Assoc 2021; Du J, Wang Q, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895839>
10. **Building An OMOP Common Data Model-Compliant Annotated Corpus for COVID-19 Clinical Trials.** J. Biomed. Inform. 2021:103790Sun Y, Butler A, Stewart LA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887457>

11. **Negative Effects of COVID-19 Stay-at-Home Mandates on Physical Intervention Outcomes: A Preliminary Study.** J. Parkinsons Dis. 2021; Templeton JM, Poellabauer C, Schneider S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867363>
12. **Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial.** Porto Biomed J 2021; 6:e134Tavares M, Farraia M, Silva S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869886>
13. **Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).** Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2021; 42:5-18Panovska-Stavridis I, Ridova N, Stojanoska T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894123>
14. **A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.** Trials 2021; 22:288McEvoy NL, Clarke JL, McElvaney OJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874981>
15. **The UPTAKE study: implications for the future of COVID-19 vaccination trial recruitment in UK and beyond.** Trials 2021; 22:296Sethi S, Kumar A, Mandal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879208>
16. **Burden and prevalence of risk factors for severe COVID-19 in the ageing European population - a SHARE-based analysis.** Z Gesundh Wiss 2021;1-10Ahrenfeldt LJ, Nielsen CR, Möller S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868899>

Vaccines (42 articles)

1. **COVID-19 VACCINE: THE CHALLENGE OF HERBAL MEDICINE COMMUNITY BELIEF IN A DEVELOPING COUNTRY - LETTER TO THE EDITOR.** Afr J Infect Dis 2021; 15:1-2Makrufardi F, Saputri A, Phillabertha PS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889795>
2. **Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe.** Allergy 2021; Wagner R, Meißner J, Grabski E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887070>
3. **Strategies used to meet the challenges of mass COVID-19 vaccination by the pharmacy department in a large academic medical center.** Am. J. Health Syst. Pharm. 2021; Li Q, Norman S, Guthrie P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895789>
4. **Association between Influenza Vaccination and severe COVID-19 outcomes at a designated COVID-only hospital in Brooklyn.** Am. J. Infect. Control 2021; Umasabor-Bubu OQ, Bubu OM, Mbah AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891988>
5. **Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1.** BMJ Case Rep. 2021; 14Patel SU, Khurram R, Lakhani A, Quirk B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888484>

6. **Adult multisystem inflammatory syndrome in a patient who recovered from COVID-19 postvaccination.** BMJ Case Rep. 2021; 14Uwaydah AK, Hassan NMM, Abu Ghoush MS, Shahin KMM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883119>
7. **Cocooning against COVID-19: The argument for vaccinating caregivers of patients with cancer.** Cancer 2021; Woodfield MC, Pergam SA, Shah PD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891713>
8. **First dose of BNT162b2 mRNA vaccine in a Health Care Worker cohort is associated with reduced symptomatic and asymptomatic SARS-CoV-2 infection.** Clin Infect Dis 2021; Lillie PJ, O'Brien P, Lawtie M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893480>
9. **Status Report on COVID-19 Vaccines Development.** Curr. Infect. Dis. Rep. 2021; 23:9Kumar A, Dowling WE, Román RG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867863>
10. **Potential Candidates against COVID-19 Targeting RNA-Dependent RNA Polymerase: A Comprehensive Review.** Curr. Pharm. Biotechnol. 2021; Agrawal N, Goyal A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33882805>
11. **A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters.** Emerg Microbes Infect 2021:1-27Zhang BZ, Wang X, Yuan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890550>
12. **Perspectives on RNA Vaccine Candidates for COVID-19.** Front Mol Biosci 2021; 8:635245Borah P, Deb PK, Al-Shar'i NA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869282>
13. **The role of nanotechnology in current COVID-19 outbreak.** Heliyon 2021; 7:e06841Tavakol S, Zahmatkeshan M, Mohammadinejad R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880422>
14. **Stability analysis of SEIR model related to efficiency of vaccines for COVID-19 situation.** Heliyon 2021; 7:e06812Wintachai P, Prathom K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880423>
15. **The COVID-19 vaccine social media infodemic: healthcare providers' missed dose in addressing misinformation and vaccine hesitancy.** Hum Vaccin Immunother 2021:1-3Hernandez RG, Hagen L, Walker K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33890838>
16. **Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China.** Hum Vaccin Immunother 2021:1-5Wang G, Zhu L, Zhu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33886411>
17. **COVID-19 vaccine acceptance in pregnant women.** Int J Gynaecol Obstet 2021; Goncu Ayhan S, Oluklu D, Atalay A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872386>
18. **Acceptability of COVID-19 Vaccine in Africa.** Int J MCH AIDS 2021; 10:134-138Wirsiy FS, Nkfusai CN, Ako-Arrey DE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868778>
19. **The importance of a timely second dose of the 2021 COVID-19 mRNA vaccine depends on the protection afforded by a first dose and subsequent risk of**

- anaphylaxis.** *J Allergy Clin Immunol Pract* 2021; Shaker M, Phillips E, Blumenthal KG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892171>
20. **The Nature and Extent of COVID-19 Vaccination Hesitancy in Healthcare Workers.** *J. Community Health* 2021;1-8Biswas N, Mustapha T, Khubchandani J, Price JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33877534>
 21. **Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.** *J Hepatol* 2021; Rabinowich L, Grupper A, Baruch R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892006>
 22. **Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers.** *J Korean Med Sci* 2021; 36:e110Song JY, Cheong HJ, Kim SR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33876589>
 23. **People's Willingness to Vaccinate Against COVID-19 Despite Their Safety Concerns: Twitter Poll Analysis.** *J Med Internet Res* 2021; 23:e28973Eibensteiner F, Ritschl V, Nawaz FA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872185>
 24. **Covid-19 mRNA Vaccination: Age and Immune Status and its Association with Axillary Lymph Node PET/CT Uptake.** *J Nucl Med* 2021; Eifer M, Tau N, Alhoubani Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893188>
 25. **State estimation-based control of COVID-19 epidemic before and after vaccine development.** *J Process Control* 2021; 102:1-14Rajaei A, Raeiszadeh M, Azimi V, Sharifi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867698>
 26. **India's role in COVID-19 vaccine diplomacy.** *J Travel Med* 2021; Sharun K, Dhama K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870417>
 27. **Returning to a Normal Life via COVID-19 Vaccines in the United States: A Large-scale Agent-Based Simulation Study.** *JMIR Med Inform* 2021; 9:e27419Li J, Giabbanelli P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872188>
 28. **Antibody response to BNT162b2 vaccine in maintenance hemodialysis patients.** *Kidney Int* 2021; Attias P, Sakhi H, Rieu P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887317>
 29. **Low immunization rates among kidney transplant recipients who received two doses of the mRNA-1273 SARS-CoV-2 vaccine.** *Kidney Int* 2021; Benotmane I, Gautier-Vargas G, Cognard N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887315>
 30. **Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients on haemodialysis. A call to arms.** *Kidney Int* 2021; Billany RE, Selvaskandan H, Adenwalla SF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887316>
 31. **Experience with SARS-COV-2 BNT162b2 mRNA vaccine in dialysis patients.** *Kidney Int* 2021; Yanay NB, Freiman S, Shapira M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33887318>
 32. **Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty®).** *Leg. Med. (Tokyo)* 2021; 51:101895Edler C, Klein A, Schröder AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33895650>
 33. **Lessons from the United Kingdom's COVID-19 vaccination strategy.** *Med. J. Aust.* 2021; Harnden A, Earnshaw A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893643>

34. **[Attitude towards vaccination against SARS-CoV-2 : Survey among employees in hospitals before and after the start of vaccinations in German hospitals].** Med Klin Intensivmed Notfmed 2021;1-10Janssens U, Kluge S, Marx G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33877427>
35. **Management of COVID-19: Current Status and Future Prospects.** Microbes Infect 2021;104832Kabir MA, Ahmed R, Chowdhury R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33872807>
36. **Why are COVID-19 vaccines still in short supply?** MRS Bull 2021;1-2Pradhan R, Allen A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33867658>
37. **Parsonage Turner syndrome after COVID-19 vaccination.** Muscle Nerve 2021; Mahajan S, Zhang F, Mahajan A, Zimnowodzki S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33890680>
38. **Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials.** Nepal J Epidemiol 2021; 11:959-982Sathian B, Asim M, Banerjee I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33868742>
39. **"Unilateral axillary lymphadenopathy following COVID-19 vaccination: A case report and imaging findings".** Radiol Case Rep 2021; Dominguez JL, Eberhardt SC, Revels JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868525>
40. **The UPTAKE study: implications for the future of COVID-19 vaccination trial recruitment in UK and beyond.** Trials 2021; 22:296Sethi S, Kumar A, Mandal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879208>
41. **Developing standard safety outcomes for COVID-19 vaccines.** Vaccine 2021; Buttery JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33888324>
42. **Using Contingent Valuation Method to Estimate Adults' Willingness to Pay for a Future Coronavirus 2019 Vaccination.** Value Health Reg Issues 2021; 24:240-246Vo NX, Huyen Nguyen TT, Van Nguyen P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33895642>

Women – pregnancy (36 articles)

1. **COVID-19 in pregnancy - characteristics and outcomes of pregnant women admitted to hospital because of SARS-CoV-2 infection in the Nordic countries.** Acta Obstet Gynecol Scand 2021; Engjom H, Aabakke AJ, Klungsøyr K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33885150>
2. **Decision-to-delivery interval and neonatal outcomes for category-1 caesarean sections during the COVID-19 pandemic.** Anaesthesia 2021; Bhatia K, Columb M, Bewlay A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891311>
3. **Gynaecological and IVF procedures billed through the Medicare Benefits Schedule (MBS) during the COVID-19 pandemic.** Aust N Z J Obstet Gynaecol 2021; Alonso A, Deans R, Nesbitt-Hawes E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33890300>
4. **COVID-19 in Women's health reducing the risk of infection to patients and staff during acute and elective hospital admission for gynaecological surgery.** Best Pract. Res. Clin. Obstet. Gynaecol. 2021; Odejinmi F, Egbase E, Clark TJ, Mallick R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879364>

5. **2. Labour and birth.** Best Pract. Res. Clin. Obstet. Gynaecol. 2021; Ross-Davie M, Brodrick A, Randall W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879365>
6. **Prioritisation of outpatient appointments and elective surgery in gynaecology.** Best Pract. Res. Clin. Obstet. Gynaecol. 2021; Sairally BZF, Clark TJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883091>
7. **Induction of labour during the COVID-19 pandemic: a national survey of impact on practice in the UK.** BMC Pregnancy Childbirth 2021; 21:310Harkness M, Yuill C, Cheyne H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33874913>
8. **Severe metabolic ketoacidosis as a primary manifestation of SARS-CoV-2 infection in non-diabetic pregnancy.** BMJ Case Rep. 2021; 14van Amesfoort JE, Werter DE, Painter RC, Hermans FJR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875510>
9. **Changes to medication abortion clinical practices in response to the COVID-19 pandemic.** Contraception 2021; Tschann M, Ly ES, Hilliard S, Lange HLH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33894247>
10. **The influence of the COVID-19 outbreak on European trainees in obstetrics and gynaecology: A survey of the impact on training and trainee.** Eur. J. Obstet. Gynecol. Reprod. Biol. 2021; 261:52-58Boekhorst F, Khattak H, Topcu EG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33892209>
11. **Retrospective observational RT-PCR analyses on 688 babies born to 843 SARS-CoV-2 positive mothers, placental analyses and diagnostic analyses limitations suggest vertical transmission is possible.** Facts Views Vis Obgyn 2021; 13:53-66Bahadur G, Bhat M, Acharya S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889861>
12. **The impact of COVID-19 on obstetrics and gynaecology trainees; how do we move on?** Facts Views Vis Obgyn 2021; 13:9-14Mallick R, Odejinmi F, Sideris M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33889856>
13. **A Translational Perspective of Maternal Immune Activation by SARS-CoV-2 on the Potential Prenatal Origin of Neurodevelopmental Disorders: The Role of the Cholinergic Anti-inflammatory Pathway.** Front. Psychol. 2021; 12:614451Reyes-Lagos JJ, Abarca-Castro EA, Echeverría JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868085>
14. **Emergent Change in a Mexican Midwifery Center Organization Amidst the COVID-19 Crisis.** Front Sociol 2021; 6:611321Alonso C, Storey AS, Fajardo I, Borboleta HS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869554>
15. **When Maintaining Relationships and Social Connectivity Matter: The Case of New Zealand Midwives and COVID-19.** Front Sociol 2021; 6:614017Crowther S, Maude R, Bradford B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869567>
16. **Pivoting to Childbirth at Home or in Freestanding Birth Centers in the US During COVID-19: Safety, Economics and Logistics.** Front Sociol 2021; 6:618210Daviss BA, Anderson DA, Johnson KC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869572>
17. **Pregnancy, Birthing, and Postpartum Experiences During COVID-19 in the United States.** Front Sociol 2021; 6:611212DeYoung SE, Mangum M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869553>

18. **Protecting Women's and Newborns' Rights in a Public Maternity Unit During the COVID-19 Outbreak: The Case of Dra. Eloísa Díaz - La Florida Hospital in Santiago, Chile.** Front Sociol 2021; 6:614021 Leiva G, Sadler M, López C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869568>
19. **Where the System Failed: The COVID-19 Pandemic's Impact on Pregnancy and Birth Care.** Glob Qual Nurs Res 2021; 8:23333936211006397 Altman MR, Gavin AR, Eagen-Torkko MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869668>
20. **Prevalence and associated factors of intimate partner violence (IPV) against women in Bangladesh amid COVID-19 pandemic.** Heliyon 2021; 7:e06619 Rayhan I, Akter K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33869852>
21. **Information Needs of Pregnant Women in the COVID-19 Pandemic from Experts' Point of View: A Qualitative Study.** Int J Community Based Nurs Midwifery 2021; 9:139-151 Rezaei F, Masaeli Z, Atighechian G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33875966>
22. **Hematologic adaptation to mask-wearing among pregnant women and obstetrical outcome during the COVID-19 pandemic.** Int J Gynaecol Obstet 2021; Friedrich L, Levin G, Maixner N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872397>
23. **COVID-19 vaccine acceptance in pregnant women.** Int J Gynaecol Obstet 2021; Goncu Ayhan S, Oluklu D, Atalay A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33872386>
24. **Early abortion care during the COVID-19 public health emergency in Ireland: Implications for law, policy, and service delivery.** Int J Gynaecol Obstet 2021; Spillane A, Taylor M, Henchion C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33893642>
25. **Premature ovarian insufficiency secondary to COVID-19 infection: An original case report.** Int J Gynaecol Obstet 2021; Wilkins J, Al-Inizi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33896002>
26. **A Framework for Protecting Pregnant Women in the Era of COVID-19 Pandemic.** Int J MCH AIDS 2021; 10:109-112 Dongarwar D, Ajewole VB, Harris K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33868776>
27. **Ultrasonography as a diagnostic aid for a neonate with gingival swelling in a COVID-19 neonatal intensive care unit.** J. Indian Soc. Pedod. Prev. Dent. 2021; 39:101-103 Kakade A, Deshmukh B, Agarwal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33885396>
28. **ACE2, TMPRSS2 and L-SIGN expression in placentae from HIV-positive pregnancies exposed to antiretroviral therapy-implications for SARS-CoV-2 placental infection.** J Infect Dis 2021; Kala S, Meteleva K, Serghides L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33880537>
29. **Pregnant women with COVID-19: the placental involvement and consequences.** J. Mol. Histol. 2021:1-9 Aghaamoo S, Ghods K, Rahmanian M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33871721>
30. **Pregnant in the United States in the COVID-19 pandemic: A collision of crises we cannot ignore.** J. Natl. Med. Assoc. 2021; Stratton P, Gorodetsky E, Clayton J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33883068>

31. **Substance use and mental health in pregnant women during the COVID-19 pandemic.** J. Reprod. Infant Psychol. 2021;1-14 Smith CL, Waters SF, Spellacy D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33870821>
32. **Sex-Based Differences in COVID-19 Outcomes.** J Womens Health (Larchmt). 2021; 30:492-501 Tejpal A, Gianos E, Cerise J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33885345>
33. **Neonatology in times of pandemic - Pregnant women with COVID-19: How much is the child at risk?** MMW-Fortschritte der Medizin 2021; 163:27 Reinhardt D.
34. **Guidance for the clinical management of infants born to mothers with suspected/confirmed COVID-19 in Singapore.** Singapore Med J 2021; Yeo KT, Biswas A, Ho SKY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33866749>
35. **Maternal insomnia during the COVID-19 pandemic: associations with depression and anxiety.** Soc. Psychiatry Psychiatr. Epidemiol. 2021;1-9 Wang J, Zhou Y, Qian W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33891160>
36. **Assessment of knowledge and opinion regarding breastfeeding practices during COVID-19 pandemic among paediatricians and obstetricians in India: an online survey.** Sudan J Paediatr 2021; 21:30-35 Malik S, Joshi P, Gupta PK, Sharma S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33879940>

to subscribe click [here](#)

mailing address is:
lansberg@gmail.com

© P.J. Lansberg